



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

30 January 2025
EMA/CHMP/57306/2025
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 27-30 January 2025

Chair: Bruno Sepodes – Vice-Chair: Outi Mäki-Ikola

Health and safety information

In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	8
1.1.	Welcome and declarations of interest of members, alternates and experts.....	8
1.2.	Adoption of agenda	8
1.3.	Adoption of the minutes	8
2.	Oral Explanations	8
2.1.	Pre-authorisation procedure oral explanations.....	8
2.1.1.	Vorasidenib - Orphan - EMEA/H/C/006284.....	8
2.2.	Re-examination procedure oral explanations	9
2.3.	Post-authorisation procedure oral explanations	9
2.3.1.	Helicobacter Test INFAI - 13C-Urea - EMEA/H/C/000140/II/0028	9
2.4.	Referral procedure oral explanations	9
3.	Initial applications	9
3.1.	Initial applications; Opinions.....	9
3.1.1.	CAPVAXIVE - Pneumococcal polysaccharide conjugate vaccine (21-valent) - EMEA/H/C/006267	9
3.1.2.	Datroway – Datopotamab deruxtecan - EMEA/H/C/006547	10
3.1.3.	Dyrupeg - Pegfilgrastim - EMEA/H/C/006407	10
3.1.4.	Eltrombopag Accord - Eltrombopag - EMEA/H/C/006459	11
3.1.5.	Ivermectin/Albendazole - Ivermectin / Albendazole - Article 58 - EMEA/H/W/005186.....	11
3.1.6.	Pavblu - Aflibercept - EMEA/H/C/006339	12
3.1.7.	Skojoy - Aflibercept - EMEA/H/C/006551	12
3.1.8.	Tivdak - Tisotumab vedotin - EMEA/H/C/005363	12
3.1.9.	Vimkunya - Chikungunya vaccine (recombinant, adsorbed) - PRIME - Article 28 - EMEA/H/C/005470.....	13
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)	13
3.2.1.	Troriluzole - Orphan - EMEA/H/C/006068	13
3.2.2.	Trastuzumab - EMEA/H/C/006219	14
3.2.3.	Diflunisal - Orphan - EMEA/H/C/006248	14
3.2.4.	AMINO ACIDS - Orphan - EMEA/H/C/005557	14
3.2.5.	Ferric citrate coordination complex - EMEA/H/C/006402	15
3.2.6.	Vorasidenib - Orphan - EMEA/H/C/006284.....	15
3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)	15
3.3.1.	Denosumab - EMEA/H/C/006490	15
3.3.2.	Denosumab - EMEA/H/C/006722	16
3.3.3.	Nipocalimab - EMEA/H/C/006379.....	16

3.3.4.	Denosumab - EMEA/H/C/006238	16
3.3.5.	Belumosudil - Orphan - EMEA/H/C/006421	16
3.3.6.	Riloncept - Orphan - EMEA/H/C/006537.....	17
3.3.7.	Denosumab - EMEA/H/C/006552	17
3.4.	Update on on-going initial applications for Centralised procedure.....	17
3.4.1.	Hydrocortisone - PUMA - EMEA/H/C/005201	17
3.4.2.	Nirogacestat - Orphan - EMEA/H/C/006071.....	17
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004	18
3.5.1.	Kizfizo - Temozolomide - Orphan - EMEA/H/C/006169.....	18
3.5.2.	CINAINU - Liquid ethanolic extract 30 per cent (W/W) of <i>Allium cepa</i> fresh bulb and <i>Citrus limon</i> fresh fruit / Dry aqueous extract of <i>paullinia cupana</i> seed / Dry hydroethanolic extract of <i>theobroma cacao</i> seed - EMEA/H/C/004155	18
3.6.	Initial applications in the decision-making phase.....	18
3.6.1.	Wainzua - Eplontersen - Orphan - EMEA/H/C/006295.....	18
3.6.2.	Osenvelt - Denosumab - EMEA/H/C/006157.....	19
3.6.3.	LEQEMBI - Lecanemab - EMEA/H/C/005966	19
3.7.	Withdrawals of initial marketing authorisation application	19
3.7.1.	Datopotamab deruxtecan Daiichi Sankyo Datopotamab deruxtecan - EMEA/H/C/006081 ..	19
3.7.2.	Nugalviq - Govorestat - Orphan - EMEA/H/C/006270	20
4.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	20
4.1.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion	20
4.1.1.	Rybrevant - Amivantamab - EMEA/H/C/005454/X/0014	20
4.1.2.	Taltz - Ixekizumab - EMEA/H/C/003943/X/0051	20
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues	21
4.2.1.	OPDIVO - Nivolumab - EMEA/H/C/003985/X/0144.....	21
4.2.2.	Evrysdi - Risdiplam - EMEA/H/C/005145/X/0024/G.....	21
4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question	22
4.3.1.	Jivi - Damoctocog alfa pegol - EMEA/H/C/004054/X/0033/G	22
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008	22
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	22

5.	Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008	22
5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....	22
5.1.1.	Abrysvo - Respiratory syncytial virus vaccine (bivalent, recombinant) - EMEA/H/C/006027/II/0007.....	22
5.1.2.	Amvuttra - Vutrisiran - Orphan - EMEA/H/C/005852/II/0015	23
5.1.3.	Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - ATMP - EMEA/H/C/004731/II/0043/G	23
5.1.4.	Calquence - Acalabrutinib - EMEA/H/C/005299/II/0028	24
5.1.5.	Columvi - Glofitamab - Orphan - EMEA/H/C/005751/II/0005	24
5.1.6.	Cystadrops - Mercaptamine - Orphan - EMEA/H/C/003769/II/0032.....	25
5.1.7.	Dapivirine Vaginal Ring 25 mg - Dapivirine - EMEA/H/W/002168/II/0027	25
5.1.8.	Darzalex - Daratumumab - Orphan - EMEA/H/C/004077/II/0076.....	26
5.1.9.	Dupixent - Dupilumab - EMEA/H/C/004390/II/0083	26
5.1.10.	FABHALTA - Iptacopan - Orphan - EMEA/H/C/005764/II/0001	27
5.1.11.	Hetlioz - Tasimelteon - Orphan - EMEA/H/C/003870/II/0040	27
5.1.12.	Imfinzi - Durvalumab - EMEA/H/C/004771/II/0069.....	28
5.1.13.	Imfinzi - Durvalumab - EMEA/H/C/004771/II/0073.....	28
5.1.14.	Jaypirca - Pirtobrutinib - EMEA/H/C/005863/II/0002.....	29
5.1.15.	Jivi - Damoctocog alfa pegol - EMEA/H/C/004054/II/0034	29
5.1.16.	NUBEQA - Darolutamide - EMEA/H/C/004790/II/0024.....	30
5.1.17.	RINVOQ - Upadacitinib - EMEA/H/C/004760/II/0056.....	30
5.1.18.	Ronapreve - Casirivimab / Imdevimab - EMEA/H/C/005814/II/0017	31
5.1.19.	RXULTI - Brexpiprazole - EMEA/H/C/003841/II/0015	31
5.1.20.	Sivextro - Tedizolid phosphate - EMEA/H/C/002846/II/0054	32
5.1.21.	Slentyto - Melatonin - EMEA/H/C/004425/II/0028	32
5.1.22.	Stelara - Ustekinumab - EMEA/H/C/000958/II/0108	33
5.1.23.	Tevimbra - Tislelizumab - EMEA/H/C/005919/II/0016	33
5.1.24.	Vyvgart - Efgartigimod alfa - Orphan - EMEA/H/C/005849/II/0020	34
5.1.25.	WS2717 OPDIVO - Nivolumab - EMEA/H/C/003985/WS2717/0146 Yervoy - Ipilimumab - EMEA/H/C/002213/WS2717/0115	34
5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	35
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	35
6.	Medical devices	35
6.1.	Ancillary medicinal substances - initial consultation	35
6.1.1.	Human serum albumin - EMEA/H/D/006611.....	35

6.2.	Ancillary medicinal substances – post-consultation update.....	35
6.3.	Companion diagnostics - initial consultation	36
6.3.1.	In vitro diagnostic medical device - EMEA/H/D/006648	36
6.3.2.	In vitro diagnostic medical device - EMEA/H/D/006668	36
6.4.	Companion diagnostics – follow-up consultation.....	36
7.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	36
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use).....	36
8.	Pre-submission issues	36
8.1.	Pre-submission issue.....	36
8.1.1.	Linerixibat – H0006241	36
8.1.2.	Tovorafenib - H0006140.....	37
8.1.3.	Lenacapavir – H0006659	37
8.1.4.	Lenacapavir – H0006658	37
8.1.5.	Plozasiran – Orphan - H0006579	37
8.2.	Priority Medicines (PRIME).....	38
9.	Post-authorisation issues	38
9.1.	Post-authorisation issues	38
9.1.1.	Ngenla - Somatrogon - Orphan - EMEA/H/C/005633/II/0016	38
9.1.2.	Zeposia - Ozanimod - EMEA/H/C/004835/R/0028	38
9.1.3.	Grastofil – Filgrastim – EMEA/H/C/002150.....	39
9.1.4.	FILSPARI - Sparsentan - EMEA/H/C/005783/II/0002, Orphan	39
9.1.5.	Helicobacter Test INFAI - 13C-Urea - EMEA/H/C/000140/II/0028	39
9.1.6.	Elfabrio - Pegunigalsidase alfa - EMEA/H/C/005618/II/0007.....	40
9.1.7.	Comirnaty - COVID-19 mRNA vaccine - EMA/VR/0000237985	40
9.1.8.	Penbraya - Meningococcal groups A, C, W,Y conjugate and group B vaccine (recombinant, adsorbed) - EMEA/H/C/006165	41
10.	Referral procedures	41
10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004	41
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004	41
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004	41
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC	41
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	41
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC	41
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	42

10.8.	Procedure under Article 107(2) of Directive 2001/83/EC	42
10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003	42
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	42
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008	42
11.	Pharmacovigilance issue	42
11.1.	Early Notification System	42
12.	Inspections	42
12.1.	GMP inspections	42
12.2.	GCP inspections	42
12.3.	Pharmacovigilance inspections.....	43
12.4.	GLP inspections	43
13.	Innovation Task Force	43
13.1.	Minutes of Innovation Task Force.....	43
13.2.	Innovation Task Force briefing meetings.....	43
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004	43
13.4.	Nanomedicines activities	43
14.	Organisational, regulatory and methodological matters	43
14.1.	Mandate and organisation of the CHMP	43
14.1.1.	Vote by Proxy	43
14.1.2.	CHMP membership.....	44
14.2.	Coordination with EMA Scientific Committees.....	44
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC)	44
14.2.2.	Paediatric Committee (PDCO).....	44
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	44
14.3.1.	Biologics Working Party (BWP)	44
14.3.2.	Scientific Advice Working Party (SAWP)	44
14.3.3.	Election of Vice-Chair – Vaccines Working Party (VWP).....	45
14.4.	Cooperation within the EU regulatory network.....	45
14.5.	Cooperation with International Regulators.....	45
14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee	45
14.7.	CHMP work plan	45
14.8.	Planning and reporting	45

14.9.	Others	45
14.9.1.	CHMP Learnings	45
15.	Any other business	46
15.1.	AOB topic.....	46
15.1.1.	GIREX rules	46
15.1.2.	Health Threats and ETF update.....	46
15.1.3.	EMA feedback to the European Commission on the use of titanium dioxide as excipient in medicinal products – safety aspects	46
15.1.4.	SAG mandate renewal and (re)nominations	46
15.1.5.	Primary biliary cholangitis therapies: an international consensus position on demonstrating treatment efficacy - conference	47
16.	List of participants	48
	Explanatory notes	53

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 27-30 January 2025

The CHMP adopted the agenda for the 27-30 January 2025 meeting.

1.3. Adoption of the minutes

CHMP minutes for 09-12 December 2024.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 7 of October and 20 January 2024.

The CHMP adopted the minutes of the 09-12 December 2024 meeting.

The CHMP adopted the minutes of the PROM meeting held on 7 October and 20 January 2024.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. Vorasidenib - Orphan - EMEA/H/C/006284

Les Laboratoires Servier; treatment of predominantly non-enhancing astrocytoma or oligodendroglioma with a IDH1 R132 mutation or IDH2 R172 mutation

Scope: Oral explanation

Action: Oral explanation to be held on 28 January 2025 at 11:00

List of Outstanding Issues adopted on 19.09.2024, 25.07.2024. List of Questions adopted on 23.04.2024.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Helicobacter Test INFAI - 13C-Urea - EMEA/H/C/000140/II/0028

Infai GmbH

Rapporteur: Christian Gartner

Scope: Oral explanation

Action: Oral explanation to be held on 29 January 2025 at 14:00

Request for Supplementary Information adopted on 17.10.2024, 30.05.2024.

An oral explanation was held on 28 January 2024. The presentation by the applicant focused on the clinical data in support of the application.

See 9.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. CAPVAXIVE - Pneumococcal polysaccharide conjugate vaccine (21-valent) - EMEA/H/C/006267

Merck Sharp & Dohme B.V.; for active immunisation for the prevention of invasive disease and pneumonia caused by *Streptococcus pneumoniae*

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 12.12.2024. List of Questions adopted on 25.07.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that erdafitinib is a new active substance, as claimed by the applicant.

The CHMP noted the letter of recommendation dated 22 January 2025.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.2. [Datroway – Datopotamab deruxtecan - EMEA/H/C/006547](#)

Daiichi Sankyo Europe GmbH; Treatment of adult patients with inoperable or metastatic HR-positive / HER2-negative breast cancer with disease progression following chemotherapy in the metastatic setting

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC),

List of Outstanding Issues adopted on 14.11.2024. List of Questions adopted on 27.06.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considers that datopotamab deruxtecan is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.3. [Dyrupeg - Pegfilgrastim - EMEA/H/C/006407](#)

CuraTeQ Biologics s.r.o.; treatment of neutropenia

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.11.2024. List of Questions adopted on 27.06.2024.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 29 January 2025.

The summary of opinion was circulated for information.

3.1.4. [Eltrombopag Accord - Eltrombopag - EMEA/H/C/006459](#)

Accord Healthcare S.L.U.; treatment of primary immune thrombocytopenia (ITP), chronic hepatitis C virus (HCV) and acquired severe aplastic anaemia (SAA)

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Revolade

List of Outstanding Issues adopted on 12.12.2024. List of Questions adopted on 25.07.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.5. [Ivermectin/Albendazole - Ivermectin / Albendazole - Article 58 - EMEA/H/W/005186](#)

Laboratorios Liconsa S.A.; prevention and treatment of lymphatic filariasis, and soil-transmitted helminths infections.

Scope: Opinion

Action: For adoption

Fixed combination application (Article 10b of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 17.10.2024. List of Questions adopted on 30.05.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted the scientific opinion for Ivermectin/Albendazole in accordance with Article 58 of Regulation (EC) No. 726/2004.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 30 January 2025.

The summary of opinion was circulated for information.

The CHMP endorsed the EMA press release.

The CHMP considered that a CHMP request for PRAC advice was no longer necessary as the issues previously identified in this application had been addressed.

3.1.6. Pavblu - Aflibercept - EMEA/H/C/006339

Amgen Technology (Ireland) Unlimited Company; treatment of age-related macular degeneration (AMD) and visual impairment

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 14.11.2024. List of Questions adopted on 27.06.2024.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.7. Skojoy - Aflibercept - EMEA/H/C/006551

Amgen Technology (Ireland) Unlimited Company; treatment of age-related macular degeneration (AMD) and visual impairment

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of Pavblu

List of Outstanding Issues adopted on 14.11.2024. List of Questions adopted on 27.06.2024.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.8. Tivdak - Tisotumab vedotin - EMEA/H/C/005363

Pfizer Europe MA EEIG; treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 17.10.2024. List of Questions adopted on 30.05.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considers that Tisotumab vedotin is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.9. [Vimkunya - Chikungunya vaccine \(recombinant, adsorbed\) - PRIME - Article 28 - EMEA/H/C/005470](#)

Bavarian Nordic A/S; prevention of disease caused by chikungunya (CHIKV) virus

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 10.12.2024. List of Questions adopted on 15.10.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considers that Chikungunya vaccine (recombinant, adsorbed) is a new active substance, as claimed by the applicant.

The CHMP noted the letter of recommendation dated 30 January 2025.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP endorsed the EMA press release.

3.2. [Initial applications; List of outstanding issues \(Day 180; Day 120 for procedures with accelerated assessment timetable\)](#)

3.2.1. [Troriluzole - Orphan - EMEA/H/C/006068](#)

Biohaven Bioscience Ireland Limited; is indicated for the treatment of adult patients with spinocerebellar ataxia genotype 3 (SCA3)

Scope: List of outstanding issues; Request by the applicant for an extension to the clock-

stop to respond to the list of outstanding issues.

Action: For adoption

List of Questions adopted on 22.02.2024.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP did not agree to the request by the applicant for an extension to the clock-stop to respond to the list of outstanding issues.

3.2.2. [Trastuzumab - EMEA/H/C/006219](#)

treatment of metastatic and early breast cancer

Scope: List of outstanding issues; Request by the applicant for an extension to the clock-stop to respond to the list of outstanding issues that are to be adopted at the January meeting.

Action: For adoption

List of Questions adopted on 30.05.2024.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to the request by the applicant for an extension to the clock-stop to respond to the list of outstanding issues adopted at the January meeting.

3.2.3. [Diflunisal - Orphan - EMEA/H/C/006248](#)

AO Pharma AB; Treatment of ATTR amyloidosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 30.05.2024.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. [AMINO ACIDS - Orphan - EMEA/H/C/005557](#)

Recordati Rare Diseases; treatment of decompensation episodes in MSUD patients

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.01.2024.

The Committee was reminded of the status of this application and its remaining outstanding

issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. Ferric citrate coordination complex - EMEA/H/C/006402

treatment of iron deficiency anaemia in adult chronic kidney disease (CKD) patients with elevated serum phosphorus levels

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.07.2024.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. Vorasidenib - Orphan - EMEA/H/C/006284

Les Laboratoires Servier; treatment of predominantly non-enhancing astrocytoma or oligodendroglioma with a IDH1 R132 mutation or IDH2 R172 mutation

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 19.09.2024, 25.07.2024. List of Questions adopted on 23.04.2024.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

The Committee agreed to the request by the applicant for an extension to the clock stop to respond to the 3rd list of outstanding issues adopted in January 2025.

See 2.1

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. Denosumab - EMEA/H/C/006490

Treatment of osteoporosis in postmenopausal women and in men, treatment of bone loss associated with hormone ablation in men with prostate cancer and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

The CHMP agreed to consult the Methodology Working Party (MWP) and adopted a list of questions to this group.

3.3.2. Denosumab - EMEA/H/C/006722

prevention of skeletal related events with advanced malignancies

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to consult the Methodology Working Party (MWP) and adopted a list of questions to this group.

3.3.3. Nipocalimab - EMEA/H/C/006379

treatment of generalised Myasthenia Gravis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. Denosumab - EMEA/H/C/006238

treatment of osteoporosis and bone loss

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to consult the Methodology Working Party (MWP) and adopted a list of questions to this group.

3.3.5. Belumosudil - Orphan - EMEA/H/C/006421

Sanofi Winthrop Industrie; Treatment of chronic graft-versus host disease (cGVHD) disease (cGVHD) after failure of at least two prior lines of systemic therapy.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. [Rilonacept - Orphan - EMEA/H/C/006537](#)

FGK Representative Service GmbH; treatment of idiopathic pericarditis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. [Denosumab - EMEA/H/C/006552](#)

Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults and treatment of adults and skeletally mature adolescents with giant cell tumour of bone.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to consult the Methodology Working Party (MWP) and adopted a list of questions to this group.

3.4. [Update on on-going initial applications for Centralised procedure](#)

3.4.1. [Hydrocortisone - PUMA - EMEA/H/C/005201](#)

prevention of bronchopulmonary dysplasia in preterm infants born less than 28 weeks of gestation.

Scope: Request by the applicant for an extension to the clock-stop to respond to the list of questions adopted in December 2024.

Action: For adoption

List of Questions adopted on 12.12.2024.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in December 2024.

3.4.2. [Nirogacestat - Orphan - EMEA/H/C/006071](#)

Springworks Therapeutics Ireland Limited; treatment of desmoid tumours

Scope: Request by the applicant for an extension to the clock-stop to respond to the list of outstanding issues adopted in December 2024.

Action: For adoption

List of Outstanding Issues adopted on 12.12.2024. List of Questions adopted on 27.06.2024.

The CHMP agreed in its January PROM meeting to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in December 2024.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Kizfizo - Temozolomide - Orphan - EMEA/H/C/006169

Orphelia Pharma; treatment of neuroblastoma

Scope: Re-examination; Questions to the SAG

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

Opinion adopted on 14.11.2024. List of Outstanding Issues adopted on 27.06.2024. List of Questions adopted on 14.12.2023.

The CHMP adopted the list of questions to the SAG.

3.5.2. CINAINU - Liquid ethanolic extract 30 per cent (W/W) of *Allium cepa* fresh bulb and *Citrus limon* fresh fruit / Dry aqueous extract of *paullinia cupana* seed / Dry hydroethanolic extract of *theobroma cacao* seed - EMEA/H/C/004155

Legacy Healthcare (France) S.A.S.; treatment of alopecia areata in children and adolescents

Scope: Re-examination; Questions to the AHEG

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 14.11.2024. List of Outstanding Issues adopted on 27.06.2024. List of Questions adopted on 12.10.2023.

The CHMP adopted the list of questions to the ad-hoc expert group (AHEG).

3.6. Initial applications in the decision-making phase

3.6.1. Wainzua - Eplontersen - Orphan - EMEA/H/C/006295

AstraZeneca AB; treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.

Scope: Revised similarity assessment report

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 17.10.2024. List of Outstanding Issues adopted on 25.07.2024. List of Questions adopted on 22.02.2024.

The CHMP adopted the revised similarity assessment report.

3.6.2. [Osenvelt - Denosumab - EMEA/H/C/006157](#)

Celltrion Healthcare Hungary Kft.; prevention of skeletal related events with advanced malignancies

Scope: Updated assessment report

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Opinion adopted on 12.12.2024. List of Outstanding Issues adopted on 14.11.2024. List of Questions adopted on 25.07.2024.

The CHMP adopted the updated assessment report.

3.6.3. [LEQEMBI - Lecanemab - EMEA/H/C/005966](#)

Eisai GmbH; a disease modifying treatment in adult patients with Mild Cognitive Impairment due to Alzheimer's disease and Mild Alzheimer's disease (Early Alzheimer's disease)

Scope: Update on the procedure

Action: For discussion

New active substance (Article 8(3) of Directive No 2001/83/EC)

As part of its decision-making process, the European Commission has asked the CHMP to consider information on the safety of Leqembi that became available after the adoption of the CHMP opinion in November 2024 and whether this may require an update of the opinion. The EC also asked the CHMP to consider whether the wording of the risk minimisation measures in Annex II of the opinion is clear enough to ensure correct implementation. The CHMP will now consider the Commission's request and provide a response after its plenary meeting in February.

3.7. [Withdrawals of initial marketing authorisation application](#)

3.7.1. [Datopotamab deruxtecan Daiichi Sankyo Datopotamab deruxtecan - EMEA/H/C/006081](#)

Daiichi Sankyo Europe GmbH; treatment of adult patients with locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC)

Scope: Withdrawal of marketing authorisation application

Action: For information

List of Outstanding Issues adopted on 14.11.2024. List of Questions adopted on 27.06.2024.

The CHMP noted the withdrawal of marketing authorisation application.

3.7.2. [Nugalviq - Govorestat - Orphan - EMEA/H/C/006270](#)

Advanz Pharma Limited; treatment of adults and children aged 2 years and older with a confirmed diagnosis of classic galactosemia

Scope: Withdrawal of marketing authorisation application.

Action: For adoption

List of Questions adopted on 25.04.2024.

The CHMP noted the withdrawal of the marketing authorisation application.

4. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008**

4.1. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion**

4.1.1. [Rybrevant - Amivantamab - EMEA/H/C/005454/X/0014](#)

Janssen-Cilag International N.V.;

Rapporteur: Filip Josephson, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection), two new strengths of 1600 mg and 2240 mg (160 mg/ml concentration) and a new route of administration (subcutaneous use)."

Action: For adoption

List of Questions adopted on 17.10.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

4.1.2. [Taltz - Ixekizumab - EMEA/H/C/003943/X/0051](#)

Eli Lilly and Co (Ireland) Limited;

Rapporteur: Kristina Dunder

Scope: "Extension application to add a new strength of 40 mg for Taltz, Solution for injection"

Action: For adoption

List of Questions adopted on 17.10.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendation dated 29 January 2025

The summary of opinion was circulated for information.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. OPDIVO - Nivolumab - EMEA/H/C/003985/X/0144

Bristol-Myers Squibb Pharma EEIG;

Rapporteur: Antonio Gomez-Outes, PRAC Rapporteur: Gabriele Maurer

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection), a new strength (600 mg) and a new route of administration (subcutaneous use). Version 40.0 of the RMP has also been submitted."

Action: For adoption

List of Questions adopted on 17.10.2024.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.2. Evrysdi - Risdiplam - EMEA/H/C/005145/X/0024/G

Roche Registration GmbH;

Rapporteur: Fátima Ventura

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (5 mg film-coated tablets) grouped with a Type II variation (C.I.4) to update sections 4.2 and 5.2 of the SmPC in order to update the recommended method of administration based on the food effect results from study BP42066; this is a phase 1, open-label, multiperiod crossover study to investigate the safety, food effect, bioavailability, and bioequivalence of oral doses of two different formulations of risdiplam in healthy subjects. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the Product Information and to align the Package Leaflets of both formulations."

Action: For adoption

List of Questions adopted on 19.09.2024.

The Committee discussed the issues identified in this application relating to quality aspects and the SmPC.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of outstanding issues and a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Jivi - Damoctocog alfa pegol - EMEA/H/C/004054/X/0033/G

Bayer AG;

Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Bianca Mulder

Scope: "Extension application to add a new strength of Jivi 4000 UI powder and solvent for solution for injection for treatment and prophylaxis of bleeding in previously treated patients \geq 12 years of age with haemophilia A (congenital factor VIII deficiency). Version 3.1 of the RMP has also been submitted.

In addition, the MAH has taken the opportunity to align the product information with the pre-specified language from the updated EC Excipient Guideline.

Action: For adoption

The Committee discussed the issues identified in this application relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Abrysvo - Respiratory syncytial virus vaccine (bivalent, recombinant) - EMEA/H/C/006027/II/0007

Pfizer Europe Ma EEIG;

Rapporteur: Jayne Crowe, Co-Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Liana Martirosyan

Scope: "Extension of indication to include active immunization of individuals 18 through 59 years of age for ABRYSV0, based on final results from C3671023 Substudy A; this is a Phase 3 double-blinded, randomised, placebo-controlled study of safety, tolerability and immunogenicity of Abrysvo in participants ≥ 18 to < 60 years of age at high risk of severe RSV disease due to certain chronic medical conditions. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. Furthermore, as part of the application the MAH is requesting a 1-year extension of the market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 12.12.2024, 19.09.2024.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.2. [Amvuttra - Vutrisiran - Orphan - EMEA/H/C/005852/II/0015](#)

Alnylam Netherlands B.V.;

Rapporteur: Janet Koenig, Co-Rapporteur: Fátima Ventura, PRAC Rapporteur: Liana Martirosyan

Scope: "Extension of indication to include treatment of wild-type or hereditary transthyretin-mediated amyloidosis in adult patients with cardiomyopathy (ATTR-CM), based on primary analysis results from study HELIOS-B (ALN-TTRSC02-003); a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. An updated version 1.3 of the RMP has also been submitted. As part of the application the MAH applied for +1 year of additional market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. [Breyanzi - Lisocabtagene maraleucel / Lisocabtagene maraleucel - ATMP - EMEA/H/C/004731/II/0043/G](#)

Bristol-Myers Squibb Pharma EEIG;

Rapporteur: Concetta Quintarelli, PRAC Rapporteur: Gabriele Maurer, CHMP Coordinator: Paolo Gasparini

Scope: "A grouped application consisting of:

C.I.6 (Type II): Extension of indication for Breyanzi to include treatment of adult patients with 3rd line + follicular lymphoma (FL) based on final results from the pivotal study JCAR017-FOL-001 (FOL-001, TRANSCEND-FL). This is a phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with relapsed or refractory (r/r) follicular Lymphoma (FL) or marginal zone lymphoma (MZL). As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.1 of the RMP has been submitted.

The group of variations leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

Action: For adoption

Request for Supplementary Information adopted on 08.11.2024.

The CHMP was updated on discussions at CAT.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the draft opinion from CAT the CHMP adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.4. Calquence - Acalabrutinib - EMEA/H/C/005299/II/0028

AstraZeneca AB;

Rapporteur: Filip Josephson, PRAC Rapporteur: Barbara Kovacic Bytyqi

Scope: "Extension of indication to include CALQUENCE in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL), based on interim results from study AMPLIFY (D8221C00001). This is a Randomized, Multicentre, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukaemia Without del(17p) or TP53 Mutation (AMPLIFY). As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.5. Columvi - Glofitamab - Orphan - EMEA/H/C/005751/II/0005

Roche Registration GmbH;

Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Jana Lukacisinova

Scope: "Extension of indication to include in combination with gemcitabine and oxaliplatin

the treatment of adult patients with relapse or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT) for COLUMVI, based on results of primary and updated analyses from study GO41944 (STARGLO) listed as a Specific Obligation in the Annex II of the Product Information, as well supportive data from the Phase Ib study GO41943. Study GO41944 (STARGLO) is a Phase III, open-label, multicentre, randomised study of glofitamab in combination with GemOx (Glofit-GemOx) vs. rituximab in combination with GemOx (R-GemOx) in patients with R/R DLBCL. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet. As part of the application, the MAH is requesting a 1-year extension of the market protection.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 14.11.2024.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.6. Cystadrops - Mercaptamine - Orphan - EMEA/H/C/003769/II/0032

Recordati Rare Diseases;

Rapporteur: Kristina Dunder, PRAC Rapporteur: Maria del Pilar Rayon

Scope: “Extension of indication to include treatment of children from 6 months of age for CYSTADROPS, based on final results from study CYT-C2-001. This is an Open-label, Single-arm, Multicentre Study to Assess the Safety of Cystadrops in Paediatric Cystinosis Patients from 6 Months to Less Than 2 Years Old. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II of the PI and the list of local representatives in the Package Leaflet.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.7. Dapivirine Vaginal Ring 25 mg - Dapivirine - EMEA/H/W/002168/II/0027

International Partnership for Microbicides Belgium AISBL;

Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Jan Neuhauser

Scope: “Extension of indication to include reducing the risk of HIV-1 infection via vaginal intercourse in HIV-uninfected women 16 years and older for Dapivirine Vaginal Ring 25 mg, based on final results from study MTN-034 (REACH) listed as a category 3 study in the RMP; this is a Phase 2a crossover trial evaluating the safety of and adherence to a vaginal matrix

ring containing dapivirine and oral emtricitabine/tenofovir disoproxil fumarate in an adolescent and young adult female population. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 1.5 of the RMP has also been submitted.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. [Darzalex - Daratumumab - Orphan - EMEA/H/C/004077/II/0076](#)

Janssen-Cilag International N.V.;

Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Carla Torre

Scope: “Extension of indication for Darzalex in combination with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma, to include also adult patients who are not eligible for stem cell transplant (SCT), based on the results of the final PFS analysis from Study CEPHEUS (54767414MMY3019), a randomised, open-label, active-controlled, multicentre phase 3 study in adult participants, comparing the clinical outcome of D-VRd with VRd in participants with untreated multiple myeloma for whom stem cell transplant is not planned as initial therapy, in terms of the primary endpoint of MRD negativity rate in participants with CR or better rate and major secondary endpoints of CR or better rate, PFS and sustained MRD negativity.

As a consequence, SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 are updated and the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the contact details of the local representatives in the Package Leaflet.

An updated RMP version 11.1 has also been submitted.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.9. [Dupixent - Dupilumab - EMEA/H/C/004390/II/0083](#)

Sanofi Winthrop Industrie;

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola

Scope: “Extension of indication to include treatment of moderate to severe chronic spontaneous urticaria in adults and adolescents 12 years and older, who are symptomatic despite treatment with H1 antihistamines and who are intolerant to or inadequately controlled by anti-IgE therapy for Dupixent, based on the results from studies EFC16461 (CUPID) study B (pivotal) and study A (supportive); EFC16461 Study B was a 24-week, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of dupilumab in adult and adolescent participants with CSU who remained symptomatic despite the use of H1-antihistamine and who were intolerant or incomplete responders to omalizumab and EFC16461 Study A was a 24-week, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of dupilumab in participants with CSU who remained symptomatic despite the use of H1-antihistamine and who were naïve to

omalizumab. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11.0 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 19.09.2024, 30.05.2024.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.10. FABHALTA - Iptacopan - Orphan - EMEA/H/C/005764/II/0001

Novartis Europharm Limited;

Rapporteur: Janet Koenig, PRAC Rapporteur: Lina Seibokiene

Scope: “Extension of indication to include, in combination with a renin-angiotensin system (RAS) inhibitor, the treatment of adult patients with complement 3 glomerulopathy (C3G) for FABHALTA, based on interim analysis results from study CLNP023B12301 (APPEAR-C3G) and supported by additional evidence of efficacy and safety data from Phase II study CLNP023X2202 (X2202) and Phase IIIb study CLNP023B12001B (C3G-REP). APPEAR-C3G is a Phase 3, multicentre, randomized, double-blind, parallel arm, placebo-controlled study to evaluate the efficacy and safety of iptacopan in patients with C3G. The study included a 6-month blinded, placebo-controlled period, followed by a 6-month period in which all patients receive open-label iptacopan (total study duration of 12 months). As a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8 and 5.1 of the SmPC are being updated. The Annex II and Package Leaflet are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024.

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.11. Hetlitz - Tasimelteon - Orphan - EMEA/H/C/003870/II/0040

Vanda Pharmaceuticals Netherlands B.V.;

Rapporteur: Jayne Crowe, PRAC Rapporteur: Adam Przybylowski

Scope: “Extension of indication to include the treatment of nighttime sleep disturbances in adults with Smith Magenis Syndrome (SMS) for HETLITZ, based on results from study VP-VEC-162-2401. This is a double-blind, randomised, two-period crossover study evaluating the effects of tasimelteon vs. placebo on sleep disturbances of individuals with Smith-Magenis Syndrome (SMS). As a consequence, sections 4.1, 4.5, 5.1, 5.2 and 5.3 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. The RMP version 5.0 has also been submitted. Furthermore, the PI is brought in line with the latest

QRD template version 10.4. As part of the application, the MAH is requesting a 1-year extension of the market protection.”

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.12. [Imfinzi - Durvalumab - EMEA/H/C/004771/II/0069](#)

AstraZeneca AB;

Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: David Olsen

Scope: “Extension of indication to include treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy for IMFINZI, based on final results from study D933QC00001 (ADRIATIC); this is a phase III, randomized, double-blind, placebo-controlled, multi-centre, global study to assess the efficacy and safety of durvalumab monotherapy and durvalumab in combination with tremelimumab compared to placebo as consolidation treatment in patients with LS-SCLC whose disease had not progressed following definitive platinum-based chemoradiation therapy (ADRIATIC). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 12, 1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to implement editorial changes to Annex II. Furthermore, the PI is brought in line with the latest QRD template version 10.4.”

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.13. [Imfinzi - Durvalumab - EMEA/H/C/004771/II/0073](#)

AstraZeneca AB;

Rapporteur: Boje Kvorning Pires Ehmsen, Co-Rapporteur: Antonio Gomez-Outes, PRAC Rapporteur: David Olsen

Scope: “Extension of indication to include IMFINZI in combination with cisplatin-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy adjuvant treatment after radical cystectomy, for the treatment of adults with muscle invasive bladder cancer (MIBC), based on an ongoing pivotal study D933RC00001 (NIAGARA); this is a

phase 3, randomized, open-label, multi-centre, global study to determine the efficacy and safety of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. The RMP version 13 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes and update the PI according to the Excipients Guideline.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.14. Jaypirca - Pirtobrutinib - EMEA/H/C/005863/II/0002

Eli Lilly Nederland B.V.;

Rapporteur: Alexandre Moreau, Co-Rapporteur: Edward Laane, PRAC Rapporteur: Bianca Mulder

Scope: “Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor for JAYPIRCA, based on interim results from study LOXO-BTK-20020 (BRUIN CLL-321); this is a phase 3 open-label, randomized study of LOXO-305 versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated CLL/SLL.

As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection.”

Request for 1 year of data exclusivity for a new indication (Article 10(5) of Directive 2001/83/EC)

Action: For adoption

Request for Supplementary Information adopted on 27.06.2024.

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.15. Jivi - Damoctocog alfa pegol - EMEA/H/C/004054/II/0034

Bayer AG;

Rapporteur: Boje Kvorning Pires Ehmsen, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Bianca Mulder

Scope: “Extension of indication to include treatment and prophylaxis of bleeding in previously treated patients ≥ 7 years of age with haemophilia A for JIVI, based on integrated analysis results from Part A of the Alfa-PROTECT study (21824) and PROTECT Kids main study (15912). Alfa-PROTECT is a Phase 3, single-group treatment, open-label study to

evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe haemophilia A. PROTECT Kids is a multi-centre, Phase 3, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated children (age <12 years) with severe haemophilia A. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.4.”

Action: For adoption

The Committee discussed the issues identified in this application relating to non-clinical, clinical and the RMP aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.16. NUBEQA - Darolutamide - EMEA/H/C/004790/II/0024

Bayer AG;

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Jan Neuhauser

Scope: “Extension of indication to include in combination with androgen deprivation therapy (ADT) the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) for NUBEQA, based on final results from study 21140 (ARANOTE); this is a randomized, double-blind, placebo-controlled Phase 3 study of darolutamide to demonstrate the superiority of darolutamide in addition to ADT over placebo plus ADT in patients with mHSPC. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI and update the Package Leaflet to more patient friendly wording based on patient council feedback.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. RINVOQ - Upadacitinib - EMEA/H/C/004760/II/0056

AbbVie Deutschland GmbH & Co. KG;

Rapporteur: Kristina Dunder, PRAC Rapporteur: Petar Mas

Scope: “Extension of indication to include treatment of giant cell arteritis (GCA) in adult patients for RINVOQ based on final results from study M16-852. This is a phase 3, global, multicentre, randomized, double-blind, PBO-controlled study evaluating the efficacy and safety of upadacitinib in subjects with GCA. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 15.0 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.18. Ronapreve - Casirivimab / Imdevimab - EMEA/H/C/005814/II/0017

Roche Registration GmbH;

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Mari Thorn

Scope: "Extension of indication to include treatment of paediatric patients from 2 to less than 12 years old, weighing at least 10kg, who do not require supplemental oxygen and who are at increased risk of progression to severe COVID-19 for Ronapreve, based on final results from study COV-2067; this was a seamless, adaptive, Phase 3, randomised, double-blinded, placebo-controlled, multi-centre study to evaluate the efficacy, safety, and tolerability of casirivimab+imdevimab combination therapy in paediatric and adult outpatients with mild to moderate COVID-19. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. A revised RMP version 4.1 has also been approved.

In addition, the MAH took the opportunity to bring the PI of both strengths in line with the current QRD template version 10.4, Annex of the excipient's guideline."

Action: For adoption

Request for Supplementary Information adopted on 14.11.2024, 30.05.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.19. RXULTI - Brexpiprazole - EMEA/H/C/003841/II/0015

Otsuka Pharmaceutical Netherlands B.V.;

Rapporteur: Paolo Gasparini, PRAC Rapporteur: Miroslava Gocova

Scope: "Extension of indication to include treatment of schizophrenia in adolescent patients aged from 13 years to 17 years for RXULTI, based on results from the following clinical studies: one phase 1 dose-escalation trial (Trial 331-10-233) and two phase 3 clinical trials (Trial 331-10-234 and ongoing Trial 331-10-236). In addition, a paediatric extrapolation study was completed (Study 331-201-00185). These studies investigated the efficacy and safety of brexpiprazole in paediatric patients (13-17 years old) with schizophrenia. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet, and to bring the PI in line with the latest QRD template version 10.4."

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.20. Sivextro - Tedizolid phosphate - EMEA/H/C/002846/II/0054

Merck Sharp & Dohme B.V.;

Rapporteur: Fátima Ventura, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication to include treatment of paediatric patients aged from birth to less than 12 years for SIVEXTRO, based on final results from studies MK-1986-013, MK-1986-014 and MK-1986-018. MK-1986-013 is a single-dose trial to evaluate pharmacokinetics (PK) and safety of oral and intravenous (IV) administration of tedizolid phosphate in patients from 2 years to <12 years of age; MK-1986-014 is an open-label, multicentre, 2-part, single and multiple dose study to assess the PK of tedizolid phosphate and its active metabolite, tedizolid, and the safety of tedizolid phosphate following single and multiple dose IV and single oral dose. MK-1986-018 is a randomised, active controlled, investigator-blind, multicentre trial to evaluate safety and efficacy in patients from birth to less than 12 years of age; As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to implement minor editorial corrections."

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.21. Slenyto - Melatonin - EMEA/H/C/004425/II/0028

RAD Neurim Pharmaceuticals EEC SARL;

Rapporteur: Kristina Dunder, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include treatment of insomnia in children and adolescents aged 2-18 with Attention-Deficit Hyperactivity Disorder (ADHD), where sleep hygiene measures have been insufficient, based on results from phase III study NEU_CH_7911 and literature. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package

Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 19.09.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.22. [Stelara - Ustekinumab - EMEA/H/C/000958/II/0108](#)

Janssen-Cilag International N.V.;

Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald

Scope: “Extension of indication to include treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy or have medical contraindications to such therapies for STELARA, based on final results from study CNTO1275CRD3004. This is a Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment Followed by Randomized Double blind Subcutaneous Ustekinumab Maintenance in Paediatric Participants with Moderately to Severely Active Crohn's Disease. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 29.1 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024.

The Committee discussed the issues identified in this application relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.23. [Tevimbra - Tislelizumab - EMEA/H/C/005919/II/0016](#)

Beigene Ireland Limited;

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder

Scope: “Extension of indication to include first-line treatment of adult patients with extensive-stage Small Cell Lung Cancer (SCLC) for Tevimbra in combination with etoposide and platinum chemotherapy based on final results from study BGB-A317-312; a phase 3, randomized, double-blind, placebo-controlled study of platinum plus etoposide with or without tislelizumab in patients with untreated extensive-stage small cell lung cancer. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The MAH also took the opportunity to make editorial changes to the SmPC, Annex II and Package Leaflet.

The supportive studies BGB-A317-309 and BGB-A317-315 are provided for the purpose of updating the safety data package as well as updated data (latest CSR versions with new

data cut-off) from the monotherapy pool (tisnelizumab used at 200mg Q3W) consisting of the studies 001, 102, 203, 204, 208, 209, 301, 302, and 303 and from the combination with chemotherapy pool consisting of the studies 205, 206, 304, 305, 306, 307 and 312. Version 2.4 of the RMP has also been submitted.”

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.24. [Vyvgart - Efgartigimod alfa - Orphan - EMEA/H/C/005849/II/0020](#)

Argenx;

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Rhea Fitzgerald

Scope: “Extension of indication to include the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) with active disease despite treatment with corticosteroids or immunoglobulins for VYVGART, based on final results from study ARGX-113-1802; this is a pivotal study to investigate the efficacy, safety and tolerability of efgartigimod PH20 SC in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP); and based on interim results from study ARGX-113-1902; this is an open-label extension study of the ARGX-113-1802 trial to investigate the long-term safety, tolerability and efficacy of efgartigimod PH20 SC in patients with (CIDP).

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC has been updated. The Package Leaflet has been updated in accordance with the SmPC. In addition, the MAH took the opportunity to implement editorial changes to the SmPC.”

Action: For adoption

Request for Supplementary Information adopted on 19.09.2024.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.25. [WS2717](#) [OPDIVO - Nivolumab - EMEA/H/C/003985/WS2717/0146](#) [Yervoy - Ipilimumab - EMEA/H/C/002213/WS2717/0115](#)

Bristol-Myers Squibb Pharma EEIG;

Lead Rapporteur: Antonio Gomez-Outes, PRAC Rapporteur: Bianca Mulder

Scope: “A Worksharing application for OPDIVO and YERVOY, as follows:

Extension of indication to include a new indication for OPDIVO in combination with ipilimumab as first line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC) based on study CA2099DW. This is a phase 3 randomised, multi-centre, open label study of Nivolumab in combination with Ipilimumab compared to Sorafenib or Lenvatinib as first-line treatment in participants with advanced HCC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 41.0 of the RMP has also been submitted.

Extension of indication to include a new indication for YERVOY in combination with

ipilimumab as first line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC) based on study CA2099DW. This is a phase 3 randomised, multi-centre, open label study of Nivolumab in combination with Ipilimumab compared to Sorafenib or Lenvatinib as first-line treatment in participants with advanced HCC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 44.0 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP noted the letter of recommendation dated 29 January 2025.

The summary of opinion was circulated for information.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

6.1.1. Human serum albumin - EMEA/H/D/006611

use in Assisted Reproductive Technologies (ART)

Scope: Day 120 list of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a request for supplementary information with a specific timetable.

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. In vitro diagnostic medical device - EMEA/H/D/006648

use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) tissue, using EnVision FLEX visualization system on Dako Omnis

Scope: List of Questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a List of questions with a specific timetable.

6.3.2. In vitro diagnostic medical device - EMEA/H/D/006668

to detect EGFR mutations in FFPE tissue from adult patients diagnosed with non-small cell lung cancer (NSCLC)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a list of questions with a specific timetable.

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. Linerixibat – H0006241

indicated for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC)

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.2. [Tovorafenib - H0006140](#)

indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have received one or more prior systemic therapies

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.3. [Lenacapavir – H0006659](#)

Use for pre-exposure prophylaxis to prevent sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.4. [Lenacapavir – H0006658](#)

Use for pre-exposure prophylaxis to prevent sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.5. [Plozasiran – Orphan - H0006579](#)

Arrowhead Pharmaceuticals Ireland Limited; is indicated as an adjunct to diet to reduce triglyceride levels in patients with familial chylomicronemia syndrome (FCS).

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated

assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

The CHMP adopted the recommendations for PRIME eligibility.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website, in the PRIME homepage, under Outcome of eligibility section.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. [Ngenla - Somatrogen - Orphan - EMEA/H/C/005633/II/0016](#)

Pfizer Europe MA EEIG;

Rapporteur: Finbarr Leacy, PRAC Rapporteur: Liana Martirosyan

Scope: Withdrawal of extension of indication application

Action: For information

Request for Supplementary Information adopted on 19.09.2024.

The CHMP noted the withdrawal of indication application.

9.1.2. [Zeposia - Ozanimod - EMEA/H/C/004835/R/0028](#)

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Fátima Ventura, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Maria del Pilar Rayon

Scope: Renewal of Marketing Authorisation for unlimited validity

Action: For adoption

Request for Supplementary Information adopted on 14.11.2024.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

9.1.3. Grastofil – Filgrastim – EMEA/H/C/002150

Accord Healthcare S.L.U.

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Sol Ruiz

Scope: Withdrawal of Marketing Authorisation due to commercial reasons

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

9.1.4. FILSPARI - Sparsentan - EMEA/H/C/005783/II/0002, Orphan

Vifor France

Rapporteur: Vilma Petrikaite, PRAC Rapporteur: Martin Huber

Scope: "Update of sections 4.8, and 5.1 of the SmPC in order to amend the frequency of the adverse drug reactions (ADRs) based on final results from study 021IGAN17001 (PROTECT) listed as a specific obligation in the Annex II; this is a randomized, multicentre, double-blind parallel-group, active control study of the efficacy and safety of sparsentan for the treatment of immunoglobulin A nephropathy. The Package Leaflet is updated accordingly. The RMP version 1.0 has also been submitted. In addition, the MAH took the opportunity to update Annex II and to bring the PI in line with the latest QRD template version 10.4. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation."

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.5. Helicobacter Test INFAI - 13C-Urea - EMEA/H/C/000140/II/0028

Infai GmbH

Rapporteur: Christian Gartner

Scope: "Update of sections 4.2, 4.3 and 5.1 of the SmPC in order to modify administration instructions and to add a new contraindication based on final results from study HPT30/J/17; this is a single-group, observer-blind, multi-centre study to quantify the sensitivity and specificity of the 13C-UBT using the new test meal for Hp in patients with dyspepsia and GERD taking PPI. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update section 6.6 of the SmPC."

Action: For adoption

Request for Supplementary Information adopted on 17.10.2024, 30.05.2024.

The CHMP adopted a negative opinion by consensus, recommending the refusal of the variation to the terms of the marketing authorisation.

See 2.3

9.1.6. Elfabrio - Pegunigalsidase alfa - EMEA/H/C/005618/II/0007

Chiesi Farmaceutici S.p.A.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Liana Martirosyan

Scope: "Update of sections 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC in order to introduce an alternative posology regimen based on results from study PB-102-F50 (BRIGHT) and interim results from its extension study CLI-06657AA1-03 (formerly presented as PB-102-F51), as well as results of the observational patient reporting outcome study CLI-06657AA1-05. CLI-06657AA1-03 is an Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102)2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease. The Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.4."

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.7. Comirnaty - COVID-19 mRNA vaccine - EMA/VR/0000237985

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "A grouped application consisting of:

C.I.4: Update of sections 4.5 and 4.8 of the SmPC in order to update information regarding concomitant administration of Comirnaty with an unadjuvanted recombinant prefusion-F-protein RSV-vaccine based on final results from study C5481001 sub-study A; this is a Phase 1/2 sub-study aimed to evaluate the safety, tolerability and immunogenicity of combined vaccine candidate(s) against infectious respiratory illnesses, including COVID-19 and RSV, in adults 65 years of age and older. The Package Leaflet is updated accordingly.

C.I.4: Update of sections 4.5 and 4.8 of the SmPC in order to update information regarding concomitant administration of Comirnaty with conjugate pneumococcal vaccine based on final results from interventional study B7471026; this is a Phase 3, randomised, double-blind study aimed to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when co-administered with a booster dose of Comirnaty in adults 65 years of age and older. The Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

9.1.8. Penbraya - Meningococcal groups A, C, W,Y conjugate and group B vaccine (recombinant, adsorbed) - EMEA/H/C/006165

Pfizer Europe MA EEIG; indicated for active immunisation to prevent invasive disease caused by *Neisseria meningitidis* groups A, B, C, W, and Y

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Jean-Michel Dogné

Scope: Withdrawal of marketing authorisation

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

The CHMP noted the withdrawal of the marketing authorisation.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

January 2025 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections.

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of

such inspections.

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections.

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections.

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Vote by Proxy

Sol Ruiz gave a proxy to Antonio Gomez-Outes for the whole meeting.

Thalia Marie Estrup Blicher gave a proxy to Margareta Bego for the whole meeting.

Simona Badoi gave a proxy to Carla Torre for the whole meeting.

Paolo Gasparini gave a proxy to Jan Mueller Berghaus for the whole meeting.

14.1.2. CHMP membership

The Chair welcomed Paulo Paixão as new alternate for Portugal and Katerina Savvidou as new alternate for Cyprus.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for January 2025.

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at January 2025 PDCO

Action: For information

Agenda of the PDCO meeting to be held on 28-31 January 2025.

Action: For information

The CHMP noted the information.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sean Barry, Vice-Chair: Andreea Barbu

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 13-16 January 2025. Table of conclusions

Action: For information

Scientific advice letters: Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.3. Election of Vice-Chair – Vaccines Working Party (VWP)

Following the call for nominations launched in December 2024, CHMP to elect the Vice-Chair from the candidates who submitted nominations.

Nomination(s) received

Action: For election

The CHMP elected Sol Ruiz as vice Chair of the Vaccines Working Party.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

14.9.1. CHMP Learnings

CHMP: Outi Mäki-Ikola

Collection, discussion and recording of CHMP learnings.

The CHMP noted the information.

15. Any other business

15.1. AOB topic

15.1.1. GIREX rules

Clock-stop extensions and feedback from GIREX

Action: For discussion

The CHMP noted the information.

15.1.2. Health Threats and ETF update

Health Threats and ETF update

Action: For information

The CHMP noted the information.

15.1.3. EMA feedback to the European Commission on the use of titanium dioxide as excipient in medicinal products – safety aspects

Feedback document to the European Commission adopted in December 2024 has been slightly amended and is re-tabled for information'.

Action: For information

The CHMP noted the information.

15.1.4. SAG mandate renewal and (re)nominations

Update of the renewal of SAG mandate/call for nomination of experts for the 5 therapeutic SAGs (Neurology, Oncology, Vaccines, Infectious Diseases and Cardiovascular Issues).

Action: For discussion

The CHMP discussed the SAG mandate renewals and (re)nominations.

CHMP was presented with the Draft List of candidates for the SAGs (SAG Oncology, SAG Cardiovascular, SAG Neurology, SAG Vaccines and SAG Infectious diseases) membership nominations.

CHMP adopted the SAG Oncology membership. The CHMP members were invited to send nominations for the Neurology, Vaccines, Infectious Diseases and Cardiovascular Issues SAGs until the next February meeting.

15.1.5. Primary biliary cholangitis therapies: an international consensus position on demonstrating treatment efficacy - conference

Consensus Conference with patronage from the main scientific societies in Hepatology that aims to integrate the current knowledge in endpoints for therapy management in PBC, the role of real world evidence, and to provide a new framework for ongoing and future clinical trials on 6 May 2025.

Action: For information

The CHMP noted the information on the upcoming conference.

16. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 27-30 January 2025 CHMP meeting, which was held in-person.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Bruno Sepodes	Chair	Portugal	No interests declared	
Daniela Philadelphy	Member	Austria	No interests declared	
Christian Gartner	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Lyubina Racheva Todorova	Member	Bulgaria	No interests declared	
Gergana Lazarova	Alternate	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Katerina Savvidou	Alternate	Cyprus	No interests declared	
Tomas Radimersky	Member	Czechia	No interests declared	
Petr Vrbata	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No interests declared	
Boje Kvorning Pires Ehmsen	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member (Vice-Chair)	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Janet Koenig	Member	Germany	No interests declared	
Martin Mengel	Alternate	Germany	No interests declared	
Aris Angelis	Member	Greece	No participation in discussion, final deliberations and voting on:	3.1.1. CAPVAXIVE - Pneumococcal polysaccharide conjugate vaccine (21-valent) - EMEA/H/C/006267 5.1.20. Sivextro - Tedizolid phosphate - EMEA/H/C/002846 /II/0054 3.6.1. Wainzua - Eplontersen - Orphan - EMEA/H/C/006295

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
				5.1.4. Calquence - Acalabrutinib - EMEA/H/C/005299/II/0028 5.1.12. Imfinzi - Durvalumab - EMEA/H/C/004771/II/0069 5.1.13. Imfinzi - Durvalumab - EMEA/H/C/004771/II/0073 4.3.1. Jivi - Damoctocog alfa pegol - EMEA/H/C/004054/X/0033/G 5.1.15. Jivi - Damoctocog alfa pegol - EMEA/H/C/004054/II/0034 5.1.16. NUBEQA - Darolutamide - EMEA/H/C/004790/II/0024 9.1.1. Ngenla - Somatrogen - Orphan - EMEA/H/C/005633/II/0016 3.1.8. Tivdak - Tisotumab vedotin - EMEA/H/C/005363 5.1.1. Abrysvo - Respiratory syncytial virus vaccine (bivalent, recombinant) - EMEA/H/C/006027/II/0007
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No restrictions applicable to this meeting	
Beata Maria Jakline Ullrich	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Hjalte Kristinsson	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Finbarr Leacy	Alternate	Ireland	No interests declared	
Paolo Gasparini	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Vilma Petrikaite	Member	Lithuania	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Larisa Gorobets	Alternate	Lithuania	No restrictions applicable to this meeting	
Alexandra Branchu	Alternate	Luxembourg	No participation in discussion, final deliberations and voting on:	5.1.9. Dupixent - Dupilumab - EMEA/H/C/004390 /II/0083 3.3.5. - Belumosudil - Orphan - EMEA/H/C/006421
John Joseph Borg	Member	Malta	No interests declared	
Peter Mol	Member	Netherlands	No interests declared	
Patrick Vrijlandt	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Fatima Ventura	Member	Portugal	No restrictions applicable to this meeting	
Paulo Paixão	Alternate	Portugal	No interests declared	
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Frantisek Drafi	Member	Slovakia	No interests declared	
Jana Klimasová	Alternate	Slovakia	No restrictions applicable to this meeting	
Andreja Kranjc	Alternate	Slovenia	No interests declared	
Antonio Gomez-Outes	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Bruno Delafont	Co-opted member	France	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Nikola Gejgušová	Expert	Slovakia	No interests declared	
Mona Kassem-Youssef	Expert	France	No interests declared	
Céline Jumeau	Expert	France	No interests declared	
Elsa Grangier	Expert	France	No interests declared	
Liora Brunel	Expert	France	No interests declared	
Brenda Holingue	Expert	France	No interests declared	
Riitta Niittyvuopio	Expert	Finland	No restrictions applicable to this meeting	
Karri Penttilä	Expert	Finland	No interests declared	
Elina Asikanius	Expert	Finland	No restrictions applicable to this meeting	
Tommi Nurminen	Expert	Finland	No interests declared	
Mário Coelho da Silva Rosa	Expert	Portugal	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Mirjam Hinterleitner	Expert	Austria	No interests declared	
Elisabeth Fürst	Expert	Austria	No interests declared	
Susanne Urach	Expert	Austria	No interests declared	
Bojana Divkovic	Expert	Austria	No interests declared	
Noha Iessa	Expert	WHO	No interests declared	
Eun Mi Kim	Expert	WHO	No interests declared	
Tereza Bažantová	Expert	Czech Republic	No interests declared	
Pavla Zemanová	Expert	Czech Republic	No interests declared	
Ingrid Schellens	Expert	Netherlands	No interests declared	
Mark van Bussel	Expert	Netherlands	No interests declared	
Christine (Kris) Siezen	Expert	Netherlands	No restrictions applicable to this meeting	
Xiaoyu Niu	Expert	Netherlands	No interests declared	
Yseult Brun	Expert	France	No interests declared	
Kubéraka Mariampillai	Expert	France	No interests declared	
Anne Isabel Roth	Expert	Germany	No interests declared	
Sofia Kapanadze	Expert	Germany	No interests declared	
Franziska Brandt	Expert	Germany	No interests declared	
Miriam Fürst-Wilmes	Expert	Germany	No interests declared	
Clemens Mittmann	Expert	Germany	No interests declared	
Sylvia Kühn	Expert	Germany	No restrictions applicable to this meeting	
Georgios Aislaitner	Expert	Germany	No interests declared	
Marion Haberkamp	Expert	Germany	No interests declared	
Andreas Brandt	Expert	Germany	No interests declared	
Magdalena Schilling	Expert	Germany	No interests declared	
Jo-Birger Schmeing	Expert	Germany	No restrictions applicable to this meeting	
Christiane Ehlers Mortensen	Expert	Denmark	No interests declared	
Kinga Nowicka-Matus	Expert	Denmark	No interests declared	
Torsten Nielsen	Expert	Denmark	No interests declared	
Jeanette McCallion	Expert	Ireland	No interests declared	
Paolo Foggi	Expert	Italy	No interests declared	
Anna Vikerfors	Expert	Sweden	No interests declared	
Elisabeth Wischnitzki	Expert	Austria	No interests declared	
Anders Lignell	Expert	Sweden	No interests declared	
Adriana Ammassari	Expert	Italy	No interests declared	
Karoline Buhre	Expert	Germany	No interests declared	
André Elferink	Expert	Netherlands	No interests declared	
Lukas Aguirre Dávila	Expert	Germany	No interests declared	
Frank Holtkamp	Expert	Netherlands	No interests declared	
René Thürmer	Expert	Germany	No interests declared	
Jörg Zinserling	Expert	Germany	No interests declared	
Andreas Brandt	Expert	Germany	No interests declared	
Benjamin Hofner	Expert	Germany	No restrictions applicable to this meeting	
Robert Pollmann	Expert	Germany	No interests declared	
Claudia Reichmann	Expert	Germany	No interests declared	
Hilke Zander	Expert	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ute Friedel	Expert	Germany	No participation in discussion, final deliberations and voting on:	4.1.3. Taltz - Ixekizumab - EMEA/H/C/003943/X/0051 5.1.14. Jaypirca - Pirtobrutinib - EMEA/H/C/005863/II/0002
Jörg Engelbergs	Expert	Germany	No interests declared	
Sara Tognarelli	Expert	Germany	No restrictions applicable to this meeting	
Olga Kholmanskikh	Expert	Belgium	No restrictions applicable to this meeting	
Joelle Warlin	Expert	Belgium	No restrictions applicable to this meeting	
Ana Rita Lemos	Expert	Portugal	No interests declared	
Macarena Gajardo Alvarez	Expert	Spain	No interests declared	
Ana María Imedio Carnicero	Expert	Spain	No interests declared	
Adriana Maria Den Harder	Expert	Netherlands	No restrictions applicable to this meeting	
Rosa Elisabeth Bot	Expert	Netherlands	No restrictions applicable to this meeting	
Johanna de Groot	Expert	Netherlands	No interests declared	
Penelope Gilberts	Expert	Netherlands	No interests declared	
Wesley Smith	Expert	Netherlands	No participation in discussion, final deliberations and voting on:	5.1.22. Stelara - Ustekinumab - EMEA/H/C/000958/II/0108 3.3.3. - Nipocalimab - EMEA/H/C/006379 4.1.2. Rybrevant - Amivantamab - EMEA/H/C/005454/X/0014 5.1.8. Darzalex - Daratumumab - Orphan - EMEA/H/C/004077/II/0076
Bastian Hornung	Expert	Netherlands	No interests declared	
Sabine Mayrhofer	Expert	Germany	No interests declared	
Christoph Furtmann	Expert	Germany	No interests declared	
Susanne Høpner Rasmussen	Expert	Denmark	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Meeting run with the help of EMA staff.				

Experts were evaluated against the agenda topics or activities they participated in.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section lists issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

30 January 2025
EMA/CHMP/40034/2025

Annex to 27-30 January 2025 CHMP Minutes

Pre-submission and post-authorisations issues

Note: Starting with January 2025, EMA is publishing in Excel format the CHMP agenda annex with the regulatory procedures handled in IRIS. This is a secure online platform for managing product-related scientific and regulatory procedures with EMA. This change follows the transition of the post-authorisation regulatory procedures to IRIS. It is also in the context of the digitalisation of EMA's activities, and will help facilitate data analysis.

A. PRE-SUBMISSION ISSUES	3
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications	3
B. POST-AUTHORISATION PROCEDURES OUTCOMES	3
B.1. Annual re-assessment outcomes	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES.....	3
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal	3
B.2.2. Renewals of Marketing Authorisations for unlimited validity.....	4
B.2.3. Renewals of Conditional Marketing Authorisations	6
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES.....	7
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES	13
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects	13
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects	23
B.5.3. CHMP-PRAC assessed procedures	37
B.5.4. PRAC assessed procedures.....	45
B.5.5. CHMP-CAT assessed procedures	49
B.5.6. CHMP-PRAC-CAT assessed procedures	50
B.5.7. PRAC assessed ATMP procedures	50
B.5.8. Unclassified procedures and worksharing procedures of type I variations	52
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION	54
B.6.1. Start of procedure for New Applications: timetables for information	54



B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information	56
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information.....	57
B.6.4. Annual Re-assessments: timetables for adoption	61
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed	62
B.6.6. VARIATIONS – START OF THE PROCEDURE.....	63
B.6.7. Type II Variations scope of the Variations: Extension of indication	63
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects	67
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects	71
B.6.10. CHMP-PRAC assessed procedures.....	78
B.6.11. PRAC assessed procedures	83
B.6.12. CHMP-CAT assessed procedures	88
B.6.13. CHMP-PRAC-CAT assessed procedures.....	89
B.6.14. PRAC assessed ATMP procedures	90
B.6.15. Unclassified procedures and worksharing procedures of type I variations	90
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES	92
E.1. PMF Certification Dossiers:.....	92
Time Tables – starting & ongoing procedures: For information	92
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver	92
G. ANNEX G.....	92
G.1. Final Scientific Advice (Reports and Scientific Advice letters):	92
G.2. PRIME.....	92

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for January 2025: For adoption	Adopted
--	---------

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for January 2025: For adoption	Adopted
--	---------

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Bylvay - Odevixibat - EMA/H/C/004691/S/0023, Orphan Ipsen Pharma, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report The Marketing Authorisation remains under exceptional circumstances.
Myalepta - Metreleptin - EMA/H/C/004218/S/0039, Orphan Chiesi Farmaceutici S.p.A., Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report The Marketing Authorisation remains under exceptional circumstances.
Zokinvy - Lonafarnib - EMA/H/C/005271/S/0012, Orphan TMC Pharma (EU) Limited, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report The Marketing Authorisation remains under exceptional circumstances.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

Xenleta - Lefamulin - EMA/H/C/005048/R/0010 Nabriva Therapeutics Ireland DAC, Rapporteur: Jayne Crowe, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Eva Jirsová	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that an additional five-year renewal was required.
---	---

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Bavencio - Avelumab - EMA/H/C/004338/R/0050 Merck Europe B.V., Rapporteur: Filip Josephson, Co-Rapporteur: Paolo Gasparini, PRAC Rapporteur: Karin Erneholm	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
BYANLI - Paliperidone - EMA/H/C/005486/R/0008 Janssen-Cilag International N.V., Informed Consent of Xeplion, Rapporteur: Kristina Dunder, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Karin Bolin	Positive Opinion adopted by consensus together with the CHMP assessment report. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Daurismo - Glasdegib - EMA/H/C/004878/R/0015, Orphan Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, Co-Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Bianca Mulder Request for Supplementary Information adopted on 12.12.2024.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Fingolimod Accord - Fingolimod - EMA/H/C/005191/R/0011 Accord Healthcare S.L.U., Generic of Gilenya, Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Tiphaine Vaillant	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Gencebok - Caffeine citrate - EMA/H/C/005435/R/0012 Gennisium Pharma, Rapporteur: Alar Irs, PRAC Rapporteur: Sonja Hrabcik	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Insulin aspart Sanofi - Insulin aspart - EMA/H/C/005033/R/0020 Sanofi Winthrop Industrie, Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Robert Porszasz, PRAC Rapporteur: Mari Thorn Request for Supplementary Information adopted on 30.01.2025.	Request for supplementary information adopted with a specific timetable.
Kaftrio - Ivacaftor / Tezacaftor / Elexacaftor - EMA/H/C/005269/R/0059,	Request for supplementary information adopted with a specific timetable.

Orphan

Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Peter Mol, Co-Rapporteur: Finbarr
Leacy, PRAC Rapporteur: Martin Huber

Request for Supplementary Information adopted
on 30.01.2025.

**LIVOGIVA - Teriparatide -
EMA/H/C/005087/R/0015**

Theramex Ireland Limited, Rapporteur:
Christian Gartner, Co-Rapporteur: Paolo
Gasparini, PRAC Rapporteur: Tiphaine Vaillant
Request for Supplementary Information adopted
on 30.01.2025.

Request for supplementary information adopted
with a specific timetable.

**MVABEA - Ebola vaccine (rDNA, replication-
incompetent) -
EMA/H/C/005343/R/0023**

Janssen-Cilag International N.V., Rapporteur:
Patrick Vrijlandt, Co-Rapporteur: Jean-Michel
Race, PRAC Rapporteur: Jean-Michel Dogné

Positive Opinion adopted by consensus together
with the CHMP assessment report and
translation timetable.

Based on the review of the available
information, the CHMP was of the opinion that
the renewal of the marketing authorisation can
be granted with unlimited validity.

**Zabdeno - Ebola vaccine (rDNA,
replication-incompetent) -
EMA/H/C/005337/R/0022**

Janssen-Cilag International N.V., Rapporteur:
Patrick Vrijlandt, Co-Rapporteur: Jean-Michel
Race, PRAC Rapporteur: Jean-Michel Dogné

Positive Opinion adopted by consensus together
with the CHMP assessment report and
translation timetable.

Based on the review of the available
information, the CHMP was of the opinion that
the renewal of the marketing authorisation can
be granted with unlimited validity.

**Zeposia - Ozanimod -
EMA/H/C/004835/R/0028**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Fátima Ventura, Co-Rapporteur: Janet Koenig,
PRAC Rapporteur: Maria del Pilar Rayon
Request for Supplementary Information adopted
on 14.11.2024.

The Committee confirmed that all issues
previously identified in this application had been
addressed.

The Committee adopted a positive opinion
recommending the granting of a marketing
authorisation by consensus, together with the
CHMP assessment report and translation
timetable.
Furthermore, the CHMP considered that INN is a
new active substance, as claimed by the
applicant.

**Zercepac - Trastuzumab -
EMA/H/C/005209/R/0039**

Accord Healthcare S.L.U., Rapporteur: Sol Ruiz,
Co-Rapporteur: Karin Janssen van Doorn, PRAC
Rapporteur: Gabriele Maurer

Positive Opinion adopted by consensus together
with the CHMP assessment report.

Based on the review of the available
information, the CHMP was of the opinion that
the renewal of the marketing authorisation can
be granted with unlimited validity.

B.2.3. Renewals of Conditional Marketing Authorisations

Deltyba - Delamanid - EMA/H/C/002552/R/0076, Orphan Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Jo Robays Request for Supplementary Information adopted on 14.11.2024.	Positive Opinion adopted by consensus together with the CHMP assessment report The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Incellipan - Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMA/H/C/006051/R/0002 Seqirus Netherlands B.V., Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Mari Thorn	Positive Opinion adopted by consensus together with the CHMP assessment report The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Lorviqua - Lorlatinib - EMA/H/C/004646/R/0040 Pfizer Europe MA EEIG, Rapporteur: Boje Kvorning Pires Ehmsen, Co-Rapporteur: Paolo Gasparini, PRAC Rapporteur: Barbara Kovacic Bytyqi Request for Supplementary Information adopted on 30.01.2025.	Request for supplementary information adopted with a specific timetable.
Ondexxya - Andexanet alfa - EMA/H/C/004108/R/0049 AstraZeneca AB, Rapporteur: Jan Mueller- Berghaus, Co-Rapporteur: Antonio Gomez- Outes, PRAC Rapporteur: Bianca Mulder	Positive Opinion adopted by consensus together with the CHMP assessment report The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
Pandemic influenza vaccine H5N1 AstraZeneca - Pandemic influenza vaccine (H5N1) (live attenuated, nasal) - EMA/H/C/003963/R/0074 AstraZeneca AB, Rapporteur: Jan Mueller- Berghaus, PRAC Rapporteur: Sonja Hrabcik	Positive Opinion adopted by consensus together with the CHMP assessment report The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
WAYLIVRA - Volanesorsen - EMA/H/C/004538/R/0029, Orphan Akcea Therapeutics Ireland Limited, Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Martin Huber	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted
on 30.01.2025.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Post-authorisation safety studies

PRAC recommendations on PASS results
adopted at the PRAC meeting held on 13-16
January 2025 PRAC:

Revlimid (CAP) - EMEA/H/C/PSR/S/0049 (lenalidomide)	Adopted
--	---------

PRAC Rapporteur: Tiphaine Vaillant

Scope: Annex II of the product information is
updated to remove PASS study CC-5013-MDS-
012, as the study has been concluded. A revised
RMP version 41.1 has been adopted.

PRAC recommendation to CHMP

Action: For adoption

Signal detection

PRAC recommendations on signals adopted at
the PRAC meeting held on 13-16 January 2025
PRAC:

Signal of tumour lysis syndrome	The CHMP adopted the PRAC recommendation.
--	---

lenvatinib – LENVIMA, KISPLYX (CAP)

Rapporteur: Karin Janssen van Doorn, Co-
Rapporteur: Kristina Dunder; Janet Koenig,
PRAC Rapporteur: Mari Thorn; David Olsen

PRAC recommendation on a variation

Action: For adoption

Signal of growth of eyelashes	The CHMP adopted the PRAC recommendation.
--------------------------------------	---

afatinib – GIOTRIF (CAP)

Rapporteur: Filip Josephson, Co-Rapporteur:
Antonio Gomez-Outes, PRAC Rapporteur: Mari
Thorn

PRAC recommendation on a variation

Action: For adoption

PSUR procedures for which PRAC adopted a
recommendation for variation of the terms of
the MA at its January 2025 meeting:

EMA/H/C/PSUSA/0000045/202406	The CHMP, having considered in accordance with
-------------------------------------	--

<p>(ublituximab) CAPS: Briumvi (EMA/H/C/005914) (Ublituximab), Neuraxpharm Pharmaceuticals S.L., Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Liana Martirosyan, "27/12/2023 To: 27/06/2024"</p>	<p>Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add the adverse reactions encephalitis/meningitis/meningoencephalitis with frequency 'Uncommon'. The Package leaflet is updated accordingly.</p>
<p>EMA/H/C/PSUSA/00000136/202406 (tislelizumab) CAPS: Tevimbra (EMA/H/C/005919) (Tislelizumab), Beigene Ireland Limited, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder, "25/12/2023 To: 25/06/2024"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of sections 4.4 and 4.8 to amend a warning/precaution regarding other-immune-related adverse reactions, add a warning/precaution regarding Haemophagocytic lymphohistiocytosis and add the adverse reactions Haemophagocytic lymphohistiocytosis and Cystitis noninfective. The Package leaflet is updated accordingly.</p>
<p>EMA/H/C/PSUSA/00000226/202405 (apixaban) CAPS: Elquis (EMA/H/C/002148) (Apixaban), Bristol-Myers Squibb / Pfizer EEIG, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Bianca Mulder, "18/05/2021 To: 17/05/2024"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add the adverse reaction "Anticoagulant-related nephropathy". For anticoagulant-related nephropathy, a frequency 'not known' is assigned by PRAC because it is based on spontaneous reporting. The Package leaflet is updated accordingly.</p>
<p>EMA/H/C/PSUSA/00000531/202404 (capecitabine) CAPS: Capecitabine Accord (EMA/H/C/002386)</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and</p>

<p>(Capecitabine), Accord Healthcare S.L.U., Rapporteur: Filip Josephson Capecitabine medac (EMA/H/C/002568) (Capecitabine), medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Filip Josephson Ecansya (EMA/H/C/002605) (Capecitabine), KRKA, d.d., Novo mesto, Rapporteur: Kristina Dunder Xeloda (EMA/H/C/000316) (Capecitabine), CHEPLAPHARM Arzneimittel GmbH, Rapporteur: Janet Koenig NAPS: NAPs - EU PRAC Rapporteur: Martin Huber, "30/04/2021 To: 29/04/2024"</p>	<p>the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):</p> <p>Update of section 4.4 of the SmPC to amend a warning on phenotyping for DPD deficiency.</p>
<p>EMA/H/C/PSUSA/00001692/202406 (hydroxycarbamide (for centrally authorised product only)) CAPS: Siklos (EMA/H/C/000689) (Hydroxycarbamide), Theravia, Rapporteur: Karin Janssen van Doorn Xromi (EMA/H/C/004837) (Hydroxycarbamide), Nova Laboratories Ireland Limited, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Jo Robays, "28/06/2023 To: 28/06/2024"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the maintenance of the terms of the marketing authorisation for Siklos and the variation to the terms of the marketing authorisation(s) for Xromi, concerning the following change(s):</p> <p>Update of section 4.5 of the SmPC / Package leaflet section 2. to add a warning/precaution regarding the risk of "Interference with Continuous Glucose Monitoring systems" has been proposed within the PSUSA procedure for Xromi, based on a wording already approved for Siklos after DLP of this PSUSA.</p>
<p>EMA/H/C/PSUSA/00001937/202405 (measles / mumps / rubella vaccines (live, attenuated)) CAPS: M-M-RvaxPro (EMA/H/C/000604) (Measles, mumps and rubella vaccine (live)), Merck Sharp & Dohme B.V., Rapporteur: Jan Mueller- Berghaus NAPS: NAPs - EU PRAC Rapporteur: Gabriele Maurer, "04/05/2021 To: 04/05/2024"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for Priorix, concerning the following change(s): Update of section 4.3 of the SmPC to amend the definition of contraindication in the presence of immunosuppression and update of section 4.6 of the SmPC to update the recommendations for use in pregnancy.</p>
<p>EMA/H/C/PSUSA/00010084/202405 (dabrafenib) CAPS:</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation</p>

Finlee (EMA/H/C/005885) (Dabrafenib),
Novartis Europharm Limited, Rapporteur: Filip Josephson

Tafinlar (EMA/H/C/002604) (Dabrafenib),
Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Mari Thorn,
"27/08/2022 To: 29/05/2024"

and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.4 of the SmPC to add a warning/precaution regarding Vogt-Koyanagi-Harada (VKH)-like uveitis. For Tafinlar an update of section 4.8 of the SmPC to add information that cases suggestive of VKH syndrome have been observed and for Finlee an update of section 4.8 to reflect that cases suggestive of VKH syndrome have been observed in adults are recommended. The RMP (Version 12.0) has also been updated to delete some of the safety concerns as considered sufficiently investigated and reflected in the relevant documents for routine pharmacovigilance.

EMA/H/C/PSUSA/00010186/202405

(vedolizumab)

CAPS:

Entyvio (EMA/H/C/002782) (Vedolizumab),
Takeda Pharma A/S, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Adam Przybylkowski, "19/05/2021 To: 19/05/2024"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s):

Update of section(s) 4.8 of the SmPC to add the adverse reaction "liver enzyme increased" with a frequency common and to add the adverse reaction "hepatitis" with frequency very rare. The Package leaflet is updated accordingly.

Update of section 4.4 of the SmPC to add the occurrence of hypersensitivity reactions after switching from SC to IV administration into the existing warning on this adverse drug reaction.

EMA/H/C/PSUSA/00010395/202405

(tolvaptan (indicated for adults with autosomal dominant polycystic kidney disease (ADPKD)))

CAPS:

Jinarc (EMA/H/C/002788) (Tolvaptan), Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Paolo Gasparini, PRAC Rapporteur: Amelia Cupelli, "17/05/2021 To: 17/05/2024"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction blood creatine phosphokinase increased with a frequency not known. The

	Package leaflet is updated accordingly.
EMA/H/C/PSUSA/00010644/202405 (attezolizumab) CAPS: Tecentriq (EMA/H/C/004143) (Atezolizumab), Roche Registration GmbH, Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Carla Torre, "18/05/2023 To: 17/05/2024"	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add the adverse reaction Lichen disorders under the SOC "Skin and subcutaneous tissue disorders" and to add the adverse reaction Colitis under the SOC "Gastrointestinal disorders". The Package leaflet is updated accordingly.</p>
EMA/H/C/PSUSA/00010848/202405 (onasemnogene abeparvovec) CAPS: Zolgensma (EMA/H/C/004750) (Onasemnogene abeparvovec), Novartis Europharm Limited, Rapporteur: Emmely de Vries, PRAC Rapporteur: Karin Bolin, "24/05/2023 To: 23/05/2024"	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p><i>Update of section 4.2 and 4.4 of the SmPC</i></p> <p>Update of section 4.2 and 4.4 to indicate that routine monitoring of Troponin-I levels is not indicated. Patient Leaflet is updated accordingly.</p> <p><i>Update of section 4.4 and 4.8 of the SmPC</i></p> <p>Update of section 4.4 and 4.8 to inform about the risk of infusion-related reactions, including anaphylactic reactions. Patient Leaflet is updated accordingly.</p>
EMA/H/C/PSUSA/00010852/202405 (ozanimod) CAPS: Zeposia (EMA/H/C/004835) (Ozanimod), Bristol-Myers Squibb Pharma EEIG, Rapporteur: Fátima Ventura, PRAC Rapporteur: Maria del Pilar Rayon, "20/05/2023 To: 19/05/2024"	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product, concerning the following change(s):</p> <p>Update of section(s) 4.4 of the SmPC to add a warning/precaution regarding IRIS syndrome after discontinuation of ozanimod due to PML. The Package leaflet is updated accordingly. Changes are also reflected in the annex II of the</p>

	product information as well as annex 6 of the RMP. The RMP is updated to version 10.3
EMA/H/C/PSUSA/00010874/202406 (entrectinib) CAPS: Rozlytrek (EMA/H/C/004936) (Entrectinib), Roche Registration GmbH, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Bianca Mulder, "18/12/2023 To: 17/06/2024"	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to myocarditis with a frequency uncommon. The Package leaflet is updated accordingly.</p>
EMA/H/C/PSUSA/00010894/202406 (trastuzumab deruxtecan) CAPS: Enhertu (EMA/H/C/005124) (Trastuzumab deruxtecan), Daiichi Sankyo Europe GmbH, Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Carla Torre, "20/12/2023 To: 19/06/2024"	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add the adverse reaction pancytopenia with a frequency common. The Package leaflet is updated accordingly</p>
EMA/H/C/PSUSA/00010905/202406 (latanoprost / netarsudil) CAPS: Roclanda (EMA/H/C/005107) (Latanoprost / Netarsudil), Santen Oy, Rapporteur: Jayne Crowe, PRAC Rapporteur: Adam Przybylkowski, "17/06/2023 To: 17/06/2024"	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.4 and 4.8 of the Summary of Product Characteristics to add the adverse reaction reticular epithelial corneal oedema with a frequency not known. The Package Leaflet is updated accordingly.</p>
EMA/H/C/PSUSA/00010907/202406 (fenfluramine) CAPS: Fintepla (EMA/H/C/003933) (Fenfluramine), UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "25/06/2023 To: 24/06/2024"	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended together with the detailed explanation of the scientific grounds for the differences with the PRAC recommendation, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above</p>

	<p>mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of sections 4.4 and 4.8 of the SmPC to amend the warning regarding VHD and to add VHD with a frequency 'not known' to the adverse reactions table. The Package leaflet is updated accordingly.</p> <p>Update of Annex IID - Additional risk minimisation measures and Annex IID – Obligation to conduct post-authorisation measures to reclassify the important potential risk of VHD to important identified risk.</p>
<p>EMA/H/C/PSUSA/00010955/202406 (roxadustat) CAPS: Evrenzo (EMA/H/C/004871) (Roxadustat), Astellas Pharma Europe B.V., Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Anna Mareková, "17/12/2023 To: 16/06/2024"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add the adverse reaction Thrombocytopenia with frequency common. The Package leaflet is updated accordingly.</p>
<p>EMA/H/C/PSUSA/00011014/202406 (efgartigimod alfa) CAPS: Vyvgart (EMA/H/C/005849) (Efgartigimod alfa), Argenx, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Rhea Fitzgerald, "16/12/2023 To: 16/06/2024"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC for the IV and SC formulation to add the adverse reaction nausea with a frequency of common. The Package leaflet is updated accordingly.</p>

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

<p>Abiraterone Accord - Abiraterone acetate - EMA/H/C/005408/II/0007 Accord Healthcare S.L.U., Generic of Zytiga,</p>	<p>Positive Opinion adopted by consensus on 23.01.2025.</p>
--	---

Rapporteur: Alar Irs

Opinion adopted on 23.01.2025.

**AJOVY - Fremanezumab -
EMA/H/C/004833/II/0052**

TEVA GmbH, Rapporteur: Jan Mueller-Berghaus
Request for Supplementary Information adopted
on 19.12.2024.

Request for supplementary information adopted
with a specific timetable.

**Alprolix - Eftrenonacog alfa -
EMA/H/C/004142/II/0048, Orphan**

Swedish Orphan Biovitrum AB (publ),
Rapporteur: Daniela Philadelphy
Request for Supplementary Information adopted
on 23.01.2025.

Request for supplementary information adopted
with a specific timetable.

**Amsparity - Adalimumab -
EMA/H/C/004879/II/0011**

Pfizer Europe MA EEIG, Rapporteur: Outi Mäki-
Ikola
Opinion adopted on 23.01.2025.

Positive Opinion adopted by consensus on
23.01.2025.

**Aptivus - Tipranavir -
EMA/H/C/000631/II/0096/G**

Boehringer Ingelheim International GmbH,
Rapporteur: Jean-Michel Race
Request for Supplementary Information adopted
on 19.12.2024.

Request for supplementary information adopted
with a specific timetable.

**Besremi - Ropeginterferon alfa-2b -
EMA/H/C/004128/II/0037**

AOP Orphan Pharmaceuticals GmbH,
Rapporteur: Janet Koenig
Opinion adopted on 19.12.2024.
Request for Supplementary Information adopted
on 14.11.2024.

Positive Opinion adopted by consensus on
19.12.2024.

**BIMERVAX - Covid-19 Vaccine
(recombinant, adjuvanted) -
EMA/H/C/006058/II/0018/G**

Hipra Human Health S.L., Rapporteur: Beata
Maria Jakline Ullrich

Request for supplementary information adopted
with a specific timetable.

**Brukinsa - Zanubrutinib -
EMA/H/C/004978/II/0026/G**

BeiGene Ireland Ltd, Rapporteur: Boje Kvorning
Pires Ehmsen
Request for Supplementary Information adopted
on 16.01.2025.

Request for supplementary information adopted
with a specific timetable.

**Champix - Varenicline -
EMA/H/C/000699/II/0085/G**

Pfizer Europe MA EEIG, Rapporteur: Thalia Marie

Request for supplementary information adopted
with a specific timetable.

Estrup Blicher
Request for Supplementary Information adopted
on 30.01.2025.

Entyvio - Vedolizumab - EMA/H/C/002782/II/0084/G Takeda Pharma A/S, Rapporteur: Paolo Gasparini Opinion adopted on 19.12.2024. Request for Supplementary Information adopted on 12.09.2024.	Positive Opinion adopted by consensus on 19.12.2024.
---	---

Epruvy - Ranibizumab - EMA/H/C/006528/II/0001/G MIDAS Pharma GmbH, Rapporteur: Jan Mueller- Berghaus Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
---	---

Flixabi - Infliximab - EMA/H/C/004020/II/0090/G Samsung Bioepis NL B.V., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 16.01.2025.	Request for supplementary information adopted with a specific timetable.
---	---

Fluad Tetra - Influenza vaccine (surface antigen, inactivated, adjuvanted) - EMA/H/C/004993/II/0056/G Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Opinion adopted on 16.01.2025. Request for Supplementary Information adopted on 05.12.2024.	Positive Opinion adopted by consensus on 16.01.2025.
---	---

Gardasil - Human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - EMA/H/C/000703/II/0107/G Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder Opinion adopted on 16.01.2025. Request for Supplementary Information adopted on 10.10.2024.	Positive Opinion adopted by consensus on 16.01.2025.
--	---

Gardasil 9 - Human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMA/H/C/003852/II/0077/G Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder Opinion adopted on 23.01.2025.	Positive Opinion adopted by consensus on 23.01.2025.
---	---

Herzuma - Trastuzumab - EMA/H/C/002575/II/0067/G Celltrion Healthcare Hungary Kft., Rapporteur:	Positive Opinion adopted by consensus on 30.01.2025
---	--

<p>Jan Mueller-Berghaus</p> <p>Opinion adopted on 30.01.2025.</p> <p>Request for Supplementary Information adopted on 19.12.2024.</p>	
<p>Hizentra - Human normal immunoglobulin - EMEA/H/C/002127/II/0161</p> <p>CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus</p> <p>Request for Supplementary Information adopted on 30.01.2025.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Ituxredi - Rituximab - EMEA/H/C/006224/II/0001</p> <p>Reddy Holding GmbH, Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 23.01.2025.</p>	<p>Positive Opinion adopted by consensus on 23.01.2025.</p>
<p>KIMMTRAK - Tebentafusp - EMEA/H/C/004929/II/0009/G, Orphan</p> <p>Immunocore Ireland Limited, Rapporteur: Boje Kvorning Pires Ehmsen</p> <p>Request for Supplementary Information adopted on 30.01.2025.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Menveo - Meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/001095/II/0122/G</p> <p>GSK Vaccines S.r.l, Rapporteur: Patrick Vrijlandt</p> <p>Opinion adopted on 16.01.2025.</p> <p>Request for Supplementary Information adopted on 28.11.2024, 03.10.2024.</p>	<p>Positive Opinion adopted by consensus on 16.01.2025.</p>
<p>Odomzo - Sonidegib - EMEA/H/C/002839/II/0053/G</p> <p>Sun Pharmaceutical Industries Europe B.V., Rapporteur: Peter Mol</p> <p>Opinion adopted on 16.01.2025.</p> <p>Request for Supplementary Information adopted on 14.11.2024.</p>	<p>Positive Opinion adopted by consensus on 16.01.2025.</p>
<p>Omlyclo - Omalizumab - EMEA/H/C/005958/II/0004/G</p> <p>Celltrion Healthcare Hungary Kft., Rapporteur: Finbarr Leacy, PRAC Rapporteur: Mari Thorn</p> <p>Request for Supplementary Information adopted on 30.01.2025.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>OmvoH - Mirikizumab - EMEA/H/C/005122/II/0010/G</p> <p>Eli Lilly Nederland B.V., Rapporteur: Finbarr Leacy</p> <p>Information adopted on 23.01.2025.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

Opdualag - Nivolumab / Relatlimab - EMA/H/C/005481/II/0011/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol Opinion adopted on 30.01.2025.	Positive Opinion adopted by consensus on 30.01.2025.
Otulf - Ustekinumab - EMA/H/C/006544/II/0001/G Fresenius Kabi Deutschland GmbH, Duplicate of Fymaskina, Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald Request for Supplementary Information adopted on 16.01.2025.	Request for supplementary information adopted with a specific timetable.
Pombiliti - Cipaglucosidase alfa - EMA/H/C/005703/II/0015 Amicus Therapeutics Europe Limited, Rapporteur: Patrick Vrijlandt Opinion adopted on 19.12.2024. Request for Supplementary Information adopted on 10.10.2024.	Positive Opinion adopted by consensus on 19.12.2024.
Prevenar 20 - Pneumococcal polysaccharide conjugate vaccine (20- valent, adsorbed) - EMA/H/C/005451/II/0031/G Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphia Request for Supplementary Information adopted on 16.01.2025.	Request for supplementary information adopted with a specific timetable.
Privigen - Human normal immunoglobulin - EMA/H/C/000831/II/0211/G CSL Behring GmbH, Rapporteur: Jan Mueller- Berghaus Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
Qarziba - Dinutuximab beta - EMA/H/C/003918/II/0062/G, Orphan Recordati Netherlands B.V., Rapporteur: Peter Mol Opinion adopted on 16.01.2025. Request for Supplementary Information adopted on 21.11.2024, 12.09.2024.	Positive Opinion adopted by consensus on 16.01.2025.
Recarbrio - Imipenem / Cilastatin / Relebactam - EMA/H/C/004808/II/0034 Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson Request for Supplementary Information adopted on 23.01.2025, 19.09.2024.	Request for supplementary information adopted with a specific timetable.
Recarbrio - Imipenem / Cilastatin / Relebactam -	Request for supplementary information adopted with a specific timetable.

EMEA/H/C/004808/II/0035/G Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson Request for Supplementary Information adopted on 23.01.2025, 19.09.2024.	
Remsima - Infliximab - EMEA/H/C/002576/II/0143/G Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola Opinion adopted on 19.12.2024. Request for Supplementary Information adopted on 14.11.2024.	Positive Opinion adopted by consensus on 19.12.2024.
Respreeza - Human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0078/G CSL Behring GmbH, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 16.01.2025.	Request for supplementary information adopted with a specific timetable.
RoActemra - Tocilizumab - EMEA/H/C/000955/II/0124/G Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 19.12.2024.	Positive Opinion adopted by consensus on 19.12.2024.
SIMBRINZA - Brinzolamide / Brimonidine - EMEA/H/C/003698/II/0027/G Novartis Europharm Limited, Rapporteur: Antonio Gomez-Outes Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
Simulect - Basiliximab - EMEA/H/C/000207/II/0122 Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
Skyrizi - Risankizumab - EMEA/H/C/004759/II/0052/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Finbarr Leacy	Request for supplementary information adopted with a specific timetable.
Sogroya - Somapacitan - EMEA/H/C/005030/II/0016, Orphan Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt Request for Supplementary Information adopted on 16.01.2025.	Request for supplementary information adopted with a specific timetable.
Spectrila - Asparaginase - EMEA/H/C/002661/II/0042/G medac Gesellschaft für klinische Spezialpräparate mbH, Rapporteur: Christian	Positive Opinion adopted by consensus on 30.01.2025.

<p>Gartner</p> <p>Opinion adopted on 30.01.2025.</p> <p>Request for Supplementary Information adopted on 31.10.2024.</p>	
<p>Spikevax - COVID-19 mRNA vaccine - EMEA/H/C/005791/II/0146</p> <p>Moderna Biotech Spain S.L., Rapporteur: Jan Mueller-Berghaus</p> <p>Request for Supplementary Information adopted on 19.12.2024.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Spikevax - COVID-19 mRNA vaccine - EMEA/H/C/005791/II/0148/G</p> <p>Moderna Biotech Spain S.L., Rapporteur: Jan Mueller-Berghaus</p> <p>Request for Supplementary Information adopted on 23.01.2025.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Steglujan - Ertugliflozin / Sitagliptin - EMEA/H/C/004313/II/0030/G</p> <p>Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder</p> <p>Opinion adopted on 16.01.2025.</p>	<p>Positive Opinion adopted by consensus on 16.01.2025.</p>
<p>STEQEYMA - Ustekinumab - EMEA/H/C/005918/II/0004/G</p> <p>Celltrion Healthcare Hungary Kft., Rapporteur: Jayne Crowe</p> <p>Request for Supplementary Information adopted on 16.01.2025.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Supemtek Tetra - Influenza quadrivalent vaccine (rDNA) - EMEA/H/C/005159/II/0015/G</p> <p>Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 19.12.2024.</p> <p>Request for Supplementary Information adopted on 07.11.2024, 03.10.2024, 06.06.2024, 08.02.2024.</p>	<p>Positive Opinion adopted by consensus on 19.12.2024.</p>
<p>Trdelvy - Sacituzumab govitecan - EMEA/H/C/005182/II/0035/G</p> <p>Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus</p> <p>Opinion adopted on 19.12.2024.</p> <p>Request for Supplementary Information adopted on 14.11.2024.</p>	<p>Positive Opinion adopted by consensus on 19.12.2024.</p>
<p>Trulicity - Dulaglutide - EMEA/H/C/002825/II/0073/G</p> <p>Eli Lilly Nederland B.V., Rapporteur: Janet Koenig</p>	<p>Positive Opinion adopted by consensus on 16.01.2025.</p>

Opinion adopted on 16.01.2025.	
Uzpruvo - Ustekinumab - EMA/H/C/006101/II/0002/G STADA Arzneimittel AG, Rapporteur: Christian Gartner Request for Supplementary Information adopted on 19.12.2024, 11.07.2024.	Request for supplementary information adopted with a specific timetable.
Uzpruvo - Ustekinumab - EMA/H/C/006101/II/0005 STADA Arzneimittel AG, Rapporteur: Christian Gartner Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
Vazkepa - Icosapent ethyl - EMA/H/C/005398/II/0028/G Amarin Pharmaceuticals Ireland Limited, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 30.01.2025.	Request for supplementary information adopted with a specific timetable.
VEYVONDI - Vonicog alfa - EMA/H/C/004454/II/0037 Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
WS2549/G Hexacima- EMA/H/C/002702/WS2549/0159/G Hexyon- EMA/H/C/002796/WS2549/0163/G Sanofi Winthrop Industrie, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.01.2025. Request for Supplementary Information adopted on 07.11.2024.	Positive Opinion adopted by consensus on 16.01.2025.
WS2563 Axura-EMA/H/C/000378/WS2563/0090 Memantine Merz- EMA/H/C/002711/WS2563/0025 Merz Pharmaceuticals GmbH, Lead Rapporteur: Antonio Gomez-Outes Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
WS2727 Esperoct- EMA/H/C/004883/WS2727/0025 NovoEight- EMA/H/C/002719/WS2727/0044 NovoSeven-	Request for supplementary information adopted with a specific timetable.

EMA/H/C/000074/WS2727/0125
NovoThirteen-
EMA/H/C/002284/WS2727/0032
Refixia-EMA/H/C/004178/WS2727/0038
Novo Nordisk A/S, Lead Rapporteur: Jan
Mueller-Berghaus
Request for Supplementary Information adopted
on 19.12.2024, 05.09.2024.

WS2741 Flebogamma DIF- EMA/H/C/000781/WS2741/0086 Instituto Grifols, S.A., Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
---	---

WS2747/G Nuwiq- EMA/H/C/002813/WS2747/0063/G Vihuma- EMA/H/C/004459/WS2747/0045/G Octapharma AB, Lead Rapporteur: Jan Mueller- Berghaus Request for Supplementary Information adopted on 23.01.2025, 31.10.2024.	Request for supplementary information adopted with a specific timetable.
---	---

WS2748 Silodosin Recordati- EMA/H/C/004964/WS2748/0015 Silodyx-EMA/H/C/001209/WS2748/0056 Urorec-EMA/H/C/001092/WS2748/0059 Recordati Ireland Ltd, Lead Rapporteur: Margareta Bego Request for Supplementary Information adopted on 19.12.2024, 14.11.2024.	Request for supplementary information adopted with a specific timetable.
--	---

WS2770/G Filgrastim Hexal- EMA/H/C/000918/WS2770/0079/G Zarzio- EMA/H/C/000917/WS2770/0080/G Sandoz GmbH, Lead Rapporteur: Peter Mol Request for Supplementary Information adopted on 19.12.2024.	Request for supplementary information adopted with a specific timetable.
---	---

WS2773/G ProQuad- EMA/H/C/000622/WS2773/0169/G Merck Sharp & Dohme B.V., Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
---	---

WS2777/G	Positive Opinion adopted by consensus on
-----------------	--

Dengue Tetravalent Vaccine (Live, Attenuated) Takeda- EMA/H/W/005362/WS2777/0020/G Qdenga- EMA/H/C/005155/WS2777/0021/G Takeda GmbH, Lead Rapporteur: Sol Ruiz Opinion adopted on 16.01.2025.	16.01.2025.
WS2780 Riltrava Aerosphere- EMA/H/C/005311/WS2780/0017 Trixeo Aerosphere- EMA/H/C/004983/WS2780/0024 AstraZeneca AB, Lead Rapporteur: Finbarr Leacy, Lead PRAC Rapporteur: Jan Neuhauser	Request for supplementary information adopted with a specific timetable.
WS2781/G Efficib- EMA/H/C/000896/WS2781/0117/G Janumet- EMA/H/C/000861/WS2781/0115/G Ristfor- EMA/H/C/001235/WS2781/0104/G Velmetia- EMA/H/C/000862/WS2781/0123/G Merck Sharp & Dohme B.V., Lead Rapporteur: Patrick Vrijlandt Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
WS2782/G Januvia- EMA/H/C/000722/WS2782/0088/G Ristaben- EMA/H/C/001234/WS2782/0082/G TESAVEL- EMA/H/C/000910/WS2782/0088/G Xelevia- EMA/H/C/000762/WS2782/0097/G Merck Sharp & Dohme B.V., Lead Rapporteur: Patrick Vrijlandt Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
WS2796 Fluenz-EMA/H/C/006514/WS2796/0005 Pandemic influenza vaccine H5N1 AstraZeneca- EMA/H/C/003963/WS2796/0075 AstraZeneca AB, Lead Rapporteur: Christophe Focke Opinion adopted on 30.01.2025.	Positive Opinion adopted by consensus on 30.01.2025.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

ADCETRIS - Brentuximab vedotin - EMA/H/C/002455/II/0113, Orphan Takeda Pharma A/S, Rapporteur: Peter Mol, "Update of section 5.1 of the SmPC in order to update clinical information based on final results from ECHELON-1 final OS analysis data (C25003 CSR addendum 3). This is a randomized, open- label, phase 3 trial of A+AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma. In addition, the MAH took the opportunity to update the PI according to the Excipients Guideline and to introduce minor formatting changes to the PI." Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
AGAMREE - Vamorolone - EMA/H/C/005679/II/0009, Orphan Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: Janet Koenig, "Type II - C.I.4 - To update sections 4.2 and 6.6 of the SmPC to add information concerning the administration of the product via enteral feeding tubes. The package leaflet is also updated with the information. This variation is submitted to address a recommendation for further quality development that was made at the time of the assessment of the initial application for the marketing authorisation." Opinion adopted on 16.01.2025.	Positive Opinion adopted by consensus on 16.01.2025.
Beyfortus - Nirsevimab - EMA/H/C/005304/II/0028 Sanofi Winthrop Industrie, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.8 and 5.1 based on primary analysis and first- year analysis results from study VAS00006 (HARMONIE). This is an ongoing phase IIIb randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus in infants (under 12 months) in order to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab. In addition, the MAH took the opportunity to introduce minor formatting changes." Request for Supplementary Information adopted on 30.01.2025.	Request for supplementary information adopted with a specific timetable.
Cimzia - Certolizumab pegol - EMA/H/C/001037/II/0110	Positive Opinion adopted by consensus on 30.01.2025.

UCB Pharma S.A., Rapporteur: Kristina Dunder, "Update of sections 4.6 and 5.2 of the SmPC in order to update information on pregnancy based on final results from study UP0085, OTIS Phase I report and post marketing data. UP0085 is a Phase 1b, prospective, longitudinal, interventional, open-label study evaluating the impact of pregnancy on the PK of CZP. OTIS Phase I report presents the formal analysis of pregnancy outcome and infant and child follow-up data from the OTIS CZP Pregnancy Registry (RA0023). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.4." Request for Supplementary Information adopted on 14.11.2024, 13.06.2024.

Drovelis - Drospirenone / Estetrol - EMEA/H/C/005336/II/0026

Positive Opinion adopted by consensus on 30.01.2025.

Gedeon Richter Plc., Rapporteur: Kristina Dunder, "Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update information on paediatric population based on results from study MIT-Es001-C303. This is a Phase III, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate and 3 mg Drospirenone in Post-menarchal Female Adolescents for 6 cycles. The Package Leaflet is updated accordingly." Opinion adopted on 30.01.2025. Request for Supplementary Information adopted on 14.11.2024, 25.07.2024.

Emblaveo - Aztreonam / Avibactam - EMEA/H/C/006113/II/0002

Positive Opinion adopted by consensus on 30.01.2025.

Pfizer Europe Ma EEIG, Rapporteur: Filip Josephson, "Submission of the corrected report from study C3601002 (REVISIT). This is a Phase 3 Prospective, Randomized, Multicenter, Open-Label, Central Assessor Blinded, Parallel Group, Comparative Study to Determine the Efficacy, Safety and Tolerability of Aztreonam Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem ± Colistin (MER ± COL) for the Treatment of Serious Infections due to Gram Negative Bacteria, Including Metallo β-Lactamase (MBL) Producing Multidrug Resistant Pathogens, for Which There are Limited or no

**EVOTAZ - Atazanavir / Cobicistat -
EMA/H/C/003904/II/0050**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Fátima Ventura, “Update of sections 4.3 and 4.5
of the SmPC in order to add a new
contraindication and to include Drug-Drug
Interactions (DDIs) information for the
coadministration of Atazanavir/cobicistat
(ATV/COBI) with the kinase inhibitor,
fostamatinib, and the gonadotropin-releasing
hormone receptor antagonist, elagolix based on
post-marketing safety data. The Package Leaflet
is updated accordingly. In addition, the MAH
took the opportunity to introduce editorial
changes to the PI.”

Request for Supplementary Information adopted
on 30.01.2025.

Request for supplementary information adopted
with a specific timetable.

**Eylea - Aflibercept -
EMA/H/C/002392/II/0095**

Bayer AG, Rapporteur: Jean-Michel Race,
“Update of section 4.8 of the SmPC in order to
add ‘scleritis’ to the list of adverse drug
reactions (ADRs) with frequency of ‘0.2 cases
per 1 million injections’ based on
pharmacovigilance data. The Package Leaflet is
updated accordingly. In addition, the MAH took
the opportunity to add warnings for polysorbate
into the SmPC and the Package Leaflet in line
with the instructions in the most recent updates
to the Appendix of the EC Excipient Guideline.”
Opinion adopted on 19.12.2024.

Request for Supplementary Information adopted
on 24.10.2024.

Positive Opinion adopted by consensus on
19.12.2024.

**Helicobacter Test INFAI - 13C-Urea -
EMA/H/C/000140/II/0028**

Infai GmbH, Rapporteur: Christian Gartner,
“Update of sections 4.2, 4.3 and 5.1 of the
SmPC in order to modify administration
instructions and to add a new contraindication
based on final results from study HPT30/J/17;
this is a single-group, observer-blind, multi-
centre study to quantify the sensitivity and
specificity of the 13C-UBT using the new test
meal for Hp in patients with dyspepsia and
GERD taking PPI. The Package Leaflet is
updated accordingly. In addition, the MAH took
the opportunity to update section 6.6 of the
SmPC.”

See 9.1

Negative Opinion adopted by consensus on
30.01.2025.

Request for Supplementary Information adopted on 17.10.2024, 30.05.2024.

HEPLISAV B - Hepatitis B surface antigen (rDNA) - EMEA/H/C/005063/II/0037

Dynavax GmbH, Rapporteur: Filip Josephson, "Update of section 4.9 of the SmPC in order to revise information regarding overdose to indicate "Not Applicable" following review of overall safety data. In addition, the MAH took the opportunity to make some editorial updates to the PI and bring it in line with the latest QRD template."

Request for Supplementary Information adopted on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

Imbruvica - Ibrutinib - EMEA/H/C/003791/II/0088/G

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "A grouped application consisting of:

C.I.4: Update of section 5.1 of the SmPC based on results from Study CLL3011 (GLOW study).

This is a Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

C.I.4: Update of section 5.1 of the SmPC based on results from Study PCYC-1116-CA. This is an Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)."

Request for Supplementary Information adopted on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

Inrebic - Fedratinib - EMEA/H/C/005026/II/0026, Orphan

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol, "Update of sections 4.4 and 4.8 of the SmPC in order to add 'Uveitis' to the list of adverse drug reactions (ADRs) with frequency 'common' based on a cumulative safety review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes to the PI."

Request for Supplementary Information adopted on 23.01.2025.

Request for supplementary information adopted with a specific timetable.

Lydisilka - Drospirenone / Estetrol -

Positive Opinion adopted by consensus on

<p>EMEA/H/C/005382/II/0026</p> <p>Estetra SRL, Duplicate of Drovelis, Rapporteur: Kristina Dunder, "Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update information on paediatric population based on results from study MIT-Es001-C303. This is a Phase III, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate and 3 mg Drospirenone in Post-menarchal Female Adolescents for 6 cycles. The Package Leaflet is updated accordingly."</p> <p>Opinion adopted on 30.01.2025.</p> <p>Request for Supplementary Information adopted on 14.11.2024, 25.07.2024.</p>	30.01.2025.
<p>LysaKare - L-lysine hydrochloride / L-arginine hydrochloride -</p> <p>EMEA/H/C/004541/II/0019</p> <p>Advanced Accelerator Applications, Rapporteur: Janet Koenig, "Update of sections 4.2, 4.4 and 4.9 of the SmPC in order to align it with Lutathera SmPC based on post-marketing data and literature. In addition, the MAH took the opportunity to implement editorial changes to the PI and to update the list of local representatives in the Package Leaflet."</p> <p>Request for Supplementary Information adopted on 16.01.2025.</p>	Request for supplementary information adopted with a specific timetable.
<p>MenQuadfi - Meningococcal Group A, C, W and Y conjugate vaccine -</p> <p>EMEA/H/C/005084/II/0037</p> <p>Sanofi Winthrop Industrie, Rapporteur: Daniela Philadelphia, "Update of section 4.8 of the SmPC in order to add "Febrile convulsions" and "seizures" to the list of adverse drug reactions (ADRs) with frequency not known, based on a safety review. The Package Leaflet is updated accordingly. The MAH took the opportunity to include editorial changes in the product information."</p> <p>Opinion adopted on 23.01.2025.</p> <p>Request for Supplementary Information adopted on 24.10.2024.</p>	Positive Opinion adopted by consensus on 23.01.2025.
<p>Nuvaxovid - Covid-19 Vaccine (recombinant, adjuvanted) -</p> <p>EMEA/H/C/005808/II/0084</p> <p>Novavax CZ a.s., Rapporteur: Patrick Vrijlandt,</p>	Positive Opinion adopted by consensus on 19.12.2024.

"Submission of the final report from clinical study 2019nCoV-302 listed as a category 3 study in the RMP. This is a Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) with Matrix-M1TM Adjuvant in Adult Participants 18 – 84 Years of Age in the United Kingdom."

Opinion adopted on 19.12.2024.

Request for Supplementary Information adopted on 17.10.2024.

Nuvaxovid - Covid-19 Vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0090

Novavax CZ a.s., Rapporteur: Patrick Vrijlandt, "Submission of the final report from clinical study 2019nCoV-301 (Adolescent part) listed as a category 3 study in the RMP. This is a phase 3 study of efficacy, effectiveness, safety, and immunogenicity in adolescents."

Request for Supplementary Information adopted on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

Nuvaxovid - Covid-19 Vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0093

Novavax CZ a.s., Rapporteur: Patrick Vrijlandt, "Submission of the final report from study 2019nCoV-314 listed as a category 3 study in the RMP. This is a phase 3, randomized, double-blinded study to evaluate the safety and immunogenicity of omicron subvariant and bivalent SARS-CoV-2 rS vaccines in adolescents (12 – 18 years) previously vaccinated with mRNA COVID-19 vaccines."

Opinion adopted on 23.01.2025.

Positive Opinion adopted by consensus on 23.01.2025.

Omjjara - Momelotinib - EMEA/H/C/005768/II/0004/G, Orphan

Glaxosmithkline Trading Services Limited, Rapporteur: Christophe Focke, "A grouped application comprised of one Type II, one Type IB and one Type IA Variation, as follows:

Type II (C.I.4): Update of section 4.8 of the SmPC in order to add 'rash' to the list of adverse drug reactions (ADRs) with frequency 'common' based on a safety review of clinical studies and post- marketing safety data. The Package Leaflet is updated accordingly. In

Request for supplementary information adopted with a specific timetable.

addition, the MAH took the opportunity to add editorial changes to the PI and update the list of local representatives in the Package Leaflet.

Type IB (C.I.z): Update of section 5.2 of SmPC in order to include minor updates to the absorption and biotransformation subsections of the PI based on data from the already submitted study GS-US-352-0102.

Type IA (A.6): Include the ATC Code L01EJ04 in Section 5.1 of the Summary of Product Characteristics (SmPC)."
Request for Supplementary Information adopted on 19.12.2024.

**Orserdu - Elacestrant -
EMA/H/C/005898/II/0009**

Positive Opinion adopted by consensus on 16.01.2025.

Stemline Therapeutics B.V., Rapporteur: Peter Mol, "Update of section 5.2 of the SmPC in order to provide additional pharmacokinetic information following the PAM procedure for study MRPO-2023-PDE004 and based on the report SLP 43753974; this is an assessment of the potential role of P-gp in the supra-proportional exposure of elacestrant and the potential impact of P-gp inhibitors on elacestrant exposure at the dose of 100 mg. In addition, the MAH took the opportunity to introduce editorial changes to the PI and to bring the PI in line with the latest QRD template version 10.4."
Opinion adopted on 16.01.2025.

**Paxlovid - Nirmatrelvir / Ritonavir -
EMA/H/C/005973/II/0059/G**

Request for supplementary information adopted with a specific timetable.

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "A grouped application consisting of:
C.I.4: Update of section 4.5 of the SmPC in order to add drug-drug interaction information with albendazole based on the post-marketing data and literature and to update information on drug-drug interactions with methadone and ethinyl estradiol based on the literature; the Package Leaflet is updated accordingly.
C.I.4: Update of section 4.5 of the SmPC in order to update information on drug-drug interactions with calcium channel antagonists based on the cumulative safety data and literature."
Request for Supplementary Information adopted

on 23.01.2025.

**Phesgo - Pertuzumab / Trastuzumab -
EMA/H/C/005386/II/0027**

Roche Registration GmbH, Rapporteur: Boje Kvorning Pires Ehmsen, "Update of sections 4.2 and 4.4 of the SmPC in order to update administration instructions based on final results from studies AL42478 and WP42873.

AL42478 is an Expanded Access, Single-Arm, Multicenter Study to Provide At Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients with HER2-positive Breast Cancer During the COVID-19 Pandemic.

WP42873 is a randomized, open-label, 2-arm, parallel group, single dose, multi-centre study in healthy male subjects to investigate the comparability of pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or using the on-body delivery system.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 30.01.2025.

Request for supplementary information adopted with a specific timetable.

**Privigen - Human normal immunoglobulin -
EMA/H/C/000831/II/0210**

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.4 of the SmPC in order to update the existing warning on 'Aseptic Meningitis Syndrome (AMS)' to add a class monitoring precaution for recurrent AMS, associated with IVIg treatment, potentially progressing to brain oedema (cerebral oedema).

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

**Rystiggo - Rozanolixizumab -
EMA/H/C/005824/II/0009/G, Orphan**

UCB Pharma, Rapporteur: Thalia Marie Estrup Blicher, "A grouped application comprised of two type II variations, as follows:

Positive Opinion adopted by consensus on 16.01.2025.

C.I.4: Update of section 4.2 of the SmPC in order to modify administration instructions to include the option of self-administration (by the patient or a caregiver) based on the results from study MG0020. This is a phase 3, open-label, crossover study to evaluate Rozanolixizumab self-administration by study participants with generalized myasthenia gravis.

C.I.4: Update of sections 4.2 and 6.6 of the SmPC in order to modify administration instructions to include additional supportive data for the manual push (MP) method based on the results from the following clinical studies MG0007 phase 3 open label extension (OLE) and UP0106 phase 1 exploratory study. UP0106A is a randomized, participant-blind, investigator-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Rozanolixizumab administered subcutaneously via manual push versus syringe driver to healthy participants. While, MG007 is an open-label extension study to evaluate Rozanolixizumab in study participants with generalized myasthenia gravis.

The Package Leaflet and Labelling are updated accordingly.”

Opinion adopted on 16.01.2025.

**Skyrizi - Risankizumab -
EMA/H/C/004759/II/0050**

Positive Opinion adopted by consensus on 23.01.2025.

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Finbarr Leacy, “Update of sections 4.8 and 5.1 of the SmPC in order to add information based on data of the final study report M15-997 (LIMITLESS) listed as a category 3 study in the RMP. This is a multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Opinion adopted on 23.01.2025.

Request for Supplementary Information adopted on 14.11.2024.

**Soliris - Eculizumab -
EMA/H/C/000791/II/0131, Orphan**
Alexion Europe SAS, Rapporteur: Antonio

Positive Opinion adopted by consensus on 19.12.2024.

Gomez-Outes, "Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study ECU-MG-303; this is a Phase 3, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in pediatric patients with refractory generalized myasthenia gravis (gMG). In addition, the MAH took the opportunity to introduce a sentence regarding polysorbate in line with QRD template and minor changes to the PI."

Opinion adopted on 19.12.2024.

Request for Supplementary Information adopted on 17.10.2024, 18.07.2024.

Spikevax - COVID-19 mRNA vaccine - EMEA/H/C/005791/II/0147

Moderna Biotech Spain S.L., Rapporteur: Jan Mueller-Berghaus, "Submission of the final report from study mRNA-1273-P205 listed as a category 3 study in the RMP. This is a Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants."

Request for Supplementary Information adopted on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

Stelara - Ustekinumab - EMEA/H/C/000958/II/0107

Janssen-Cilag International N.V., Rapporteur: Jayne Crowe, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD1003. This is a phase 1, open-label, drug interaction study to evaluate the effect of ustekinumab on cytochrome P450 enzyme activities following induction and maintenance dosing in participants with active Crohn's disease or ulcerative colitis. In addition, the MAH took the opportunity to update sections 4.8 and 5.1 to include patient exposure numbers based on results from study CNTO1275UCO3001. This is a phase 3, randomised, double-blind, placebo-controlled, parallel-group, multicentre protocol to evaluate the safety and efficacy of ustekinumab induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis."

Positive Opinion adopted by consensus on 19.12.2024.

During the procedure the MAH has also taken the opportunity to update the PI based on the

QRD template, which includes a warning on the polysorbate threshold.

The requested variation proposed amendments to the Summary of Product Characteristics & Patient Information Leaflet”

Opinion adopted on 19.12.2024.

Request for Supplementary Information adopted on 19.09.2024.

**Strensiq - Asfotase alfa -
EMA/H/C/003794/II/0070, Orphan**

Alexion Europe SAS, Rapporteur: Paolo Gasparini, “Update of section 5.1 of the SmPC in order to reflect data on effectiveness of asfotase alfa in treating adults with paediatric-onset with hypophosphatasia (HPP) based on real world evidence [RWE], and publications from the Global HPP Registry (ALXN-HPP-501), an observational study [EmPATHY] and UK managed access agreement study another observational prospective study. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.4 and add editorial changes to the Labelling.”

Request for Supplementary Information adopted on 19.12.2024.

Request for supplementary information adopted with a specific timetable.

**Sunlenca - Lenacapavir -
EMA/H/C/005638/II/0025**

Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, “Update of sections 4.2 and 4.4 of the SmPC in order to reinforce the importance of injecting Sunlenca subcutaneously and not intradermally, and to add a new warning on ‘Injection Site Reactions with Improper Administration’ to describe that intradermal administration has been associated with serious injection site reactions including necrosis and ulcer, based on a cumulative safety review. Moreover, section 4.8 was updated to include necrosis as an example of an injection site reaction. The Package Leaflet is updated accordingly. The Instructions for Use (IFU) of Sunlenca solution for injection have also been updated to improve readability for healthcare professionals. In addition, the MAH took the opportunity to introduce editorial and formatting changes to the PI.”

Opinion adopted on 30.01.2025.

Positive Opinion adopted by consensus on 30.01.2025.

**Trodelvy - Sacituzumab govitecan -
EMA/H/C/005182/II/0037**

Request for supplementary information adopted with a specific timetable.

Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.2, 4.4 and 6.6 of the SmPC in order to add information on the timing of fatal infections as well as recommendations on the use of primary prophylaxis with G-CSF in patients who are at high risk for neutropenia, based on clinical trials data, post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."

**Truqap - Capivasertib -
EMA/H/C/006017/II/0002**

Positive Opinion adopted by consensus on 23.01.2025.

AstraZeneca AB, Rapporteur: Janet Koenig, "Update of section 5.1 of the SmPC in order to update the clinical efficacy information to reflect a new overall survival (OS) interim analysis pertaining to study D3615C00001 (CAPItello-291) in order to fulfil REC 004; this is a phase III double-blind randomised study assessing the efficacy and safety of capivasertib + fulvestrant versus placebo + fulvestrant as treatment for locally advanced (inoperable) or metastatic Hormone Receptor positive, Human Epidermal Growth Factor Receptor 2 negative (HR+/HER2-) breast cancer following recurrence or progression on or after treatment with an aromatase inhibitor. In addition, the MAH took the opportunity to introduce minor formatting changes to the PI and to update the list of local representatives in the Package Leaflet."

Opinion adopted on 23.01.2025.

**Uptravi - Selexipag -
EMA/H/C/003774/II/0042/G**

Positive Opinion adopted by consensus on 19.12.2024.

Janssen-Cilag International N.V., Rapporteur: Janet Koenig, "A grouped application comprised of 3 Type II Variations as follows:

C.I.4: Update of sections 4.2 and 5.2 of the SmPC in order to update pharmacokinetic information based on results from the paediatric PK study AC-065A203; this is a phase 2 multicenter, open-label, single-arm study to evaluate the safety, tolerability and pharmacokinetics of selexipag in children from 2 years to less than 18 years of age with pulmonary arterial hypertension (PAH).

C.I.4: Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy and safety information based on results from study AC-065A310 (SALTO); this is a phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel group study with open-label extension period to assess the efficacy and safety of selexipag as add-on to standard of care in children from 2 years to less than 18 years of age with pulmonary arterial hypertension (PAH).

C.I.4: Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy information based on results from the pharmacodynamic (PD) similarity/comparison study to compare the PD and clinical responses for efficacy based on study AC-065A203, study AC-065A310 and study AC-065A302 in paediatric participants from 2 years to less than 18 years of age and adult participants with PAH.

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the Product Information.

”

Opinion adopted on 19.12.2024.

Request for Supplementary Information adopted on 12.09.2024, 16.05.2024.

Voydeya - Danicopan -

EMA/H/C/005517/II/0004/G, Orphan

Alexion Europe, Rapporteur: Antonio Gomez-Outes, “A grouped application comprised of two Type II variations, as follows:

C.I.4: Update of sections 4.8 and 5.1 of the SmPC in order to update the list of adverse drug reactions and update clinical efficacy and safety information, based on final results from study ALXN2040-PNH-301; this is a Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in patients with Paroxysmal Nocturnal Hemoglobinuria who have clinically evident Extravascular Hemolysis (EVH). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet to bring it in line with the latest QRD template version.

Positive Opinion adopted by consensus on 23.01.2025.

C.I.13: Submission of the final report from study ACH471-101; this is a multicenter, open-label, multiple dose Phase 2 study to assess efficacy, safety, and tolerability of add-on danicopan to background eculizumab therapy in adult participants with PNH.”

Opinion adopted on 23.01.2025.

Vyloy - Zolbetuximab -

EMA/H/C/005868/II/0003/G, Orphan

Astellas Pharma Europe B.V., Rapporteur: Jan Mueller-Berghaus, “Submission of results from studies GLOW (8951-CL-0302) and SPOTLIGHT (8951-CL-0301). GLOW is a Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ)

Adenocarcinoma. SPOTLIGHT is a Phase 3, Global, Multicenter, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.”

Opinion adopted on 23.01.2025.

Positive Opinion adopted by consensus on 23.01.2025.

Xtandi - Enzalutamide -

EMA/H/C/002639/II/0068/G

Astellas Pharma Europe B.V., Rapporteur: Antonio Gomez-Outes, “Grouped application comprising two type II variations as follows: C.I.4 - Update of sections 4.2, 4.4 and 4.8 in order to add a new warning on Dysphagia related to product size and to add dysphagia to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of the MAH safety database and literature search.

C.I.4 – Update of section 4.8 of the SmPC in order to add decreased appetite to the list of adverse drug reactions (ADRs) with frequency Not known based on the cumulative review of the MAH safety database and literature search. The Package Leaflet is updated accordingly.”

Opinion adopted on 16.01.2025.

Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 16.01.2025.

on 26.09.2024.

WS2758

Vfend-EMA/H/C/000387/WS2758/0155

Pfizer Europe MA EEIG, Lead Rapporteur:

Patrick Vrijlandt, "Update of section 4.3 of the SmPC in order to add a contraindication for concomitant use with finerenone based on post-marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement administrative changes to section 4.5 of the SmPC and other editorial changes to the PI, as well as to update the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 30.01.2025.

Request for supplementary information adopted with a specific timetable.

B.5.3. CHMP-PRAC assessed procedures

ASPAVELI - Pegcetacoplan -

EMA/H/C/005553/II/0028, Orphan

Swedish Orphan Biovitrum AB (publ),

Rapporteur: Alexandre Moreau, PRAC

Rapporteur: Kimmo Jaakkola, "Update of section 4.8 of the SmPC in order to add urticaria/hives to the list of adverse drug reactions (ADRs) with frequency "common" and to add anaphylactic reaction and anaphylactic shock to the list of ADRs with frequency "uncommon", based on post-marketing data and literature; the Package Leaflet is updated accordingly. The RMP version 3.1 has also been submitted."

Request for Supplementary Information adopted on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

Bylvay - Odevixibat -

EMA/H/C/004691/II/0022/G, Orphan

Ipsen Pharma, Rapporteur: Patrick Vrijlandt,

PRAC Rapporteur: Adam Przybylowski, "A

grouped application including two type II variations:

- Update of sections 4.2, 4.4, 4.8, and 5.1 of the SmPC based on the clinical study report for the completed 72 weeks of Study A4250-008; an open-label, phase III study to evaluate the long-term efficacy and safety of odevixibat in children with PFIC (category 3 study in the RMP; MEA 002).

The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to

Request for supplementary information adopted with a specific timetable.

implement minor editorial changes in the SmPC and the Package Leaflet. An updated RMP version 6.1 is included in this submission.

- Submission of the clinical study report for Study A4250-J001; a Phase I PK study in healthy Japanese adult male patients.”

Request for Supplementary Information adopted on 16.01.2025.

**Elfabrio - Pegunigalsidase alfa -
EMA/H/C/005618/II/0007**

See 9.1

Chiesi Farmaceutici S.p.A., Rapporteur:
Alexandre Moreau, PRAC Rapporteur: Liana Martirosyan, “Update of sections 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC in order to introduce an alternative posology regimen based on results from study PB-102-F50 (BRIGHT) and interim results from its extension study CLI-06657AA1-03 (formerly presented as PB-102-F51), as well as results of the observational patient reporting outcome study CLI-06657AA1-05. CLI-06657AA1-03 is an Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102)2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease. The Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.4.”

**Epruvy - Ranibizumab -
EMA/H/C/006528/II/0002/G**

Request for supplementary information adopted with a specific timetable.

MIDAS Pharma GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Karin Bolin
Request for Supplementary Information adopted on 16.01.2025.

**FILSPARI - Sparsentan -
EMA/H/C/005783/II/0002, Orphan**

See 9.1

Request for supplementary information adopted with a specific timetable.

Vifor France, Rapporteur: Vilma Petrikaite, PRAC Rapporteur: Martin Huber, “Update of sections 4.8, and 5.1 of the SmPC in order to amend the frequency of the adverse drug reactions (ADRs) based on final results from study 021IGAN17001 (PROTECT) listed as a specific obligation in the Annex II; this is a randomized, multicenter, double-blind parallel-group, active control study of the efficacy and safety of

sparsentan for the treatment of immunoglobulin A nephropathy. The Package Leaflet is updated accordingly. The RMP version 1.0 has also been submitted. In addition, the MAH took the opportunity to update Annex II and to bring the PI in line with the latest QRD template version 10.4. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation.”

Request for Supplementary Information adopted on 30.01.2025, 17.10.2024.

**Inrebic - Fedratinib -
EMA/H/C/005026/II/0020, Orphan**

Positive Opinion adopted by consensus on 30.01.2025.

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Peter Mol, PRAC Rapporteur: Sonja Hrabcik, “Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update information regarding thiamine levels based on a review of the primary results of the study FEDR-MF-002. This is a Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared with BAT in subjects with DIPSS intermediate-2 or high-risk primary MF, post-PV MF, or post-ET MF and previously treated with ruxolitinib. The RMP version 3 has also been submitted.”

Opinion adopted on 30.01.2025.

Request for Supplementary Information adopted on 17.10.2024, 25.04.2024.

**Kadcyla - Trastuzumab emtansine -
EMA/H/C/002389/II/0071/G**

Request for supplementary information adopted with a specific timetable.

Roche Registration GmbH, Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Karin Erneholm, “A grouped application consisting of: C.I.4 (Type II): Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study BO27938 (KATHERINE) listed as a PAES in the Annex II and as a category 3 study in the RMP. This is a Randomized, Multicenter, Open Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy. The Package Leaflet is updated in accordance. The RMP version 16.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local

representatives in the Package Leaflet, to bring the PI in line with the latest QRD template version 10.4, to update the PI in accordance with the latest EMA excipients guideline, and to implement editorial changes to the PI. Furthermore, the MAH took the opportunity to update Annex II-D and to implement editorial changes to the Labelling section.

Request for Supplementary Information adopted on 16.01.2025, 31.10.2024.

**Ocrevus - Ocrelizumab -
EMA/H/C/004043/II/0041**

Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Gabriele Maurer, "Update of sections 4.6 and 5.3 of the SmPC in order to amend the recommendations for breast-feeding during ocrelizumab therapy, based on newly available clinical data. The Package Leaflet is updated accordingly. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 16.01.2025, 31.10.2024, 11.07.2024.

Request for supplementary information adopted with a specific timetable.

**Pluvicto - Lutetium (177Lu) vipivotide
tetraxetan - EMA/H/C/005483/II/0022**

Novartis Europharm Limited, Rapporteur: Janet Koenig, PRAC Rapporteur: John Joseph Borg, "Update of section 4.8 of the SmPC in order to update safety information based on final results from study PSMA-617-01 (CAAA617A12301 – VISION) listed as a category 3 study in the RMP; this is an international, prospective, open-label, multicenter, randomized Phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI."

Request for Supplementary Information adopted on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

**Pyramax - Pyronaridine / Artesunate -
EMA/H/W/002319/II/0036**

Shin Poong Pharmaceutical Co., Ltd.,
Rapporteur: Jean-Michel Race, PRAC

Request for supplementary information adopted with a specific timetable.

Rapporteur: Zoubida Amimour, "Update of sections 4.4 and 4.6 of the SmPC with revised recommendations for treatment during pregnancy. The Package Leaflet has been updated accordingly. An updated RMP version 18 was provided as part of the application."
Request for Supplementary Information adopted on 16.01.2025.

**Pyzchiva - Ustekinumab -
EMA/H/C/006183/II/0005/G**

Positive Opinion adopted by consensus on 30.01.2025.

Samsung Bioepis NL B.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald
Opinion adopted on 30.01.2025.
Request for Supplementary Information adopted on 14.11.2024.

**Ranivisio - Ranibizumab -
EMA/H/C/005019/II/0017/G**

Request for supplementary information adopted with a specific timetable.

Midas Pharma GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Karin Bolin
Request for Supplementary Information adopted on 16.01.2025.

**Shingrix - Herpes zoster vaccine
(recombinant, adjuvanted) -
EMA/H/C/004336/II/0076**

Request for supplementary information adopted with a specific timetable.

GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, PRAC Rapporteur: Sonja Hrabcik, "Update of sections 4.8 and 5.1 of the SmPC to include the final results of study ZOSTER-049, listed as a category 3 study in the RMP. This is a Phase 3b, open label, multi-country, long-term follow-up study that assessed the prophylactic efficacy, safety, and immunogenicity persistence of Shingrix in adults ≥50 years of age at the time of primary vaccination in studies ZOSTER 006 and ZOSTER-022. The study also assessed 1 or 2 additional doses of Shingrix on a 0 or 0, 2-month schedule in two subgroups of older adults. The updated RMP version 8.0 is also included. In addition, the MAH took the opportunity to implement editorial changes to the SmPC, Labelling and Package Leaflet; and to bring the PI in line with the latest QRD template version 10.4."
Request for Supplementary Information adopted on 16.01.2025, 05.09.2024.

**Spinraza - Nusinersen -
EMA/H/C/004312/II/0034/G, Orphan**
Biogen Netherlands B.V., Rapporteur: Fátima

Positive Opinion adopted by consensus on 16.01.2025.

Ventura, PRAC Rapporteur: Karin Bolin, "A grouped application consisting of:

C.I.4: Update of sections 5.1 and 5.2 of the SmPC based on final results from study CS11 (SHINE) listed as a PAES in the Annex II. The Annex II and the RMP v12.1 are updated accordingly. SHINE is a phase III, open-label extension study for patients with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of ISIS 396443.

C.I.4: Update of section 5.1 of the SmPC based on interim results from study CS5 (NURTURE, 232SM201). NURTURE is a Phase II, open-label study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of nusinersen delivered intrathecally to patients with genetically diagnosed and presymptomatic SMA.

C.I.4: Update of section 5.1 of the SmPC in order to relocate the updated information regarding immunogenicity from SmPC section 4.8 to section 5.1 as per applicable CHMP guidance. The data has been revised based on an updated integrated analysis across several studies.

C.I.4: Update of section 5.1 of the SmPC based on the outcome of a systematic literature review (SLR) and Natural History data from an International SMA registry (ISMAR)."

Opinion adopted on 16.01.2025.

Request for Supplementary Information adopted on 05.09.2024.

Sunlenca - Lenacapavir -

EMA/H/C/005638/II/0022/G

Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins, "Grouping of two type II variations:

- Update of section 5.1 of the SmPC to include efficacy and resistance data based on week 156 interim data from Study GS-US-200-4625; a phase 2/3 study to evaluate the safety and efficacy of long-acting capsid inhibitor GS-6207 in combination with an optimized background regimen in heavily treatment experienced people living with HIV-1 infection with multidrug resistance (category 3 study in the RMP). Additionally, upon request by the CHMP following the assessment of II/0013, the

Request for supplementary information adopted with a specific timetable.

MAH proposes to update section 4.8 of the SmPC to include information related to injection site nodules and induration that were non-resolved at the end of follow-up.

- Provision of the final study report of Study GS-US-200-4334: a phase 2 randomized, open label, active controlled study evaluating the safety and efficacy of long-acting capsid inhibitor GS-6207 in combination with other antiretroviral agents in people living with HIV (category 3 study in the RMP).

An updated RMP version 2.1 was included as part of the application.”

Request for Supplementary Information adopted on 16.01.2025.

Trumenba - Meningococcal group B vaccine (recombinant, adsorbed) -

EMA/H/C/004051/II/0053

Pfizer Europe MA EEIG, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Jean-Michel Dogné, “Update of sections 4.4 and 5.1 of the SmPC in order to amend an existing warning on immunocompromised individuals and to add immunogenicity data in individuals 10 years of age and above with complement deficiencies or splenic dysfunction based on final results from study B1971060; listed as a category 3 study in the RMP. This was an open-label, single-arm, multicentre trial in which up to 50 immunocompromised participants ≥10 years of age with asplenia (anatomic or functional) or complement deficiency have been enrolled and received Trumenba on a 2-dose, 0- and 6-month schedule. The RMP version 8.0 has been approved. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC.”

Opinion adopted on 16.01.2025.

Request for Supplementary Information adopted on 05.09.2024.

Positive Opinion adopted by consensus on 16.01.2025.

Truqap - Capivasertib -

EMA/H/C/006017/II/0001

AstraZeneca AB, Rapporteur: Janet Koenig, PRAC Rapporteur: Sonja Hrabcik, “Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update the posology recommendation and the warning regarding Diabetic Ketoacidosis (DKA) and to add it to the list of adverse drug reactions (ADRs) with a frequency “uncommon”, based on a safety review. The Package Leaflet is

Positive Opinion adopted by consensus on 30.01.2025.

updated accordingly. The RMP version 2 has also been submitted. In addition, the MAH also took the opportunity to remove post authorisation measures (PAMs) which were incorrectly added to Annex II.D at time of granting of the Marketing Authorisation, to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.4.”
Opinion adopted on 30.01.2025.
Request for Supplementary Information adopted on 14.11.2024.

**Vabysmo - Faricimab -
EMA/H/C/005642/II/0016**

Roche Registration GmbH, Rapporteur: Jayne Crowe, PRAC Rapporteur: Carla Torre, “Update of section 5.1 of the SmPC to reflect the long-term safety profile of faricimab in patients with diabetic macular edema (DME) based on the final results from study GR41987 (Rhone-X) listed as a category 3 study of the RMP. Rhone-X was a phase III interventional, multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with diabetic macular edema. The RMP version 7.0 has also been submitted.”
Request for Supplementary Information adopted on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

**WEZENLA - Ustekinumab -
EMA/H/C/006132/II/0003/G**

Amgen Technology (Ireland) Unlimited Company, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Rhea Fitzgerald

Opinion adopted on 16.01.2025.
Request for Supplementary Information adopted on 31.10.2024.

Positive Opinion adopted by consensus on 16.01.2025.

**XALKORI - Crizotinib -
EMA/H/C/002489/II/0084**

Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, “Submission of the final report from study CRZ-NBALCL listed as a category 3 study in the RMP. This is a phase I/II study to evaluate the adverse effects of ocular toxicity and bone toxicity and impaired bone growth associated with crizotinib in paediatric and young adult patients with recurrent/refractory anaplastic lymphoma kinase-positive anaplastic large cell

Request for supplementary information adopted with a specific timetable.

lymphoma or neuroblastoma. The RMP version 9.2 is updated accordingly.”
Request for Supplementary Information adopted on 16.01.2025.

**Xenpozyme - Olipudase alfa -
EMA/H/C/004850/II/0012/G, Orphan**

Sanofi B.V., Rapporteur: Patrick Vrijlandt, PRAC
Rapporteur: Martin Huber, “A grouped application consisting of:

C.I.4: Update of sections 4.4 and 4.8 of the SmPC in order to update safety information based on final results from study DFI12712 ASCEND, listed as a category 3 study in the RMP; this is a Phase 2/3, multicenter, randomised, double-blinded, placebo-controlled, repeat-dose study to evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of olipudase alfa in patients with AMSD. The Package Leaflet is updated accordingly. The RMP version 3.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.4 and to implement editorial changes to the SmPC.

Request for supplementary information adopted with a specific timetable.

C.I.4: Update of sections 4.4 and 4.8 of the SmPC in order to update safety information based on final results from study LTS13632 listed as a category 3 study in the RMP; this is a long-term study the ongoing safety and efficacy of olipudase alfa in patients with ASMD. The Package Leaflet is updated accordingly. The RMP version 3.0 has also been submitted.”

Request for Supplementary Information adopted on 16.01.2025, 31.10.2024.

B.5.4. PRAC assessed procedures

PRAC Led
**CRYSVITA - Burosumab -
EMA/H/C/004275/II/0040, Orphan**
Kyowa Kirin Holdings B.V. PRAC Rapporteur:
Gabriele Maurer, PRAC-CHMP liaison: Jan
Mueller-Berghaus, “Submission of an updated
RMP version 8.0 in order to remove
hyperphosphataemia as an important potential
risk and to add a specific adverse drug reaction
follow-up form/questionnaire for increased
parathyroid hormone levels as a routine

Positive Opinion adopted by consensus on
16.01.2025.

pharmacovigilance activity.”
Opinion adopted on 16.01.2025.
Request for Supplementary Information adopted
on 03.10.2024.

PRAC Led
Enbrel - Etanercept -
EMA/H/C/000262/II/0255
Pfizer Europe MA EEIG, PRAC Rapporteur:
Monica Martinez Redondo, PRAC-CHMP liaison:
Antonio Gomez-Outes, “Update of sections 4.2
and 4.4 of the SmPC in order to remove
information regarding the Patient Card, based
on final results from study B1801309 (BSR
Register of Anti-TNF Treated Patients and
Prospective Surveillance Study for Adverse
Events: Enbrel). This is a non-interventional
PASS study listed as a category 3 study in the
RMP. The Annex II and Package Leaflet are
updated accordingly. The RMP version 7.7 has
also been submitted. In addition, the MAH took
the opportunity to introduce minor editorial and
formatting changes to the PI as well as to
update the list of local representatives in the
Package Leaflet and align the PI with the QRD
version 10.4.”
Request for Supplementary Information adopted
on 16.01.2025.

Request for supplementary information adopted
with a specific timetable.

PRAC Led
Erbix - Cetuximab -
EMA/H/C/000558/II/0103
Merck Europe B.V., PRAC Rapporteur: Mari
Thorn, PRAC-CHMP liaison: Filip Josephson,
“Submission of an updated RMP version 19.2 in
order to re-classify important identified risks
and important potential risks and to remove
them from the summary of safety concerns,
following the PRAC assessment for
PSUSA/00000635/202309.”
Opinion adopted on 16.01.2025.

Positive Opinion adopted by consensus on
16.01.2025.

PRAC Led
Fintepla - Fenfluramine -
EMA/H/C/003933/II/0028, Orphan
UCB Pharma SA, PRAC Rapporteur: Martin
Huber, PRAC-CHMP liaison: Janet Koenig,
“Submission of a revised protocol for study
EP0218 listed as an obligation in the Annex II of
the Product Information. This is a Long-term
Registry in approved indications for
fenfluramine, with a specific focus on

Request for supplementary information adopted
with a specific timetable.

cardiovascular events and growth retardation. The RMP version 4.0 is updated accordingly. In addition, the MAH introduced minor amendments in the targeted follow-up questionnaire for cardiovascular adverse events.”

Request for Supplementary Information adopted on 30.01.2025.

PRAC Led

Kaftrio - Ivacaftor / Tezacaftor / Elexacaftor -

EMA/H/C/005269/II/0052/G, Orphan

Vertex Pharmaceuticals (Ireland) Limited, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “Grouped application comprising two type II variations as follows:

Type II (C.I.3.b) – Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on rash and to add hypersensitivity to the list of adverse drug reactions (ADRs) with frequency “not known” following the outcome of procedure PSUSA/00010868/202310. The Package Leaflet is updated accordingly.

Type II (C.I.z) – Submission of post-marketing breast-feeding case reports.”

Request for Supplementary Information adopted on 16.01.2025, 05.09.2024.

Request for supplementary information adopted with a specific timetable.

PRAC Led

Kaftrio - Ivacaftor / Tezacaftor / Elexacaftor - EMA/H/C/005269/II/0055, Orphan

Vertex Pharmaceuticals (Ireland) Limited, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “Update of section 4.6 of the SmPC in order to amend the existing wording on exposure during pregnancy following PSUR procedure (EMA/H/C/PSUSA/00010868/202310).”

Request for Supplementary Information adopted on 16.01.2025, 31.10.2024.

Request for supplementary information adopted with a specific timetable.

PRAC Led

POTELIGEO - Mogamulizumab - EMA/H/C/004232/II/0026, Orphan

Kyowa Kirin Holdings B.V., Rapporteur: Peter Mol, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Boje Kvorning Pires Ehmsen, “Update of section 4.8 of the SmPC in order to add 'granuloma' to the list of adverse drug reactions (ADRs) with frequency

Request for supplementary information adopted with a specific timetable.

'unknown', based on post marketing data; the Package Leaflet is updated accordingly.”
Request for Supplementary Information adopted on 16.01.2025.

PRAC Led
Ruconest - Conestat alfa -
EMA/H/C/001223/II/0088/G

Positive Opinion adopted by consensus on 16.01.2025.

Pharming Group N.V, PRAC Rapporteur: Jan Neuhauser, PRAC-CHMP liaison: Daniela Philadelphia, “Submission of an updated RMP version 20.0 in order to request the early termination of the EU registry study C1 1412, as well as to update safety information based on cumulative data from clinical trials, the EU registry data, post-marketing data and literature. A request for the extension of the due date for the European survey of educational materials for Ruconest is also included.”
Opinion adopted on 16.01.2025.
Request for Supplementary Information adopted on 03.10.2024.

PRAC Led
Uptravi - Selexipag -
EMA/H/C/003774/II/0045

Positive Opinion adopted by consensus on 16.01.2025.

Janssen-Cilag International N.V., PRAC Rapporteur: Zoubida Amimour, PRAC-CHMP liaison: Alexandre Moreau, “Submission of the final report from study 67896049PAH0002 (EXTRACT) and interim report for study AC-065A401 (EXPOSURE), listed as a category 3 study in the RMP. EXTRACT is a Retrospective Medical Chart Review of Patients with PAH newly treated with either Uptravi (selexipag) or any other PAH-specific therapy. EXPOSURE is an observational cohort study of PAH patients newly treated with either Uptravi (selexipag) or any other PAH-specific therapy, in clinical practice.”
Opinion adopted on 16.01.2025.
Request for Supplementary Information adopted on 03.10.2024, 13.06.2024.

PRAC Led
Veklury - Remdesivir -
EMA/H/C/005622/II/0062

Positive Opinion adopted by consensus on 16.01.2025.

Gilead Sciences Ireland UC, PRAC Rapporteur: Eva Jirsová, PRAC-CHMP liaison: Petr Vrbata, “Submission of the final report from study COVID-PR (CO-US-540-6127 listed as a category 3 study in the RMP. This is a non-

interventional, patient-reporting, post marketing cohort study designed to collect safety data from pregnant and recently pregnant women treated with monoclonal antibodies or antiviral drugs for mild, moderate, or severe COVID-19 at any time from the first day of the last menstrual period to the end of pregnancy. The RMP version 8.2 is updated accordingly.”
Opinion adopted on 16.01.2025.

PRAC Led

WS2794

Segluromet-

EMA/H/C/004314/WS2794/0026

Steglatro-

EMA/H/C/004315/WS2794/0025

Steglujan-

EMA/H/C/004313/WS2794/0029

Merck Sharp & Dohme B.V., Lead PRAC

Rapporteur: Bianca Mulder, PRAC-CHMP liaison:

Patrick Vrijlandt, “Submission of the final report

from study 8835-062 listed as a category 3

study in the RMP for Steglatro, Steglujan and

Segluromet. This is a non-interventional post-

authorization safety study (PASS) to assess the

risk of diabetic ketoacidosis (DKA) among type

2 diabetes mellitus patients treated with

ertugliflozin compared to patients treated with

other antihyperglycemic agents. The RMP

version 2.3 have also been submitted.”

Request for Supplementary Information adopted

on 16.01.2025.

Request for supplementary information adopted with a specific timetable.

B.5.5. CHMP-CAT assessed procedures

CARVYKTI - Ciltacabtagene autoleucel -

EMA/H/C/005095/II/0035, Orphan,

ATMP

Janssen-Cilag International NV, Rapporteur: Jan

Mueller-Berghaus, CHMP Coordinator: Jan

Mueller-Berghaus

Opinion adopted on 30.01.2025, 24.01.2025.

Positive Opinion adopted by consensus on 30.01.2025.

Imlygic - Talimogene laherparepvec -

EMA/H/C/002771/II/0068, ATMP

Amgen Europe B.V., Rapporteur: Maija

Tarkkanen, CHMP Coordinator: Johanna

Lähteenä

Opinion adopted on 30.01.2025, 24.01.2025.

Positive Opinion adopted by consensus on 30.01.2025.

Zolgensma - Onasemnogene abeparvovec -

EMA/H/C/004750/II/0055, Orphan,

Positive Opinion adopted by consensus on

ATMP Novartis Europharm Limited, Rapporteur: Emmely de Vries, CHMP Coordinator: Peter Mol Opinion adopted on 30.01.2025, 24.01.2025.	30.01.2025.
WS2813/G Tecartus- EMA/H/C/005102/WS2813/0055/G Yescarta- EMA/H/C/004480/WS2813/0086/G Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus.	Positive Opinion adopted by consensus on 16.01.2025.

B.5.6. CHMP-PRAC-CAT assessed procedures

Kymriah - Tisagenlecleucel - EMA/H/C/004090/II/0092, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Gabriele Maurer, "Update of section 4.2 of the SmPC in order to update the 'monitoring after infusion' recommendations, based on existing clinical trial data as well as literature references reporting real word experience. The Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to introduce a minor change to the HCP educational programme in the Annex II in order to enhance readability." Request for Supplementary Information adopted on 24.01.2025.	Request for supplementary information adopted with a specific timetable.
--	---

B.5.7. PRAC assessed ATMP procedures

PRAC Led CARVYKTI - Ciltacabtagene autoleucel - EMA/H/C/005095/II/0034, Orphan, ATMP Janssen-Cilag International NV, PRAC Rapporteur: Jo Robays, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of an updated RMP version 5.2 in order to add a new important identified risk of "Secondary malignancy of T-cell origin", to change the important potential risk of "Second primary malignancies" to "Second primary malignancy except secondary malignancy of T-cell origin", and to include an additional pharmacovigilance	Request for supplementary information adopted with a specific timetable.
--	---

activity for testing of secondary malignancies of T-cell origin, following the PRAC recommendation for the Secondary malignancy of T-cell origin signal (EPITT no: 20040)."

Request for Supplementary Information adopted on 24.01.2025.

PRAC Led

Strimvelis - Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - EMEA/H/C/003854/II/0040, Orphan, ATMP

Fondazione Telethon ETS, PRAC Rapporteur: Liana Martirosyan, PRAC-CHMP liaison: Patrick Vrijlandt, "Submission of an updated RMP version 7.0 in order to propose amendments to the STRIM-005 and STRIM-003 study protocols, as well as revised timelines for completion of both studies. In addition, the Annex II is updated accordingly. Following the request for supplementary information, the MAH submitted an updated RMP (Version 7.1) and further amendments to the STRIM-005 (protocol version: 3.1) and STRIM-003 (clinical protocol number: 5.1) study protocols."

Opinion adopted on 30.01.2025, 24.01.2025.

Request for Supplementary Information adopted on 13.09.2024.

Positive Opinion adopted by consensus on 30.01.2025.

PRAC Led

WS2771

Tecartus-

EMEA/H/C/005102/WS2771/0054

Yescarta-

EMEA/H/C/004480/WS2771/0084

Kite Pharma EU B.V., Lead PRAC Rapporteur: Karin Erneholm, PRAC-CHMP liaison: Boje Kvorning Pires Ehmsen, "Submission of an updated RMP version 4.3 for Tecartus and version 11.1 for Yescarta following the PRAC recommendation for the Secondary malignancy of T-cell origin signal (EPITT no: 20040), and of a PASS protocol for a framework for the sampling and testing of secondary malignancies of T-cell origin."

Request for Supplementary Information adopted on 24.01.2025.

Request for supplementary information adopted with a specific timetable.

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2737 Olanzapine Glenmark- EMA/H/C/001085/WS2737/0044 Olanzapine Glenmark Europe- EMA/H/C/001086/WS2737/0041 Olazax-EMA/H/C/001087/WS2737/0036 Olazax Disperzi- EMA/H/C/001088/WS2737/0038 Glenmark Arzneimittel GmbH, Generic of Olansek (SRD), Zyprexa, Zyprexa Velotab, Lead Rapporteur: Alexandre Moreau Opinion adopted on 30.01.2025. Request for Supplementary Information adopted on 12.12.2024.	Positive Opinion adopted by consensus on 30.01.2025.
WS2765/G Aflunov- EMA/H/C/002094/WS2765/0087/G Foclivia- EMA/H/C/001208/WS2765/0090/G Zoonotic Influenza Vaccine Seqirus- EMA/H/C/006375/WS2765/0006/G Seqirus S.r.l., Informed Consent of Aflunov, Lead Rapporteur: Maria Grazia Evandri Opinion adopted on 19.12.2024. Request for Supplementary Information adopted on 31.10.2024.	Positive Opinion adopted by consensus on 19.12.2024.
WS2774/G Dapagliflozin Viatris- EMA/H/C/006006/WS2774/0005/G Viatris Limited, Generic of Forxiga, Lead Rapporteur: Tomas Radimersky Request for Supplementary Information adopted on 16.01.2025.	Request for supplementary information adopted with a specific timetable.
WS2786 BiResp Spiromax- EMA/H/C/003890/WS2786/0045 DuoResp Spiromax- EMA/H/C/002348/WS2786/0045 Teva Pharma B.V., Lead Rapporteur: John Joseph Borg Opinion adopted on 16.01.2025. Request for Supplementary Information adopted on 05.12.2024.	Positive Opinion adopted by consensus on 16.01.2025.
WS2788 Biopoin- EMA/H/C/001036/WS2788/0057 Eporatio-	Positive Opinion adopted by consensus on 16.01.2025.

EMA/H/C/001033/WS2788/0056

ratiopharm GmbH, Lead Rapporteur: Alexandre

Moreau

Opinion adopted on 16.01.2025.

WS2790

M-M-RvaxPro-

EMA/H/C/000604/WS2790/0129

ProQuad-

EMA/H/C/000622/WS2790/0170

Merck Sharp & Dohme B.V., Lead Rapporteur:

Jan Mueller-Berghaus

Opinion adopted on 19.12.2024.

Positive Opinion adopted by consensus on
19.12.2024.

WS2791/G

Aflunov-

EMA/H/C/002094/WS2791/0091/G

Foclivia-

EMA/H/C/001208/WS2791/0095/G

Zoonotic Influenza Vaccine Seqirus-

EMA/H/C/006375/WS2791/0009/G

Seqirus S.r.l., Lead Rapporteur: Maria Grazia

Evandri

Request for Supplementary Information adopted
on 19.12.2024.

Request for supplementary information adopted
with a specific timetable.

WS2795

Glyxambi-

EMA/H/C/003833/WS2795/0063

Jentadueto-

EMA/H/C/002279/WS2795/0076

Trajenta-

EMA/H/C/002110/WS2795/0057

Boehringer Ingelheim International GmbH, Lead

Rapporteur: Patrick Vrijlandt

Opinion adopted on 16.01.2025.

Positive Opinion adopted by consensus on
16.01.2025.

WS2797

Vfend-EMA/H/C/000387/WS2797/0157

Pfizer Europe MA EEIG, Lead Rapporteur:

Patrick Vrijlandt

Opinion adopted on 23.01.2025.

Positive Opinion adopted by consensus on
23.01.2025.

WS2811/G

Abseamed-

EMA/H/C/000727/WS2811/0112/G

Binocrit-

EMA/H/C/000725/WS2811/0112/G

Epoetin alfa Hexal-

EMA/H/C/000726/WS2811/0112/G

Sandoz GmbH, Lead Rapporteur: Alexandre

Moreau

Positive Opinion adopted by consensus on
16.01.2025.

Opinion adopted on 16.01.2025.

WS2812/G

Filgrastim Hexal-

EMA/H/C/000918/WS2812/0080/G

Zarzio-

EMA/H/C/000917/WS2812/0081/G

Sandoz GmbH, Lead Rapporteur: Peter Mol

Opinion adopted on 16.01.2025.

Positive Opinion adopted by consensus on
16.01.2025.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

Nadofaragene firadenovec -

EMA/H/C/005856, ATMP

treatment of adult patients with high-grade (HG),
Bacillus Calmette-Guérin (BCG)-unresponsive
non-muscle invasive bladder cancer (NMIBC).,

Nogapendekin alfa inbakicept -

EMA/H/C/006622

treatment of adult patients with BCG-
unresponsive non-muscle invasive bladder
cancer (NMIBC) with carcinoma in situ (CIS)
with or without papillary tumours

Blarcamesine - EMA/H/C/006475

treatment of Alzheimer's disease and dementia

Influenza and COVID-19 vaccine -

EMA/H/C/006472

immunisation for the prevention of diseases
associated with seasonal influenza viruses and
SARS-CoV-2

Donidalorsen - EMA/H/C/006554

for routine prevention of recurrent attacks of
hereditary angioedema (HAE)

Trofinetide - EMA/H/C/006482, Orphan

Comharsa Life Sciences Limited, Treatment of
Rett syndrome in adults and paediatric patients
2 years of age and older

Denosumab - EMA/H/C/006722

prevention of skeletal related events with
advanced malignancies

Aflibercept - EMA/H/C/006745

treatment of age-related macular degeneration
(AMD) and visual impairment, treatment of age-
related macular degeneration (AMD), visual
impairment and retinopathy of prematurity

(ROP)

Depemokimab - EMEA/H/C/006446

As an add-on maintenance treatment of asthma, and as an add-on treatment of inadequately controlled Chronic rhinosinusitis with nasal polyps (CRSwNP)

Iloperidone - EMEA/H/C/006561

treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar I disorder

Germanium (68Ge) chloride / Gallium

(68Ga) chloride - EMEA/H/C/006639

indicated for in vitro radiolabelling of specific carrier molecules to be used for positron emission tomography (PET) imaging

Golimumab - EMEA/H/C/006621

treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Eflornithine - EMEA/H/C/006067, Orphan

Norgine B.V., treatment of high-risk neuroblastoma responsive to prior multiagent, multimodality therapy

Lutetium (177Lu) chloride -

EMEA/H/C/006596

used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride

Imlunestrant - EMEA/H/C/006184

treatment of adult patients with estrogen receptor (ER)-positive

In vitro diagnostic medical device -

EMEA/H/D/006656

assay to assess the mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6) in formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) tissue using EnVision FLEX visualization system on Dako Omnis automated staining instrument

mRNA-1283 - EMEA/H/C/006428

Active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 12 years of age and older.

Aficamten - EMEA/H/C/006228

treatment of symptomatic obstructive

hypertrophic cardiomyopathy (oHCM) in adult patients

Denosumab - EMEA/H/C/006492

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment of bone loss associated with hormone ablation in men with prostate cancer and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients.

Ranibizumab - EMEA/H/C/006502

Treatment of: neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to choroidal neovascularisation (CNV), retinopathy of prematurity (ROP) with zone.

Teplizumab - EMEA/H/C/005496

To delay both the onset of Stage 3 type 1 diabetes (T1D) and the progression of Stage 3 T1D

Autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding human Wiskott-Aldrich syndrome protein - EMEA/H/C/006525, Orphan, ATMP

Fondazione Telethon Ets, treatment of patients with Wiskott-Aldrich Syndrome (WAS)

Mavorixafor - EMEA/H/C/006496, Orphan

X4 Pharmaceuticals (Austria) GmbH, Treatment of WHIM syndrome

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Koselugo - Selumetinib -

EMEA/H/C/005244/X/0018/G, Orphan

AstraZeneca AB, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Mari Thorn, "Extension application to introduce a new pharmaceutical form (Granules in capsules for opening) associated with new strengths (5 mg and 7.5 mg capsule) grouped with a Type II variation (C.I.4) to update sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to align the SmPC and

labelling of Koselugo capsules and Koselugo granules in capsules for opening. The Package Leaflet and Labelling are updated accordingly. The RMP version 3.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

**Lunsumio - Mosunetuzumab -
EMA/H/C/005680/X/0015, Orphan**

Roche Registration GmbH, Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Mari Thorn, “Extension application to introduce a new pharmaceutical form (solution for injection) associated with two new strengths (5 mg and 45 mg) and new route of administration (subcutaneous use). The RMP (version 3.0) is updated in accordance.”

**Remsima - Infliximab -
EMA/H/C/002576/X/0149**

Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, “Extension application to introduce a new pharmaceutical form (concentrate for solution for infusion) associated with a new strength (40 mg/ml).”

**Saphnelo - Anifrolumab -
EMA/H/C/004975/X/0023**

AstraZeneca AB, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Liana Martirosyan, “Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new route of administration (subcutaneous use) and a new strength (120 mg).”

**Spinraza - Nusinersen -
EMA/H/C/004312/X/0038, Orphan**

Biogen Netherlands B.V., Rapporteur: Fátima Ventura, PRAC Rapporteur: Karin Bolin, “Extension application to add a new strength of 28 mg and 50 mg. The RMP (version 12.x) is updated in accordance (version 12.2 is under assessment in procedure EMA/H/C/004312/II/0034/G).”

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

**Adempas - Riociguat -
EMA/H/C/002737/X/0041**

Bayer AG, Rapporteur: Patrick Vrijlandt, PRAC
Rapporteur: Kimmo Jaakkola, "Extension
application to introduce a new pharmaceutical
form associated with a new strength (0.15
mg/ml granules for oral suspension) for the
Pulmonary arterial hypertension (PAH)
paediatric indication. As a consequence, the film
coated tablets presentations are updated to
accommodate the new pharmaceutical form. In
addition, contact details for local representatives
of Belgium, Luxembourg, Greece and Ireland,
have also been updated."

List of Questions adopted on 17.10.2024.

**Deutivacaftor / Tezacaftor / Vanzacaftor -
EMA/H/C/006382, Orphan**

Vertex Pharmaceuticals (Ireland) Limited,
indicated for the treatment of cystic fibrosis
List of Questions adopted on 19.09.2024.

**L-Acetylleucine - EMA/H/C/006327,
Orphan**

Intrabio Ireland Limited, is indicated in adults
and children from birth for chronic treatment of
Niemann-Pick Type C (NPC).
List of Questions adopted on 17.10.2024.

Atropine - EMA/H/C/006385, PUMA

treatment of myopia in children aged 3 years
and older
List of Questions adopted on 19.09.2024.

**Obecabtagene autoleucel -
EMA/H/C/005907, Orphan, ATMP**

Autolus GmbH, treatment of patients with
relapsed or refractory B cell precursor acute
lymphoblastic leukaemia (ALL)
List of Questions adopted on 19.07.2024.

Deutetrabenazine - EMA/H/C/006371

treatment of tardive dyskinesia
List of Questions adopted on 25.07.2024.

Denosumab - EMA/H/C/006434

treatment of osteoporosis and bone loss
List of Questions adopted on 19.09.2024.

Denosumab - EMA/H/C/006435

prevention of skeletal related events with
advanced malignancies
List of Questions adopted on 19.09.2024.

Denosumab - EMA/H/C/006269

prevention of skeletal related events with

advanced malignancies
List of Questions adopted on 17.10.2024.

Denosumab - EMEA/H/C/006268
treatment of osteoporosis and bone loss
List of Questions adopted on 17.10.2024.

Denosumab - EMEA/H/C/006199
prevention of skeletal related events with
advanced malignancies, treatment of adults and
skeletally mature adolescents with giant cell
tumour of bone
List of Questions adopted on 19.09.2024.

Denosumab - EMEA/H/C/006526
treatment of osteoporosis and bone loss
List of Questions adopted on 12.12.2024.

Denosumab - EMEA/H/C/006376
prevention of skeletal related events with
advanced malignancies, treatment of adults and
skeletally mature adolescents with giant cell
tumour of bone
List of Questions adopted on 19.09.2024.

**Emtricitabine / Tenofovir alafenamide -
EMEA/H/C/006469**
for the treatment of human immunodeficiency
virus type 1 (HIV-1)
List of Questions adopted on 17.10.2024.

Inavolisib - EMEA/H/C/006353
treatment of adult patients with PIK3CA-
mutated, hormone receptor (HR)-positive,
human epidermal growth factor receptor 2
(HER2)-negative, locally advanced or metastatic
breast cancer
List of Questions adopted on 19.09.2024.

Denosumab - EMEA/H/C/006152
for the treatment of osteoporosis and bone loss.
List of Questions adopted on 19.09.2024.

**Autologous cartilage-derived articular
chondrocytes, in-vitro expanded -
EMEA/H/C/004594, ATMP**
repair of symptomatic, localised, full-thickness
cartilage defects of the knee joint grade III or
IV
List of Questions adopted on 19.04.2024.

Octreotide - EMEA/H/C/006322, Orphan
Camurus AB, treatment of acromegaly
List of Questions adopted on 19.09.2024.

Resmetirom - EMEA/H/C/006220

for the treatment of adults with nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis

List of Questions adopted on 27.06.2024.

REZOLSTA - Darunavir / Cobicistat - EMEA/H/C/002819/X/0054/G

Janssen-Cilag International N.V., Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Amelia Cupelli, "Extension application to introduce a new strength (675 mg/150 mg film-coated tablets) grouped with an extension of indication (C.I.6.a) to include, treatment of HIV-1 infected paediatric patients (aged 6 years and older with body weight at least 25 kg) for REZOLSTA, based on the 48-week ad hoc interim results from study GS-US-216-0128 (Cohort 2); this is a Phase II/III, multicentre, open-label, multicohort interventional study evaluating efficacy, safety, and pharmacokinetics of cobicistat-boosted darunavir in HIV-1 infected children. As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.1, 6.3, 6.5 and 8 of the SmPC and Annex II are updated. The Package Leaflet and Labelling are updated in accordance. Version 7.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.4."

List of Questions adopted on 17.10.2024.

Sepiapterin - EMEA/H/C/006331, Orphan

PTC Therapeutics International Limited, treatment of hyperphenylalaninemia (HPA) in adult and paediatric patients with phenylketonuria (PKU)

List of Questions adopted on 19.09.2024.

Spikevax - COVID-19 mRNA vaccine - EMEA/H/C/005791/X/0140

Moderna Biotech Spain S.L., Rapporteur: Jan Mueller-Berghaus, "Extension application to add a new strength of 25 µg, XBB.1.5, Dispersion for injection."

List of Questions adopted on 14.11.2024.

Teprotumumab - EMEA/H/C/006396

treatment of moderate to severe Thyroid Eye Disease (TED).

List of Questions adopted on 19.09.2024.

Teriparatide - EMEA/H/C/005687

treatment of osteoporosis

List of Questions adopted on 09.11.2023.

Denosumab - EMEA/H/C/006534

prevention of skeletal related events with
advanced malignancies

List of Questions adopted on 12.12.2024.

Aflibercept - EMEA/H/C/006192

treatment of age-related macular degeneration
(AMD), visual impairment and retinopathy of
prematurity (ROP)

List of Questions adopted on 25.07.2024.

Tegomil fumarate - EMEA/H/C/006427

treatment of multiple sclerosis

List of Questions adopted on 25.07.2024.

Xofluza - Baloxavir marboxil -**EMEA/H/C/004974/X/0022**

Roche Registration GmbH, Rapporteur: Thalia
Marie Estrup Blicher, PRAC Rapporteur: Sonja
Hrabcik, "Extension application to add a new
pharmaceutical form (granules) associated with
three new strengths (10, 30 and 40 mg)
packaged in sachet (PET/alu/PET)."

List of Questions adopted on 14.11.2024.

Human albumin solution -**EMEA/H/D/006540**

Ex vivo heart perfusion

List of Questions adopted on 14.11.2024.

Denosumab - EMEA/H/C/006377

for the treatment of osteoporosis and bone loss

List of Questions adopted on 19.09.2024.

**Dorocubicel / Allogeneic umbilical cord-
derived CD34- cells, non-expanded -****EMEA/H/C/005772, Orphan, ATMP**

Cordex Biologics International Limited,
treatment of adult patients with haematological
malignancies

List of Questions adopted on 11.10.2024.

Zanidatamab - EMEA/H/C/006380, Orphan

Jazz Pharmaceuticals Ireland Limited, Treatment
of biliary tract cancer

List of Questions adopted on 17.10.2024.

B.6.4. Annual Re-assessments: timetables for adoption

Ceplene - Histamine dihydrochloride -

EMA/H/C/000796/S/0049

Laboratoires Delbert, Rapporteur: Jayne Crowe,
PRAC Rapporteur: Eamon O Murchu

Defitelio - Defibrotide -**EMA/H/C/002393/S/0069, Orphan**

Gentium S.r.l., Rapporteur: Kristina Dunder,
PRAC Rapporteur: Mari Thorn

Livmarli - Maralixibat -**EMA/H/C/005857/S/0019, Orphan**

Mirum Pharmaceuticals International B.V.,
Rapporteur: Janet Koenig, PRAC Rapporteur:
Adam Przybylkowski,

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

ARIKAYCE liposomal - Amikacin -**EMA/H/C/005264/R/0014, Orphan**

Insmed Netherlands B.V., Rapporteur: Jayne
Crowe, Co-Rapporteur: Ewa Balkowiec Iskra,
PRAC Rapporteur: Jean-Michel Dogné

Arsenic trioxide medac - Arsenic trioxide -**EMA/H/C/005218/R/0006**

medac Gesellschaft für klinische
Spezialpräparate mbH, Generic of TRISENOX,
Rapporteur: Daniela Philadelphia, PRAC
Rapporteur: Tiphaine Vaillant

Cabazitaxel Accord - Cabazitaxel -**EMA/H/C/005178/R/0012**

Accord Healthcare S.L.U., Rapporteur: Hrefna
Gudmundsdottir, PRAC Rapporteur: Tiphaine
Vaillant

Columvi - Glofitamab -**EMA/H/C/005751/R/0012, Orphan**

Roche Registration GmbH, Rapporteur: Boje
Kvorning Pires Ehmsen, PRAC Rapporteur: Jana
Lukacisinova

Jyseleca - Filgotinib -**EMA/H/C/005113/R/0038**

Alfasigma S.p.A., Rapporteur: Kristina Dunder,
Co-Rapporteur: Jean-Michel Race, PRAC
Rapporteur: Petar Mas

Koselugo - Selumetinib -**EMA/H/C/005244/R/0019, Orphan**

AstraZeneca AB, Rapporteur: Alexandre Moreau,
PRAC Rapporteur: Mari Thorn

Lumebblue - Methylthioninium chloride -
EMA/H/C/002776/R/0007

Cosmo Technologies Limited, Rapporteur: Boje
Kvorning Pires Ehmsen, PRAC Rapporteur: Mari
Thorn

Lunsumio - Mosunetuzumab -
EMA/H/C/005680/R/0014, Orphan

Roche Registration GmbH, Rapporteur: Boje
Kvorning Pires Ehmsen, PRAC Rapporteur: Mari
Thorn

Lytgobi - Futibatinib -
EMA/H/C/005627/R/0008

Taiho Pharma Netherlands B.V., Rapporteur:
Peter Mol, PRAC Rapporteur: Mari Thorn

PHELINUN - Melphalan -
EMA/H/C/005173/R/0005

ADIENTE S.r.l., Rapporteur: Peter Mol, PRAC
Rapporteur: Mari Thorn

Raxone - Idebenone -
EMA/H/C/003834/R/0043, Orphan

Chiesi Farmaceutici S.p.A., Rapporteur: John
Joseph Borg, PRAC Rapporteur: Amelia Cupelli

Rozlytrek - Entrectinib -
EMA/H/C/004936/R/0026

Roche Registration GmbH, Rapporteur: Paolo
Gasparini, PRAC Rapporteur: Bianca Mulder

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Clopidogrel Zentiva - Clopidogrel -
EMA/H/C/000975/II/0092

Zentiva k.s., Duplicate of Clopidogrel BMS
(SRD), Informed Consent of Iscover,
Rapporteur: Fátima Ventura, PRAC Rapporteur:
Carla Torre, "Extension of indication to include,
in combination with acetylsalicylic acid (ASA),
patients with ST segment elevation acute
myocardial infarction (STEMI) who are
undergoing percutaneous coronary intervention
(PCI) for CLOPIDOGREL ZENTIVA. As a
consequence, sections 4.1, 4.2, 4.4 and 5.1 of
the SmPC are updated. Version 0.1 of the RMP
has also been submitted. In addition, the
Marketing authorisation holder (MAH) took the

opportunity to update the list of local representatives in the Package Leaflet, introduce minor editorial changes to the PI and bring it in line with the latest QRD template version 10.4.

Flucelvax - Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) - EMEA/H/C/006532/II/0001

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz, PRAC Rapporteur: Gabriele Maurer, "Extension of indication to include treatment of children from 6 months of age and older for FLUCELVAX, based on results from study V130_14. This is a Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 4.0 of the RMP is also being submitted.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the MAH took the opportunity to implement changes to sections 4.4 and 4.5 of the SmPC.

Imbruvica - Ibrutinib - EMEA/H/C/003791/II/0092

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Barbara Kovacic Bytyqi, "Extension of indication to include IMBRUVICA in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplantation (ASCT), based on results from study MCL3003. This is a randomized, 3-arm, parallel-group, open-label, international, multicenter Phase 3 study. The purpose of Study MCL3003 is to compare 3 alternating courses of R CHOP/R-DHAP followed by ASCT (control Arm A), versus the combination with ibrutinib in induction and maintenance (experimental Arm A+I), or the experimental arm without ASCT (experimental

Arm I) in participants with previously untreated MCL who are eligible for ASCT. Consequently, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Version 23.1 of the RMP has also been submitted.”

LUTATHERA - Lutetium (177Lu)

oxodotreotide -

EMA/H/C/004123/II/0058, Orphan

Advanced Accelerator Applications, Rapporteur:

Janet Koenig, PRAC Rapporteur: Adam

Przybylowski, “Extension of indication to

include the treatment of unresectable or

metastatic, somatostatin receptor-positive

gastroenteropancreatic neuroendocrine tumours

(GEP-NETs) in adolescents aged 12 years and

older for LUTATHERA based on primary analysis

results from study CAAA601A32201 (also

referred to as NETTER-P) as well as results from

modelling and simulation analysis of PK and

dosimetry data of Lutathera in adolescents.

NETTER-P study is a Phase II, multicenter open-

label study which evaluated the safety and

dosimetry of Lutathera in adolescent patients

with somatostatin receptor positive

gastroenteropancreatic neuroendocrine tumours

(GEP-NETs) and pheochromocytoma and

paragangliomas (PPGLs). As a consequence,

sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 11 of

the SmPC are updated. The Package Leaflet is

updated in accordance. Version 4.0 of the RMP

has also been submitted.

Paxlovid - Nirmatrelvir / Ritonavir -

EMA/H/C/005973/II/0061/G

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel

Race Co-Rapporteur: Fátima Ventura, PRAC

Rapporteur: Martin Huber, “A grouped

application comprised of a Type II Variation and

a Type IB Variation, as follows:

Type II (C.I.6.a): Extension of indication to

include treatment of coronavirus disease 2019

(COVID-19) in paediatric patients 6 years of age

and older weighing at least 20 kg for PAXLOVID,

based on the final analysis of Cohorts 1 and 2

from pivotal Study C4671026; this is a Phase

2/3, Interventional Safety, Pharmacokinetics,

and Efficacy, Open-Label, Multi-Center, Single-Arm Study to Investigate Orally Administered PF 07321332 (Nirmatrelvir)/Ritonavir in Nonhospitalized Symptomatic Pediatric Participants With COVID-19 Who Are at Risk of Progression to Severe Disease. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection.

Type IB (B.II.e.5.a.2): To add a new pack-size ; the Package Leaflet and Labelling are updated accordingly.”

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**SARCLISA - Isatuximab -
EMA/H/C/004977/II/0035**

Sanofi Winthrop Industrie, Rapporteur: Peter Mol, Co-Rapporteur: Alexandre Moreau,
“Extension of indication to include, in combination with bortezomib, lenalidomide and dexamethasone, the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant (ASCT) for SARCLISA, based on the results from study IIT15403 (GMMG-HD7); this is a randomized phase III study designed to assess the efficacy and safety of Sarclisa for the induction and maintenance treatment of NDMM. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial and formatting changes to the PI.”

**Simponi - Golimumab -
EMA/H/C/000992/II/0121**

Janssen Biologics B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Karin Bolin,
“Extension of indication to include treatment of paediatric ulcerative colitis for SIMPONI, based on results from study CNTO148UCO3003; this is

a Phase 3 Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNF α Monoclonal Antibody, Administered Subcutaneously in Paediatric Participants with Moderately to Severely Active Ulcerative Colitis; As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 of the SmPC are updated. Version 28.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is updated in accordance with the latest EMA excipients guideline and aligned with the latest QRD template version 10.4.”

**Tevimbra - Tislelizumab -
EMA/H/C/005919/II/0018**

Beigene Ireland Limited, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder, “Extension of indication for Tevimbra in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable NSCLC based on interim results from study BGB-A317-315. Study BGB-A317-315 is a phase 3 randomized, placebo-controlled, double-blind study to compare the efficacy and safety of neoadjuvant treatment with tislelizumab plus platinum-based doublet chemotherapy followed by adjuvant tislelizumab versus neoadjuvant treatment with placebo plus platinum-based doublet chemotherapy followed by adjuvant placebo in patients with resectable Stage II or IIIA NSCLC. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.7 of the RMP has also been submitted.”

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

**Adtralza - Tralokinumab -
EMA/H/C/005255/II/0023**

LEO Pharma A/S, Rapporteur: Jayne Crowe

**Advate - Octocog alfa -
EMA/H/C/000520/II/0124**

Takeda Manufacturing Austria AG, Rapporteur:

Jan Mueller-Berghaus

Briumvi - Ublituximab -

EMA/H/C/005914/II/0023/G

Neuraxpharm Pharmaceuticals S.L., Rapporteur:

Ewa Balkowiec Iskra

Ceprothin - Human protein C -

EMA/H/C/000334/II/0143/G

Takeda Manufacturing Austria AG, Rapporteur:

Jan Mueller-Berghaus

**Cervarix - human papillomavirus vaccine
[types 16, 18] (recombinant, adjuvanted,
adsorbed) - EMA/VR/0000232276**

GlaxoSmithKline Biologicals, Rapporteur:

Christophe Focke, PL: Elisa Pedone,

**CooperSurgical Inc ART Media - Human
albumin solution -**

EMA/H/D/002307/II/0012

Coopersurgical Inc., Rapporteur: Kristina

Dunder

Cosentyx - Secukinumab -

EMA/H/C/003729/II/0124

Novartis Europharm Limited, Rapporteur: Outi

Mäki-Ikola

ELAHERE - Mirvetuximab soravtansine -

EMA/H/C/005036/II/0001/G, Orphan

AbbVie Deutschland GmbH & Co. KG,

Rapporteur: Johanna Lähteenvujo

Entyvio - Vedolizumab -

EMA/H/C/002782/II/0088/G

Takeda Pharma A/S, Rapporteur: Paolo

Gasparini

EVRA - Ethinylestradiol / Norelgestromin -

EMA/H/C/000410/II/0054

Gedeon Richter Plc., Rapporteur: Patrick

Vrijlandt

**Fluad - Influenza vaccine (surface antigen,
inactivated, adjuvanted) -**

EMA/H/C/006538/II/0001/G

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

GIVLAARI - Givosiran -

EMA/H/C/004775/II/0022, Orphan

Alnylam Netherlands B.V., Rapporteur: Patrick

Vrijlandt

GONAL-f - Follitropin alfa -**EMA/H/C/000071/II/0177/G**

Merck Europe B.V., Rapporteur: Patrick Vrijlandt

Hizentra - Human normal immunoglobulin -**EMA/H/C/002127/II/0163**

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Hizentra - Human normal immunoglobulin -**EMA/H/C/002127/II/0164**

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Idacio - Adalimumab -**EMA/H/C/004475/II/0024/G**

Fresenius Kabi Deutschland GmbH, Rapporteur: Peter Mol, PRAC Rapporteur: Karin Bolin

Lamzede - Velmanase alfa -**EMA/H/C/003922/II/0040/G, Orphan**

Chiesi Farmaceutici S.p.A., Rapporteur: Patrick Vrijlandt

LifeGlobal Media - Human albumin solution**- EMA/H/D/004287/II/0009**

Coopersurgical Inc., Rapporteur: Maria Grazia Evandri

Origio - Human albumin solution -**EMA/H/D/000830/II/0021**

Coopersurgical Inc., Rapporteur: Jayne Crowe

Ozempic - Semaglutide -**EMA/H/C/004174/II/0051**

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt

Paxlovid - Nirmatrelvir / Ritonavir -**EMA/H/C/005973/II/0060**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race

POTELIGEO - Mogamulizumab -**EMA/H/C/004232/II/0028/G, Orphan**

Kyowa Kirin Holdings B.V., Rapporteur: Peter Mol

Privigen - Human normal immunoglobulin -**EMA/H/C/000831/II/0213**

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

Privigen - Human normal immunoglobulin -**EMA/H/C/000831/II/0214**

CSL Behring GmbH, Rapporteur: Jan Mueller-

Berghaus

Roclanda - Latanoprost / Netarsudil -

EMA/H/C/005107/II/0031/G

Santen Oy, Rapporteur: Jayne Crowe

Semglee - Insulin glargine -

EMA/H/C/004280/II/0053

Biosimilar Collaborations Ireland Limited,

Rapporteur: Janet Koenig

Simulect - Basiliximab -

EMA/H/C/000207/II/0123/G

Novartis Europharm Limited, Rapporteur: Jan

Mueller-Berghaus

Skyrizi - Risankizumab -

EMA/H/C/004759/II/0054/G

AbbVie Deutschland GmbH & Co. KG,

Rapporteur: Finbarr Leacy

Skyrizi - Risankizumab -

EMA/H/C/004759/II/0056/G

AbbVie Deutschland GmbH & Co. KG,

Rapporteur: Finbarr Leacy

Sondelbay - Teriparatide -

EMA/H/C/005827/II/0008

Accord Healthcare S.L.U., Rapporteur: Finbarr

Leacy

TAKHZYRO - Lanadelumab -

EMA/H/C/004806/II/0043/G, Orphan

Takeda Pharmaceuticals International AG

Ireland Branch, Rapporteur: Kristina Dunder

Trulicity - Dulaglutide -

EMA/H/C/002825/II/0073/G

Eli Lilly Nederland B.V., Rapporteur: Janet

KoenigOpinion adopted on 16.01.2025.

Ultomiris - Ravulizumab -

EMA/H/C/004954/II/0048

Alexion Europe SAS, Rapporteur: Antonio

Gomez-Outes

Vyloy - Zolbetuximab -

EMA/H/C/005868/II/0006/G, Orphan

Astellas Pharma Europe B.V., Rapporteur: Jan

Mueller-Berghaus

Wegovy - Semaglutide -

EMA/H/C/005422/II/0027

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt

WS2622

HyQvia-EMA/H/C/002491/WS2622/0103

Kiovig-EMA/H/C/000628/WS2622/0130

Takeda Manufacturing Austria AG, Lead

Rapporteur: Jan Mueller-Berghaus

WS2804/G

Aerius-

EMA/H/C/000313/WS2804/0108/G

Azomyr-

EMA/H/C/000310/WS2804/0112/G

Neoclarityn-

EMA/H/C/000314/WS2804/0106/G

Organon N.V., Duplicate of Allex (SRD),

Azomyr, Opulis (SRD), Lead Rapporteur:

Christophe Focke

WS2805/G

Celldemic-

EMA/H/C/006052/WS2805/0003/G

Incellipan-

EMA/H/C/006051/WS2805/0003/G

Seqirus Netherlands B.V., Lead Rapporteur:

Daniela Philadelphia

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

AQUIPTA - Atogepant -

EMA/H/C/005871/II/0008

AbbVie Deutschland GmbH & Co. KG,

Rapporteur: Janet Koenig, "Update of section

4.6 of the SmPC in order to amend information on pregnancy and lactation based on data from study M22-394; this is a phase 1 lactation study to evaluate the pharmacokinetics and safety of ubrogepant and atogepant in healthy adult lactating female subjects one to six months post-partum. The Package Leaflet is updated accordingly."

Cerezyme - Imiglucerase -

EMA/H/C/000157/II/0136

Sanofi B.V., Rapporteur: Patrick Vrijlandt,

"Update of sections 4.4 and 4.8 of the SmPC in order to add 'Transient hypertension' to the list of adverse drug reactions (ADRs) with frequency not known as well as to reflect the warning on Infusion-associated reactions (IARs), based on a safety review. The Package Leaflet is updated accordingly."

Efmody - Hydrocortisone -

EMA/H/C/005105/II/0013

Neurocrine Netherlands B.V., Rapporteur: Patrick Vrijlandt, "Update of sections 4.2, 4.4, 4.5, and 4.8 of the SmPC based on the pooled safety analysis of DIUR-006; this is a phase 3 extension study of efficacy, safety and tolerability of Chronocort in the treatment of congenital adrenal hyperplasia. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes to the PI."

Enhertu - Trastuzumab deruxtecan -

EMA/H/C/005124/II/0054

Daiichi Sankyo Europe GmbH, Rapporteur: Boje Kvorning Pires Ehmsen, "Submission of the final report from study DS8201-A-U201 listed as a Recommendation (REC). This is a phase 2 multicenter, open-label efficacy and safety study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2- positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1."

Fexinidazole Winthrop - Fexinidazole -

EMA/H/W/002320/II/0021

Sanofi Winthrop Industrie, Rapporteur: Fátima Ventura, "Submission of the final report from study DNDi-FEX-09-HAT. This is a phase 3b, open-label study assessing effectiveness, safety and compliance with fexinidazole in patients with human African trypanosomiasis due to T.b. gambiense at any stage."

Fintepla - Fenfluramine -

EMA/H/C/003933/II/0030, Orphan

UCB Pharma SA, Rapporteur: Thalia Marie Estrup Blicher, "Update of section 5.1 of the SmPC in order to include new efficacy data for Lennox-Gastaut syndrome (LGS) based on final results from EP0214 'ZX008-1601' study. This phase 3 Open-Label Extension (OLE) international multicenter study was conducted in two parts and two cohorts. Part 1 was a randomized, double-blind, placebo-controlled trial of two fixed doses of ZX008 (fenfluramine hydrochloride) oral solution as adjunctive therapy for seizures in children and adults with LGS. Part 2 was an open-label extension to assess the long-term safety and tolerability of ZX008 in children and adults."

Imbruvica - Ibrutinib -

EMA/H/C/003791/II/0091

Janssen-Cilag International N.V., Rapporteur:
Filip Josephson, "Submission of the final report from study PCYC-1142-CA (CAPTIVATE). This is a Phase 2, international, multicenter study of the combination of ibrutinib plus venetoclax in subjects with treatment-naïve chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma(SLL) in order to assess both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy."

IMCIVREE - Setmelanotide -

EMA/H/C/005089/II/0034, Orphan

Rhythm Pharmaceuticals Netherlands B.V.,
Rapporteur: Karin Janssen van Doorn, "Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs) based on the availability of new safety data. The Package Leaflet is updated accordingly."

Inrebic - Fedratinib -

EMA/H/C/005026/II/0027, Orphan

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Peter Mol, "Update of sections 4.2 and 5.2 of the SmPC in order to add administration option based on results from clinical trial FEDR-CP-005. This is a phase 1, open-label, single-center, 2-part crossover study to evaluate the relative bioavailability of fedratinib when administered as contents of capsules dispersed in a nutritional supplement orally or via nasogastric tube or administered orally as divided doses of intact capsules with a nutritional supplement in healthy adult subjects. The Package Leaflet is being updated accordingly. In addition, the MAH took the opportunity to add editorial changes to the PI."

Keytruda - Pembrolizumab -

EMA/H/C/003820/II/0165

Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini, "C.I.13: Submission of the final safety analysis report of participants with hematologic malignancies enrolled in MSD Sponsored studies who received an allogeneic hematopoietic stem cell transplantation (HSCT) following therapy with pembrolizumab."

Metalyse - Tenecteplase -

EMA/H/C/000306/II/0075/G

Boehringer Ingelheim International GmbH,
Rapporteur: Janet Koenig, "A grouped application comprised of 4 Type II Variations, as

follows:

C.I.4: Update of sections 4.3 and 4.4 of the SmPC in order to update the safety information pertaining to the prevention of bleeding risk related to thrombolytic treatment based on a dataset consisting of literature review including published clinical study outcomes. The Package Leaflet is updated accordingly.

C.I.4: Update of sections 4.2 and 4.4 of the SmPC in order to update the safety information for patients with body weight < 50 kg based on the dataset consisting of reanalysis of existing clinical data and literature review. The Package Leaflet is updated accordingly.

C.I.4: Update of sections 4.3 and 4.4 of the SmPC related to the medical recommendations for prior stroke patients based on a dataset consisting of reanalysis of existing clinical data and literature review. The Package Leaflet is updated accordingly.

C.I.4: Update of sections 4.2 and 4.4 of the SmPC in order to revise the medical recommendation in line with the most current medical knowledge in treatment guidelines. The Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes to the PI, as well as to update the excipient information according to the latest EU Excipients Guideline. Furthermore, the PI is being brought in line with the latest QRD template (version 10.4)."

**Nuvaxovid - Covid-19 Vaccine
(recombinant, adjuvanted) -
EMA/H/C/005808/II/0097/G**

Novavax CZ a.s., Rapporteur: Patrick Vrijlandt,
"Submission of the final clinical study reports from clinical study 2019nCoV-313 Part 1 and Part 2 listed as a category 3 study in the RMP. This is A 2-Part Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS -CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID-19 Vaccinated and Baseline SARS-CoV-2

Seropositive COVID-19 Vaccine Naïve Participants.”

**OZAWADE - Pitolisant -
EMA/H/C/005117/II/0012**

Bioprojet Pharma, Rapporteur: Peter Mol,
“Submission of the study note PH24048. This is an update of the final PopPK model (PH20043) submitted at initial Marketing Authorisation Approval integrating the results of study 15-03 (HAROSA III). In addition, the results of re-estimated model parameters and covariates are provided.”

**Rezzayo - Rezafungin -
EMA/H/C/005900/II/0007, Orphan**

Mundipharma GmbH, Rapporteur: Fátima Ventura, “ Update of sections 4.8, and 5.1 of the SmPC based on final results of China extension part from study ReSTORE; this is a pivotal Phase 3, multicentre, randomised, double-blind study of the efficacy and safety of rezafungin versus the active control caspofungin IV, followed by optional oral fluconazole step-down, in the treatment of subjects with IC; updated population PK modelling was also presented; the Package Leaflet is updated accordingly.”

**Samsca - Tolvaptan -
EMA/H/C/000980/II/0051**

Otsuka Pharmaceutical Netherlands B.V.,
Rapporteur: Paolo Gasparini, “Update of section 4.5 of the SmPC in order to add drug-drug interaction information with St John’s wort based on literature and to implement the recommendation from EMA on the risk of drug interactions with Hypericum perforatum (St John's Wort) and antiretroviral medicinal products. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

**Skytrofa - Lonapegsomatropin -
EMA/H/C/005367/II/0036, Orphan**

Ascendis Pharma Endocrinology Division A/S,
Rapporteur: Patrick Vrijlandt, “Update of section 5.1 of the SmPC in order to update efficacy and safety information following the request by CHMP in the outcome for procedure EMA/H/C/005367/P46/003.1 based on final results from the paediatric study CT-301EXT

(enliGHten). In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.4.”

**Tabrecta - Capmatinib -
EMA/H/C/004845/II/0016**

Novartis Europharm Limited, Rapporteur:
Antonio Gomez-Outes, “Update of sections 4.8 and 5.1 of the SmPC in order to update information on based on the results of the clinical study CINC280A2201 'GEOMETRY mono-1' and add 'body temperature increased' to the list of adverse drug reactions (ADRs) with frequency 'very common'. CINC280A2201 is a global, multi-cohort, non-randomized, open-label Phase II study designed to evaluate the efficacy and safety of single-agent capmatinib in adult patients with epidermal growth factor receptor (EGFR) wild type (wt), advanced non-small cell lung cancer (NSCLC). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes to the PI.”

**Taltz - Ixekizumab -
EMA/H/C/003943/II/0054**

Eli Lilly and Co (Ireland) Limited, Rapporteur:
Kristina Dunder, “Update section 4.8 of the SmPC to add eczematous eruptions (dyshidrotic eczema and exfoliative dermatitis) to the list of adverse drug reactions (ADRs) with frequency uncommon and rare, respectively, following a review of all associated data. The package leaflet is updated in accordance.”

**Vectibix - Panitumumab -
EMA/H/C/000741/II/0105**

Amgen Europe B.V., Rapporteur: Eva Skovlund,
“Update of section 4.8 of the SmPC in order to update the information regarding the incidence of infusion-related reactions to reflect the total number of subjects. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial and administrative changes to the PI and to bring it in line with the latest QRD template version 10.4, and to update the list of local representatives in the Package Leaflet.”

**Vyloy - Zolbetuximab -
EMA/H/C/005868/II/0005, Orphan**

Astellas Pharma Europe B.V., Rapporteur: Jan Mueller-Berghaus, “Update of section 5.1 of the

SmPC in order to update immunogenicity data based on the validation report for the new method (8951-ME-0016) to replace the method originally used to test ADA samples from the pivotal studies SPOTLIGHT and GLOW. In addition, the MAH took the opportunity to introduce minor formatting changes to the PI.”

**Xarelto - Rivaroxaban -
EMA/H/C/000944/II/0113**

Bayer AG, Rapporteur: Kristina Dunder, “Update of section 4.8 of the SmPC in order to add ‘splenic rupture’ to the list of adverse drug reactions (ADRs) with frequency ‘very rare’ based on the data from the clinical trials, post-marketing data sources and literature; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial updates as agreed with QRD group.”

**Xeljanz - Tofacitinib -
EMA/H/C/004214/II/0068**

Pfizer Europe MA EEIG, Rapporteur: Paolo Gasparini, “Update of section 4.6 of the SmPC in order to update information on breast-feeding section based on literature and post-marketing data. In addition, the MAH took the opportunity to introduce editorial changes to the PI and update the list of local representatives in the Package Leaflet.”

**Zejula - Niraparib -
EMA/H/C/004249/II/0057/G, Orphan**

GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang, “C.I.4: Update of section 4.5 of the SmPC in order to update information on pharmacokinetic drug-drug interactions based on Physiologically based on results from pharmacokinetic (PBPK) modelling; this is Evaluation of GSK3985771 (Niraparib) Drug-Drug Interaction (DDI) Risk Assessment as a Perpetrator using PBPK Modelling; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and introduce editorial changes to the PI.
C.I.4: Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on results from Refined PRIMA Model; this is an amendment to addendum to population pharmacokinetic and exposure-

response modelling of niraparib in PRIMA study;
the Package Leaflet is updated accordingly.”

WS2793

Braftovi-

EMA/H/C/004580/WS2793/0042

Mektovi-

EMA/H/C/004579/WS2793/0036

Pierre Fabre Medicament, Lead Rapporteur:
Janet Koenig, “Submission of the final report
from study C4221004, aiming at investigating
the potential associations between baseline
tumor biomarkers and treatment outcome in the
2-part Phase III Randomized, Open Label,
Multicenter Study of LGX818 Plus MEK162
Versus Vemurafenib and LGX818 Monotherapy
in Patients with Unresectable or Metastatic BRAF
V600 Mutant Melanoma (COLUMBUS study).”

WS2818

PecFent-

EMA/H/C/001164/WS2818/0062

Gruenthal GmbH, Lead Rapporteur: Janet
Koenig, “Update of section 4.5 of the SmPC in
order to add drug-drug interaction information
between opioids and anticholinergics; the
Package Leaflet is updated accordingly.”

**Dengue Tetravalent Vaccine (Live,
Attenuated) Takeda-**

EMA/H/W/005362/WS2809/0021

Qdenga-

EMA/H/C/005155/WS2809/0022

Takeda GmbH, Lead Rapporteur: Sol Ruiz,
“Update of section 4.8 of the SmPC in order to
add eye pain to the list of adverse drug
reactions (ADRs) with frequency uncommon
based on post-marketing data; the Package
Leaflet is updated accordingly. In addition, the
MAH took the opportunity to update the list of
local representatives in the Package Leaflet and
to introduce editorial changes to the PI.”

B.6.10. CHMP-PRAC assessed procedures

Bavencio - Avelumab -

EMA/H/C/004338/II/0051

Merck Europe B.V., Rapporteur: Filip Josephson,
PRAC Rapporteur: Karin Erneholm, “Update of
sections 4.4 and 4.8 of the SmPC in order to
add “neutropenia” to the list of adverse drug
reactions (ADRs) with frequency “not known”

based on post marketing data and literature. The Package Leaflet is updated accordingly. The RMP version 8.2 has also been submitted. In addition, the MAH took the opportunity to update the PI in accordance with the latest EMA excipients guideline.”

**Columvi - Glofitamab -
EMA/H/C/005751/II/0010, Orphan**

Roche Registration GmbH, Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Jana Lukacisinova, “Submission of the updated 2-year follow-up report from study NP30179 listed as a Specific Obligation in the Annex II of the Product Information. This is a multicenter, open-label Phase I/II study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of escalating doses of glofitamab in patients with relapsed/refractory B-cell Non-Hodgkin’s Lymphoma (NHL). The Annex II and the RMP version 4.0 are updated accordingly. Consequently, the MAH proposes a switch from conditional marketing authorisation to full marketing authorisation.”

**Kayfanda - Odevixibat -
EMA/H/C/006462/II/0001/G**

Ipsen Pharma, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Adam Przybylkowski, “A grouped application consisting of:
C.I.4: Update of sections 4.4, 4.8, and 5.1 of the SmPC based on results from Study A4250-015 listed as a category 3 study in the RMP; this is a Phase 3, multicentre, open-label extension study to evaluate the long-term safety and efficacy of odevixibat in patients with ALGS. The Package Leaflet is updated accordingly. The RMP version 6.2 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI.

C.I.13: Submission of the 72 week report from study A4250-008. This is a Phase 3, multicentre, open-label extension study to investigate the long-term efficacy and safety of odevixibat in patients with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2).”

**Kisplyx - Lenvatinib -
EMA/H/C/004224/II/0061**

Eisai GmbH, Rapporteur: Karin Janssen van

Doorn, PRAC Rapporteur: David Olsen, "Submission of the final report from study E7080-G000-307 listed as a category 3 study in the RMP. This is a multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of subjects with advanced renal cell carcinoma. The RMP version 18.0 has also been submitted."

Litfulo - Ritlecitinib -

EMA/H/C/006025/II/0007

Pfizer Europe MA EEIG, Rapporteur: Peter Mol, PRAC Rapporteur: Adam Przybylkowski, "Update of section 4.8 of the SmPC in order to update of the long-term efficacy and safety information based on interim results from study B7981032 listed as a category 3 study in the RMP; this is a Phase 3 Open-Label, Multi-Center, Long-Term Study Investigating the Safety and Efficacy of PF-06651600 in Adult and Adolescent Participants With Alopecia Areata. The RMP version 2 has also been submitted."

Nuvaxovid - Covid-19 Vaccine

(recombinant, adjuvanted) -

EMA/H/C/005808/II/0096/G

Novavax CZ a.s., Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Gabriele Maurer

PONVORY - Ponesimod -

EMA/H/C/005163/II/0018/G

Laboratoires Juvisé Pharmaceuticals, Rapporteur: Peter Mol, PRAC Rapporteur: Karin Erneholm, "Grouped application comprised of two Type II Variations, as follows:

C.I.13: Submission of the final report from study AC-058B202; this is a Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of 10, 20, and 40 mg/day Ponesimod, an Oral S1P1 Receptor Agonist, in Patients with Relapsing-remitting Multiple Sclerosis.

C.I.13: Submission of the final report from study AC-058B303 (OPTIMUM-LT); this is a Multicenter, Non-Comparative Extension to Study AC-058B301, to Investigate the Long-Term Safety, Tolerability, and Control of Disease

of Ponesimod 20 mg in Subjects with Relapsing Multiple Sclerosis.
The RMP version 4.1 has also been submitted.”

Rozlytrek - Entrectinib -

EMA/H/C/004936/II/0025

Roche Registration GmbH, Rapporteur: Paolo Gasparini, PRAC Rapporteur: Bianca Mulder, “Submission of the final integrated analysis report for bone biomarkers based on GO40782 [STARTRK-2], CO40778 [STARTRK-NG], and BO41932 [TAPISTRY] studies (PAESs). The RMP version 6 has also been submitted.”

Tibsovo - Ivosidenib -

EMA/H/C/005936/II/0012, Orphan

Les Laboratoires Servier, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen, “Submission of an updated RMP version 2.1 for TIBSOVO and a replacement study protocol for study S095031-218. This is a phase 1, multicenter, open-label, safety and pharmacokinetic study of orally administered ivosidenib in participants with IDH1-mutated malignancies and hepatic or renal impairment. Study milestones in RMP were updated accordingly.”

Tysabri - Natalizumab -

EMA/H/C/000603/II/0150

Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, “Update of sections 4.2 and 4.4 of the SmPC in order to modify administration instructions to add the option for self-administration or administration by a caregiver and to update educational guidance, based on supportive data including final results from study 101MS330; this is a Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab Administered to Japanese Participants With Relapsing-Remitting Multiple Sclerosis via a Subcutaneous Route of Administration. The Annex II, Labelling and Package Leaflet are updated accordingly. The RMP version 32.1 has also been submitted.”

Yondelis - Trabectedin -

EMA/H/C/000773/II/0070

Pharma Mar, S.A., Rapporteur: Boje Kvorning Pires Ehmsen, PRAC Rapporteur: Marie Louise

Schougaard Christiansen, "Update of sections 4.4 and 4.6 of the SmPC in order to update the contraceptive precautions when receiving Yondelis, in line with EMA recommendations. The Package Leaflet is updated accordingly. The RMP version 11.1 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.4."

ZTALMY - Ganaxolone -

EMA/H/C/005825/II/0015/G, Orphan

Marinus Pharmaceuticals Emerald Limited,
Rapporteur: Peter Mol, PRAC Rapporteur: Adam Przybylkowski, "A grouped application consisting of five Type II variations, as follows:

C.I.13: Submission of the final report from non-clinical study 1022-9241 listed as a category 3 study in the RMP. This is a 26-Week Toxicity Study of Ganaxolone Metabolite, M2, by Oral Gavage in the Sprague-Dawley rat with a 2-Week Recovery Period. The RMP version 3 has also been submitted.

C.I.13: Submission of the final report from non-clinical study 20447815 listed as a category 3 study in the RMP. This is a An Oral (Gavage) Study of the Effects of M2 (Ganaxolone Metabolite) Administration on Embryo/Fetal Development in CD (Sprague Dawley) IGS Rat. The RMP version 3 has also been submitted.

C.I.13: Submission of the final report from Weight of Evidence (WoE) assessment to evaluate the need for a 2-year carcinogenicity study in rats with GNX, listed as a category 3 study in the RMP.

C.I.13: Submission of the final report from WoE assessment to evaluate the need for a 2-year carcinogenicity study in rats with M2, listed as a category 3 study in the RMP.

C.I.13: Submission of the final report from WoE assessment to evaluate the need for a juvenile toxicity study with M2, listed as a category 3 study in the RMP. "

WS2798

Nilemdo-

EMA/H/C/004958/WS2798/0045

Nustendi-**EMA/H/C/004959/WS2798/0050**

Daiichi Sankyo Europe GmbH, Lead Rapporteur: Patrick Vrijlandt, Lead PRAC Rapporteur: Kimmo Jaakkola, "Update of sections 4.2, 4.4, and 5.2 of the SmPC in order to amend information concerning renal impairment based on the final results from Study 1002-071 listed as a category 3 study in the RMP; this is a phase 1, open-label, single-dose study to evaluate the pharmacokinetics of bempedoic acid in healthy subjects with normal renal function and subjects with end-stage renal disease receiving HD; the Package Leaflet is updated accordingly. The RMP version 7.0 has also been submitted."

B.6.11. PRAC assessed procedures

PRAC Led

Alunbrig - Brigatinib / Brigatinib -**EMA/H/C/004248/II/0056**

Takeda Pharma A/S, PRAC Rapporteur: Carla Torre, PRAC-CHMP liaison: Fátima Ventura, "Submission of the final report from Brigatinib-5007 study listed as a category 3 study in the RMP. This is a non-interventional cohort study to provide real-world evidence of the occurrence of early-onset pulmonary events in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer treated with brigatinib: a post-authorisation safety study. The RMP version 7 has also been submitted. The MAH proposes the removal of the additional risk minimization measure, the Alunbrig Patient Alert Card (PAC), for the risk of early-onset pulmonary events (EOPEs). In addition, the MAH took the opportunity to introduce editorial changes to the PI."

PRAC Led

Cinryze - C1 ESTERASE INHIBITOR**(HUMAN) - EMA/H/C/001207/II/0104**

Takeda Manufacturing Austria AG, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of sections 4.6, 5.1 and 5.3 of the SmPC based on final results from the Icatibant Outcome Survey (IOS), listed as an imposed PASS in the Annex II. This is a prospective, observational disease registry. The Package Leaflet is updated accordingly. The RMP version 11.1 has also

been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to bring the product information in line with the latest QRD template version 10.4 and to update Annex II of the PI.”

PRAC Led

Cosentyx - Secukinumab -

EMA/H/C/003729/II/0127

Novartis Europharm Limited, PRAC Rapporteur: Monica Martinez Redondo, PRAC-CHMP liaison: Antonio Gomez-Outes, “Update section 4.4 of the SmPC to update the safety information following the PSUSA PSUSA/00010341/202312 procedure in order to assess the safety topics of tuberculosis and hepatitis C virus with secukinumab. The Package Leaflet is updated accordingly.”

PRAC Led

Fasenra - Benralizumab -

EMA/H/C/004433/II/0054

AstraZeneca AB, PRAC Rapporteur: David Olsen, PRAC-CHMP liaison: Ingrid Wang, “Submission of the final report from study D3250R00042 listed as a category 3 study in the RMP. This is a noninterventional, descriptive post authorisation safety study of the incidence of malignancy in severe asthma patients receiving benralizumab and other therapies. The RMP version 7.1 has also been submitted.”

PRAC Led

Firazyr - Icatibant -

EMA/H/C/000899/II/0061

Takeda Pharmaceuticals International AG Ireland Branch PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, “Update of section 4.6 based on final results from the Icatibant Outcome Survey (IOS) registry listed as a category 3 study in the RMP; this is a prospective, observational disease registry. The RMP version 8 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI and to bring the PI in line with the latest QRD template version 10.4.”

PRAC Led

Imbruvica - Ibrutinib -

EMA/H/C/003791/II/0093

Janssen-Cilag International N.V., PRAC

Rapporteur: Barbara Kovacic Bytyqi, PRAC-CHMP liaison: Selma Arapovic Dzakula, "Submission of the study report for additional pharmacovigilance analysis to further evaluate the risk of hemorrhage in participants receiving ibrutinib and concomitant vitamin K antagonists with or without antiplatelet drugs, listed as a category 3 study in the RMP."

PRAC Led

**Lonsurf - Trifluridine / Tipiracil -
EMA/H/C/003897/II/0031**

Les Laboratoires Servier, PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study DIM-95005-001 (PROMETCO), listed as a category 3 PASS in the RMP. This is a non-interventional, observational, real world evidence prospective cohort study in the management of metastatic colorectal cancer. The RMP version 11.1 has also been submitted as the missing information "Use in patients in worse condition than ECOG 0-1" has been removed based on the results from PROMETCO. The PART II - section SVII 1 & SVII 2 has been updated to comply with GVP module V revision 2."

PRAC Led

**Mimpara - Cinacalcet -
EMA/H/C/000570/II/0076**

Amgen Europe B.V., PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study 20180204 listed as a category 3 study in the RMP. This is a non-interventional observational registry study to evaluate the use and safety of cinacalcet among paediatric patients with secondary hyperparathyroidism (HPT)."

PRAC Led

**OPDIVO - Nivolumab -
EMA/H/C/003985/II/0149**

Bristol-Myers Squibb Pharma EEIG, PRAC Rapporteur: Gabriele Maurer, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final clinical study report (CSR) for the PASS study CA209234 listed as a category 3 study in the RMP. This is an observational, multicenter, prospective study in patients treated with nivolumab for melanoma and lung cancer in order assess the safety experience, survival, adverse event management, and outcomes of

adverse events associated with nivolumab (monotherapy or with ipilimumab) in routine oncology care facilities. The RMP version 42.0 has also been submitted.”

PRAC Led

Revlimid - Lenalidomide -

EMA/H/C/000717/II/0130

Bristol-Myers Squibb Pharma EEIG, PRAC
Rapporteur: Tiphaine Vaillant, PRAC-CHMP
liaison: Alexandre Moreau, “Submission of the final report from study CC-5013-MCL-005 listed as a category 3 study in the RMP. This is a non-interventional, post-authorization safety study of patients with relapsed or refractory mantle cell lymphoma to further investigate and characterize the association of lenalidomide with tumor flare reaction and high tumor burden. The RMP version 42.0 has also been submitted.”

PRAC Led

Spravato - Esketamine -

EMA/H/C/004535/II/0026

Janssen-Cilag International N.V., PRAC
Rapporteur: Terhi Lehtinen, PRAC-CHMP liaison: Outi Mäki-Ikola, “Submission of the final study report for the non-interventional study PCSNSP002812 listed as a category 3 study in the RMP. This is a survey in order to assess the effectiveness of SPRAVATO educational materials for additional risk minimization measures in the European Union. The RMP version 8.1 has also been submitted.”

PRAC Led

Zejula - Niraparib -

EMA/H/C/004249/II/0058, Orphan

GlaxoSmithKline (Ireland) Limited, PRAC
Rapporteur: Jan Neuhauser, PRAC-CHMP
liaison: Christian Gartner, “Submission of the final report from study 3000-04-001/GSK213705 listed as a category 3 study in the RMP; this is a non-interventional PASS to evaluate the risks of myelodysplastic syndrome/acute myeloid leukemia and second primary malignancies in adult patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer receiving maintenance treatment with Zejula. The RMP version 10.0 has also been submitted.”

PRAC Led

WS2802

Entresto-
EMA/H/C/004062/WS2802/0070

Neparvis-
EMA/H/C/004343/WS2802/0067
Novartis Europharm Limited, Lead PRAC
Rapporteur: Karin Erneholm, PRAC-CHMP
liaison: Thalia Marie Estrup Blicher, "Submission of the final report for study CLCZ696B2014 listed as a category 3 study in the RMP; this is a non-interventional post-authorization multi-database safety study to characterize the risk of angioedema and other specific safety events of interest in association with use of Entresto (sacubitril/valsartan) in adult patients with heart failure. The RMP version 9.0 for Entresto and Neparvis has also been submitted."

PRAC Led
WS2803
Entresto-
EMA/H/C/004062/WS2803/0071

Neparvis-
EMA/H/C/004343/WS2803/0068
Novartis Europharm Limited, Lead PRAC
Rapporteur: Karin Erneholm, PRAC-CHMP
liaison: Thalia Marie Estrup Blicher, "Submission of the final report for study CLCZ696B2015 listed as a category 3 study in the RMP for Entresto and Neparvis; this is a non-interventional post-authorization multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of sacubitril/valsartan. The RMP version 9.0 for Entresto and Neparvis has also been submitted."

PRAC Led
WS2808
Iscover-
EMA/H/C/000175/WS2808/0158
Plavix-EMA/H/C/000174/WS2808/0160
Sanofi Winthrop Industrie, Lead PRAC
Rapporteur: Carla Torre, PRAC-CHMP liaison: Fátima Ventura, "C.I.11.z (IB) - To provide a new RMP version to update the FUQ in Annex 4."
."

PRAC Led
WS2815
Anoro Ellipta-
EMA/H/C/002751/WS2815/0049

Laventair Ellipta-**EMA/H/C/003754/WS2815/0052**

GlaxoSmithKline (Ireland) Limited, Lead PRAC
Rapporteur: Amelia Cupelli, PRAC-CHMP liaison:
Paolo Gasparini, "Submission of an updated RMP
version 10.0 for Anoro Ellipta and Laventair
Ellipta Inhalation powder, pre-dispensed [55µg/
22µg] following completion of Category 1 PASS
201038 in order to remove the safety concerns
accordingly."

PRAC Led

WS2816**Incruse Ellipta-****EMA/H/C/002809/WS2816/0043****Rolufta Ellipta-****EMA/H/C/004654/WS2816/0027**

GlaxoSmithKline (Ireland) Limited, Lead PRAC
Rapporteur: Amelia Cupelli, PRAC-CHMP liaison:
Paolo Gasparini, "Submission of an updated RMP
version 8.0 for Incruse Ellipta and Rolufta Ellipta
in order to reflect the completion of the
category 1 PASS study 201038 and remove the
safety concerns accordingly."

PRAC Led

WS2819**Ozempic-****EMA/H/C/004174/WS2819/0053****Wegovy-****EMA/H/C/005422/WS2819/0029**

Novo Nordisk A/S, Lead PRAC Rapporteur: Mari
Thorn, PRAC-CHMP liaison: Kristina Dunder, "To
align the RMPs to the version approved for
Rybelsys on 3 October 2024."

B.6.12. CHMP-CAT assessed procedures

Abecma - Idecabtagene vicleucel -**EMA/H/C/004662/II/0058/G, Orphan,
ATMP**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Rune Kjekken, CHMP Coordinator: Ingrid Wang

Breyanzi - Lisocabtagene maraleucel /**Lisocabtagene maraleucel -****EMA/H/C/004731/II/0055/G, ATMP**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Concetta Quintarelli, CHMP Coordinator: Paolo
Gasparini

CARVYKTI - Ciltacabtagene autoleucel -

**EMA/H/C/005095/II/0037, Orphan,
ATMP**

Janssen-Cilag International NV, Rapporteur: Jan
Mueller-Berghaus, CHMP Coordinator: Jan
Mueller-Berghaus

**Casgevy - Exagamglogene autotemcel -
EMA/H/C/005763/II/0012/G, Orphan,
ATMP**

Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Jan Mueller-Berghaus, CHMP
Coordinator: Jan Mueller-Berghaus

**Luxturna - Voretigene neparvovec -
EMA/H/C/004451/II/0054/G, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Sol
Ruiz

**Yescarta - Axicabtagene ciloleucel -
EMA/H/C/004480/II/0085, Orphan,
ATMP**

Kite Pharma EU B.V., Rapporteur: Jan Mueller-
Berghaus, "Submission of the final report from
study KT-US-482-0147 (ZUMA-26). This is a
Prospective, Noninterventional, Clinical Efficacy
Study Investigating and Analysing the Impact of
Tumor Cd19 Antigen Expression and Density on
Response to Axicabtagene Ciloleucel Treatment
Using a Quantitative Flow Cytometry Method."

WS2813/G

Tecartus-

EMA/H/C/005102/WS2813/0055/G

Yescarta-

EMA/H/C/004480/WS2813/0086/G

Kite Pharma EU B.V., Lead Rapporteur: Jan
Mueller-Berghaus, Quality

WS2821/G

Tecartus-

EMA/H/C/005102/WS2821/0056/G

Yescarta-

EMA/H/C/004480/WS2821/0087/G

Kite Pharma EU B.V., Lead Rapporteur: Jan
Mueller-Berghaus, Quality

B.6.13. CHMP-PRAC-CAT assessed procedures

**Ciltacabtagene autoleucel -
EMA/H/C/005095/II/0036, Orphan,
ATMP**

Janssen-Cilag International NV, "Update of

sections 4.8, and 5.1 of the SmPC in order to update the list of adverse drug reactions (ADRs), and update clinical efficacy and safety information based on second interim analysis from study 68284528MMY3002 (CARTITUDE-4); this is a phase 3 randomized study comparing ciltacabtagene autoleucel, a chimeric antigen receptor T cell (CAR-T) therapy directed against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in subjects with relapsed and lenalidomide-refractory multiple myeloma; The RMP version 5.3 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2774/G

Dapagliflozin Viatris-

EMA/H/C/006006/WS2774/0005/G

Viatris Limited, Generic of Forxiga, Lead
Rapporteur: Tomas Radimersky

Request for Supplementary Information adopted
on 16.01.2025.

WS2788

Biopoin-

EMA/H/C/001036/WS2788/0057

Eporatio-

EMA/H/C/001033/WS2788/0056

ratiopharm GmbH, Lead Rapporteur: Alexandre
Moreau

Opinion adopted on 16.01.2025.

WS2795

Glyxambi-

EMA/H/C/003833/WS2795/0063

Jentadueto-

EMA/H/C/002279/WS2795/0076

Trajenta-

EMA/H/C/002110/WS2795/0057

Boehringer Ingelheim International GmbH, Lead
Rapporteur: Patrick Vrijlandt
Opinion adopted on 16.01.2025.

WS2797

Vfend-EMA/H/C/000387/WS2797/0157

Pfizer Europe MA EEIG, Lead Rapporteur:
Patrick Vrijlandt
Opinion adopted on 23.01.2025.

WS2807

Ebymect-

EMA/H/C/004162/WS2807/0068

Xigduo-EMA/H/C/002672/WS2807/0078

AstraZeneca AB, Lead Rapporteur: Kristina
Dunder

WS2810/G

Copalia-

EMA/H/C/000774/WS2810/0138/G

Copalia HCT-

EMA/H/C/001159/WS2810/0116/G

Dafiro-

EMA/H/C/000776/WS2810/0142/G

Dafiro HCT-

EMA/H/C/001160/WS2810/0118/G

Exforge-

EMA/H/C/000716/WS2810/0137/G

Exforge HCT-

EMA/H/C/001068/WS2810/0115/G

Novartis Europharm Limited, Lead Rapporteur:
Thalia Marie Estrup Blicher

WS2811/G

Abseamed-

EMA/H/C/000727/WS2811/0112/G

Binocrit-

EMA/H/C/000725/WS2811/0112/G

Epoetin alfa Hexal-

EMA/H/C/000726/WS2811/0112/G

Sandoz GmbH, Lead Rapporteur: Alexandre
Moreau

Opinion adopted on 16.01.2025.

WS2812/G

Filgrastim Hexal-

EMA/H/C/000918/WS2812/0080/G

Zarzio-

EMA/H/C/000917/WS2812/0081/G

Sandoz GmbH, Lead Rapporteur: Peter Mol

Opinion adopted on 16.01.2025.

WS2820

Blitzima-

EMA/H/C/004723/WS2820/0081

Truxima-

EMA/H/C/004112/WS2820/0084

Celltrion Healthcare Hungary Kft., Lead

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.